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Sommario 
I neutrofili, i leucociti più abbondanti nel sangue umano, sono noti per svolgere 
funzioni effettrici cruciali per la risposta immunitaria innata e adattativa contro le 
infezioni. Inoltre, i neutrofili sono in grado di rispondere a diverse componenti di 
origine microbica inducendo la sintesi e la secrezione di svariate citochine. In questo 
contesto, l'obiettivo principale di questo studio è stato quello di verificare la capacità 
dei neutrofili umani di esprimere e produrre citochine della famiglia di IL-17, tra cui 
IL-17A, IL-1B, IL-17F e IL-17AF, dato che attualmente la letteratura è in disaccordo 
su questo argomento. Attraverso metodiche quali RT-qPCR, immunoistochimica 
(IHC), immunoblotting, misurazione di proteine mediante ELISA, 
immunoprecipitazione della cromatina (ChIP) e ChIP-seq, abbiamo valutato la 
regolazione epigenetica e trascrizionale, così come la produzione di citochine 
utilizzando popolazioni di neutrofili isolati ad un  elevato grado di purezza (> 99,7%). 
In accordo con alcuni dati precedentemente pubblicati sia dal nostro che da altri 
gruppi, abbiamo osservato che i neutrofili incubati con stimoli di diversa natura non 
esprimono ne producono, a livello di mRNA e proteina, nessuna citochina della 
famiglia di IL-17, comprese IL-17A, IL-17F, IL-17B o IL-17AF. Risultati analoghi 
sono stati ottenuti anche utilizzando neutrofili isolati da pazienti con psoriasi attiva. 
Inoltre, contrariamente a quanto osservato in studi pubblicati recentemente, anche in 
neutrofili incubati con concentrazioni molto elevate di IL-6 e IL-23, in combinazione 
con ife o conidi inattivati ottenuti da Aspergillus fumigatus, non è stata misurata nessuna 
espressione di mRNA o sintesi di proteina per IL-17A o IL-17F. In accordo con questi 
dati, sul locus genomico di IL-17A/F, in neutrofili stimolati o meno con IL-6 più IL-
23, non è stata rilevata alcuna presenza di H3K27Ac e H3K4me1, due modificazioni 
istoniche post-traduzionali che contrassegnano elementi regolatori genomici attivi o 
"poised". Tale risultato  è quindi coerente con l'incapacità dei neutrofili umani di 
esprimere l'mRNA di IL-17A o IL-17F. Un altro dato importante emerso in questo 
studio è stato la conferma che in immunoistochimica, anticorpi anti-IL-17A e IL-17B 
utilizzati in svariati lavori, danno un segnale positivo in citocentrifugati di neutrofili 
stimolati o meno con IL-6 più IL-23. In immunoblotting però gli stessi anticorpi non 
riconoscono proteine intracellulari del peso molecolare corretto per IL-17A e IL-17B 
ma altre proteine con peso molecolare molto più alto. Si può concludere quindi che il 
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segnale positivo dato da questi anticorpi in IHC è frutto di una reazione aspecifica ed 
è indipendente dalla presenza di IL-17A o IL-17B. In conclusione, i risultati esposti in 
questo studio non solo confermano e ampliano nostre osservazioni precedenti a 
riguardo dell’incapacità dei neutrofili umani di produrre IL-17A, IL-17B e IL-17F,  ma 
forniscono anche una spiegazione del motivo per cui in altre pubblicazioni queste 
citochine sono rilevate nei neutrofili. 
  
Abstract 
Neutrophils are known to perform a series of effector functions that are crucial 
for the innate and adaptive responses towards infections. Furthermore, neutrophils 
respond to various stimuli, including microbial components, by synthetizing and 
secreting a variety of cytokines. In this context, the main objective of this study was to 
re-evaluate the capacity of human neutrophils to express and produce cytokines of the 
IL-17 family, including IL-17A, IL-17B, IL-17F and IL-17AF since the current 
literature on this topic is discordant. By performing RT-qPCR, immunohistochemistry 
(IHC), immunoblotting, protein measurement via commercial ELISA, chromatin 
immunoprecipitation (ChIP) and ChIP-seq, we evaluated transcriptional and 
epigenetic regulation, as well as production of the latter cytokines by highly pure (> 
99.7 %) populations of human neutrophils. In agreement with some published data, 
we found that neutrophils do not express/produce IL-17A, IL-17F, IL-17AF or IL-
17B mRNA/protein upon incubation with a variety of agonists. Similar findings were 
observed by analyzing neutrophils obtained from active psoriatic patients. No IL-17A 
and IL-17F mRNA expression/production was found even when human neutrophils 
from healthy donors were incubated with IL-6 plus IL-23 at very elevated 
concentrations in combination with inactivated hyphae or conidia from Aspergillus 
fumigatus, unlike shown in multiple studies. Moreover, consistent with the inability of 
human neutrophils to express IL-17A and IL-17F mRNA, no deposition of H3K27Ac 
and H3K4me1, which are histone marks of, respectively, active and poised genomic 
regulatory elements, was detected at the IL-17A/F genomic locus in resting or IL-6 
plus IL-23-stimulated neutrophils. In addition, although we found that anti-IL-17A 
and anti-IL-17B commercial antibodies positively stained cytospin preparations of 
resting and activated neutrophils by IHC, these antibodies do not recognize any 
intracellular protein having the correct MW of either IL-17A or IL-17B in 
corresponding lysates of the same neutrophil preparations by immunoblotting. Since 
the same antibodies were found to strongly stain other intracellular proteins of 
neutrophils, we conclude that their ability to positively stain neutrophils derives from 
IL-17A- or IL-17B-independent unspecific binding. In conclusion, our data not only 
confirm and further support our previous original findings on the inability of human 
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neutrophils to express/produce IL-17A, IL-17B and IL-17F mRNAs/proteins, but 
also attempt to explain why other published studies continue to report the opposite.  
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1. INTRODUCTION 41 
 42 
 POLYMORPHONUCLEAR NEUTROPHILS 43 
Among leukocytes, the polymorphonuclear neutrophils are the most 44 
numerous cells present in human bloodstream. These cells are crucial players in innate 45 
immune response. Nonetheless, during the last years, research has demonstrated that 46 
neutrophils also act as important regulators of adaptive immunity. Neutrophils are 47 
indispensable for defence against pathogens, since they are the first cells to reach the 48 
inflammatory sites where they rapidly exert their effector functions. In an injury or 49 
microbial infection site, neutrophils are able to effectively counter the cause of the 50 
injury by, for example, releasing enzymes, synthetizing reactive oxygen species and 51 
producing inflammatory mediators. Neutrophils display a wide range of actions and 52 
are believed to participate in protection against intracellular pathogens such as viruses 53 
and mycobacteria, to interact with the adaptive immune system and to be involved in 54 
the resolution of inflammation. However, neutrophils have a dark side in that if they 55 
are improperly activated they lead to tissue damage, thus contributing to the 56 
development of autoimmune diseases such as psoriasis, systemic lupus erythematosus 57 
(SLE), rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibody-related 58 
(ANCA) vasculitis, or exaggerated inflammatory reactions such as inflammatory bowel 59 
diseases [1].  60 
Prior to reaching the blood circulation, neutrophils pass through a 61 
differentiation process in the bone marrow called myelopoiesis, arising from the 62 
pluripotent stem cells in a generation rate of 1 to 2 × 1011 mature neutrophils/day [2]. 63 
Once these cells are released into the bloodstream, they do not stay there for long, due 64 
to their very short lifespan, that usually ranges between 6-20 hours under healthy 65 
conditions. However, neutrophil life-span is increased when they migrate into the 66 
infection site and enter in contact with cytokines such as tumour necrosis factor alpha 67 
(TNF), type I and II interferons (IFN), granulocyte colony-stimulating factor (G-68 
CSF) and granulocyte-macrophage stimulating factor (GM-CSF) [3, 4]. Furthermore, 69 
bacterial products such as LPS and viral ssRNA have also been shown to prolong 70 
neutrophil survival [3, 5]. In the absence of infection or inflammation, neutrophils 71 
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undergo through the apoptosis process and are in turn, removed by macrophages. 72 
Apoptosis is an important homeostatic mechanism, as its alteration in neutrophils 73 
would have serious consequences for the inflammatory response and resolution of 74 
inflammation. Furthermore, the regulation of neutrophil turnover represents a critical 75 
checkpoint because neutrophils constitute the majority of leukocytes in humans, 76 
predominate at the infection sites and contain cytotoxic molecules that can damage 77 
host tissues.  78 
 79 
 80 
 Effector functions of neutrophils 81 
While circulating in the vasculature, neutrophils can rapidly migrate into the 82 
infection sites in response to chemokines such as CXCL8, which is the most potent 83 
neutrophil chemoattractant. CXCL8 is produced in response to pro-inflammatory 84 
molecules by macrophages, epithelial cells, mast cells, endothelial cells, keratinocytes,  85 
fibroblasts and neutrophils themselves [6, 7]. Moreover, products from bacteria such 86 
as fMLF and peptidoglycan can also contribute to the recruitment of neutrophils [6]. 87 
The process of neutrophil migration starts with a slow roll on the surface of the 88 
endothelial cells mediated by constitutive expression of adhesion molecules of the 89 
selectin family, which establish a low-affinity binding between L-selectin expressed by 90 
neutrophils to P- and E-selectins present on the plasma membrane of activated 91 
endothelial cells[6]. A high-affinity interaction can be then established, in the presence 92 
of chemotactic factors, between 2-integrins present on the neutrophils surface and 93 
endothelial cell intracellular adhesion molecule (ICAM)-1 and ICAM-2 on the 94 
endothelial cells. Neutrophils start to crawl on the vasculature surface and ultimately 95 
transmigrate through the endothelium into tissues without damaging these structures, 96 
following a gradient that is believed to be set up by chemotactic factors [8, 9]. 97 
Transmigration is facilitated by several surface molecules, including integrins and 98 
CAMs (ICAM1, ICAM2 and vascular cell adhesion protein 1 (VCAM1)), junctional 99 
proteins such as platelet/endothelial cell adhesion molecule 1 (PECAM1; also known 100 
as CD31), CD99, junctional adhesion molecules (JAMs) and epithelial cell adhesion 101 
molecule (ECAM) [8]. Once in the interstitial tissue, neutrophils follow chemotactic 102 
gradients in order to move in an oriented manner, locate and kill microorganisms using 103 
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their antimicrobial arsenal, including reactive oxygen species (ROS) and release of 104 
peptides, proteins and enzymes contained in granules and phagocytosis. Phagocytosis 105 
is the process whereby neutrophils bind and ingest invading microorganisms. 106 
Neutrophils recognize microbes via their pattern recognition receptors (PRRs) that 107 
bind specific structures called pathogen-associated molecular patterns (PAMPs) such 108 
as lipopolysaccharide (LPS), peptidoglycan (PGN), lipoteichoic acid (LTA) and 109 
flagellin. These PAMPs generally trigger signal transduction pathways leading to the 110 
expression of adhesion molecules, promotion of phagocytosis, release of cytokines, 111 
chemokines, ROS and degranulation. Moreover, neutrophil phagocytosis can be 112 
efficiently enhanced by antibodies and complement products that opsonize microbes. 113 
Phagocytosis leads to the formation of a phagosome that, in turn, fuses with 114 
azurophilic granules (peroxidase-positive granules) creating a vacuole lumen with 115 
antimicrobial molecules including -defensins, cathepsins, proteinase-3, elastase, 116 
azurodicin and lysozyme.  117 
 118 
 119 
 Pattern recognition receptors by neutrophils 120 
One of the most important discovery regarding the innate immunity has been 121 
the identification of pattern recognition receptors, whose importance was firstly 122 
highlighted by Charles Janeway in 1989 [10]. Today, PRRs include members of Toll-123 
like receptor (TLR) family, the C-type lectin receptors dectin 1 (also known as 124 
CLEC7A), and CLEC2 (also known as CLEC1B), as well as cytoplasmic RNA sensors 125 
(RIG-I and MDA5), cytoplasmic DNA sensors and cytoplasmic NACHT-leucine-rich 126 
repeat receptors (NLRs), some of them being components of inflammasomes [11, 12]. 127 
Among them, neutrophils express a broad range of PRRs, as illustrated in Figure 1. 128 
 129 
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 130 
Adapted from Thomas CJ and Schroder K. 2013. Trends Immunol. 34:317 [13]. 131 
Based on the data from Tamassia N and Cassatella MA. 2013. Current Opinion in Pharmacology. 132 
13:547 [12]. 133 
Figure 1 | Pattern recognition receptors expressed by neutrophils 134 
Abbreviations: CLEC, C-type lectin domain family; CLR, C-type lectin receptor; DAMP, 135 
danger-associated molecular pattern; meso-DAP, meso diaminopimelic acid; FPR, formyl 136 
peptide receptor; MDL, myeloid DAPs12-associating lectin; NLR, nucleotide-binding 137 
oligomerization domain (NOD)-like receptor; NLRC, NLR with a CARD domain; NLRP, 138 
NLR with a pyrin domain; PAMP, pathogen-associated molecular pattern; RLH, retinoic acid-139 
inducible gene (RIG)-like helicase; SAP, spliceosome-associated protein; TLR, Toll- like 140 
receptor; TREM, triggering receptor expressed on myeloid cells. (a) Described in mouse but 141 
not human neutrophils; (b) Described in human but not mouse neutrophils; (c) Described in 142 
mouse neutrophils, no data available in humans. 143 
 144 
TLRs, which to date comprises 10 members in humans (TLR1-10), were the 145 
first PRRs to be discovered and are the most studied PRRs in neutrophils. Almost all 146 
TLRs are expressed and functional in human neutrophils, with the exception of TLR3 147 
and TLR7. TLR4, which recognizes LPS, has special features in its activation pathway. 148 
In fact, while immune cells such as monocytes, macrophages and dendritic cells 149 
activate two signalling pathways downstream of TLR4, respectively coordinated by 150 
signal adaptors myeloid differentiation factor 88 (MyD88)/MyD88 adaptor-like (Mal) 151 
and TIR domain-containing adaptor protein inducing interferon β (TRIF)/TRIF-152 
related adaptor molecule (TRAM), neutrophils mobilizes only the MyD88-dependent 153 
pathway [14]. Such a cell-specific activation by LPS influences the expression profile, 154 
strength and kinetics of cytokine production by neutrophils. 155 
 156 
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 Cytokine expression by neutrophils 157 
Neutrophils have been shown to express and produce a large number of pro- 158 
and anti-inflammatory cytokines, chemokines, colony-stimulating and angiogenic 159 
factors, either constitutively or following appropriate stimulation [11] (Figure 2). The 160 
production of cytokines by neutrophils is controlled by regulatory mechanisms 161 
occurring at the level of mRNA transcription [15], stability or translation, as well as at 162 
the level of protein secretion. Moreover, cytokines are eventually stored in intracellular 163 
pools following synthesis, ready to be promptly secreted when neutrophils are 164 
stimulated with secretagogue-like molecules [16].  165 
It is important to mention two important issues for those people who want to 166 
study neutrophil-derived cytokines: 1) neutrophils possess 10/20 times less RNA than 167 
other leukocytes and consequently; 2) with few exceptions, they usually produce much 168 
lesser cytokine amounts than monocytes/macrophages or lymphocytes on a per cell 169 
basis. Hence, highly pure populations of neutrophils should be used for the evaluation 170 
of their cytokine gene expression/production profiles. Accordingly, in a study 171 
conducted in our lab, different published procedures to isolate neutrophils directly 172 
from human blood were found to generate percentages of neutrophil purity very 173 
diverse, in some cases causing artefacts [17]. By the way, the fact that a single 174 
neutrophil, per se, produce little amounts of cytokine does not mean that neutrophil-175 
derived cytokines are not important, as neutrophils usually outnumber mononuclear 176 
leukocytes in infection/inflammatory sites by one to two orders of magnitude [15, 18, 177 
19].  Neutrophil-derived cytokines can be measured in cell-free supernatants or cell 178 
lysates by using a variety of methods, including enzyme-linked immunoadsorbent 179 
assays (ELISA), immunoprecipitation, immunohistochemistry, intracellular staining by 180 
flow cytometry or confocal microscopy. The latter two techniques should be not only 181 
carefully interpreted, but also used only to support other cytokine detection methods, 182 
since elevated neutrophil autofluorescence, antibody cross-reactivity or aspecific 183 
binding of antibody to Fcγ receptors (especially CD16), could generate artefacts.  184 
 185 
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 186 
Adapted from: Tamassia, N., et al. (2018). "Cytokine production by human neutrophils: Revisiting the 187 
"dark side of the moon”. Eur J Clin Invest, 2018 [20]. 188 
 189 
Figure 2 | Cytokines that human neutrophils can potentially express and produce.  190 
Expression and/or production of the listed cytokines have been validated in human 191 
neutrophils by gene expression techniques, immunohistochemistry, enzyme-linked 192 
immunosorbent assays (ELISAs) or biological assays. 193 
 194 
 195 
Interestingly, activation of the same PRR in autologous neutrophils and 196 
monocytes may trigger distinct gene as well as cytokine expression programs [14, 21, 197 
22], reflecting cell type-specific mechanisms of transcriptional regulation. For instance, 198 
upon stimulation with LPS, IFN, an antiviral and immunomodulatory cytokine [23], 199 
is induced in human monocytes, but not in neutrophils. As explained on page 18, the 200 
activation of TLR4 by LPS in neutrophils fails to trigger the TRIF-signalling pathway, 201 
that is indeed crucial for the activation of the transcription factor interferon regulatory 202 
factor 3 (IRF3) (Figure 3). On the contrary, the activation of TLR4 by LPS in 203 
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monocytes leads to the triggering of both the MyD88-signalling pathway (and, in turn, 204 
NF-B) and the TRIF-signalling pathway (mainly activating IRF3). Activation of both 205 
NF-B and IRF3 is essential for the activation of IFN transcription [24, 25] which, 206 
in an autocrine manner, stimulates the expression of a large set of interferon-stimulated 207 
genes (ISG) displaying antiviral and immunomodulatory functions[23]. 208 
 209 
 210 
Adapted from: Ostuni, R., et al. Epigenetic regulation of neutrophil development and function. Semin 211 
Immunol 28(2): 83-93, 2016 [26]. 212 
 213 
Figure 3 | Examples of epigenetic mechanisms controlling gene expression in human 214 
neutrophils.  215 
The cartoon illustrates that the IL10 locus of neutrophils display inaccessible regulatory 216 
regions, as evidenced by the absence of histone marks associated with active transcription. 217 
Such a chromatin conformation prevents the binding of transcription factors (TFs) activated 218 
by TLR ligands or other PAMPs, therefore preventing IL-10 mRNA transcription. By contrast, 219 
the CXCL8 locus has an accessible conformation that is ensured by the constitutive binding 220 
of both PU.1 and C/EBPβ. Upon neutrophil activation, NF-кB is recruited to its 221 
corresponding binding sites and thus promotes transcription of CXCL8 mRNA. Figure also 222 
shows that the IL6 locus of neutrophil is not accessible under basal state. However, upon 223 
appropriate stimulation, pioneer TFs such as PU.1 and C/EBPβ initiate chromatin opening, 224 
in turn favoring the binding of activated TFs and ultimately activating IL-6 mRNA 225 
transcription. Finally, even if the IFNβ genomic locus is not in a closed conformation, no 226 
IFNβ mRNA transcription occurs in TLR-stimulated neutrophils because of the inability to 227 
activate IRF3 by TLR-dependent signals. 228 
 229 
 230 
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Beyond discrete transcription factor (TF) activation, chromatin organization 231 
may represent another critical factor at the basis of the transcriptional differences 232 
observed in neutrophils and monocytes. Indeed, pro-inflammatory TFs activated by 233 
external stimuli such as TLR ligands largely act within a pre-established chromatin 234 
landscape [27]. On the other hand, recent studies in neutrophils and monocytes have 235 
shown that chromatin-dependent mechanisms control their expression of interleukin-236 
10 (IL-10), a potent anti-inflammatory cytokine that prevents inflammatory and 237 
autoimmune diseases[28]. Specifically, a comparative analysis at the IL10 genomic locus 238 
of histone modifications associated with permissive chromatin, precisely H3K4me3 239 
(localized at the transcription start site of active genes), H3K27Ac and H4Ac (both 240 
associated with activated regulatory elements), and H3K4me1 (a histone mark mainly 241 
associated with active and poised enhancers), revealed that these histone modifications 242 
are detectable in autologous monocytes, but not in autologous neutrophils, already at 243 
the steady-state. Furthermore, H3K4me3 and H3K27Ac marks were shown to further 244 
increase in monocytes stimulated with TLR2 and TLR4 ligands (Pam3CYS4 and LPS 245 
respectively) or serum amyloid A (SAA), while remaining undetectable in neutrophils 246 
[21, 29]. In accordance with what observed for histone modifications, chromatin 247 
immunoprecipitation (ChIP) of a number of transcription factors, previously proposed 248 
to bind to and/or transactivate the IL-10 gene in various cells of human or mouse 249 
origin [30], revealed no binding of C/EBPβ, c-FOS, SP1 and NF-Bp50 to the IL-10 250 
promoter of neutrophils, either constitutively or upon activation with LPS. These data, 251 
generated using highly purified human neutrophils isolated by antibody conjugated 252 
magnetic beads, provided a mechanism explaining why human neutrophils are unable 253 
to produce IL-10 [31-34]. Such an issue has been in fact controversial for many years, 254 
as a number of studies were reporting a production of IL-10 by human neutrophils, 255 
under resting or stimulatory conditions [35-39]. In our opinion, controversial reports 256 
are explained by the scarce purity of neutrophil preparations used to evaluate the 257 
production of IL-10, therefore avoiding the essential exclusion of contaminant cells, 258 
such as lymphocytes or monocytes, which can strongly affect the final results [17, 21]. 259 
Confirming this hypothesis, studies conducted by our laboratory with a preparation of 260 
highly purified neutrophils (> 99.7 ± 0.2 %) have never detected mRNA 261 
expression/production of IL-10 in response to plenty of inflammation-associated 262 
stimuli, such as PRR agonists (LPS, R848, Pam3CSK4, poly(I:C), curdlan), SAA, 263 
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cytokines (IFNγ, TNFα, GM-CSF or G-CSF), chemoattractants (fMLF) or insoluble 264 
immunocomplexes [21]. By contrast, autologous monocytes promptly produce 265 
detectable amounts of IL-10 when stimulated with SAA, TLR ligands or curdlan [21]. 266 
Although it cannot be excluded that specific stimulatory conditions may revert the 267 
non-permissive state of the chromatin in their IL10 locus, human neutrophils are 268 
unable to express IL-10 upon stimulation with TLR ligands or SAA. The bottom line 269 
is that caution must be taken with studies that report IL-10 expression by human 270 
neutrophils stimulated with TLR-ligands, especially when contamination with other 271 
leukocytes is not excluded. The latter precaution is, anyway, mandatory when cytokine 272 
production and/or gene expression by neutrophils need to be investigated [18, 40]. 273 
Not only the expression of IL-10 in human neutrophils has been a target of 274 
debate for a long time, but also of other cytokines such as IL-6 and IL-17. IL-6 is a 275 
pleiotropic cytokine displaying both pro- and anti-inflammatory activities, playing a 276 
crucial role in host defence against pathogens and acute stress [41]. However, 277 
uncontrolled IL-6 regulation can contribute to the pathogenesis of inflammatory and 278 
autoimmune diseases [41], as well as cancer [42]. Conflicting results have been 279 
published on the ability of neutrophils to accumulate IL-6 mRNA, either constitutively 280 
or after stimulation [43, 44]. In addition, several studies have reported a remarkable 281 
production of IL-6 by neutrophils stimulated with LPS, GM-CSF or TNFα [43], while 282 
other studies did not reproduce the same data [45, 46]. It is important to note that 283 
different culture conditions, time points of analysis and methods to detect IL-6 284 
production were used in these various studies. Still, these controversial publications 285 
rarely met the employment of neutrophil preparations free of contaminant monocytes, 286 
which are major producers of IL-6 [45]. As illustrated in Figure 4, the regulation of 287 
expression/production of IL-6 by neutrophils was recently found to be regulated at 288 
chromatin reorganization level. Specifically, data have shown the absence of 289 
H3K4me3, H3K27Ac, H4Ac and H3K4me1 histone marks in highly purified resting 290 
neutrophils [47]. However, incubation of neutrophils with either R848, a synthetic 291 
mimic viral ssRNA recognized by TLR8, or very high concentrations (10 µg/ml) of 292 
LPS increased the presence of these histone marks at the IL6 locus, in accordance with 293 
the ability of TLR ligands to promote chromatin reorganization and de novo formation 294 
of latent enhancers [48-50]. Interestingly, histone modifications were prominently 295 
detected after an overnight incubation, while PU.1 and C/EBPβ were recruited at the 296 
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IL6 locus as early as 6 h after R848 stimulation, suggesting a “pioneer” activity of these 297 
TF also in human neutrophils [51, 52]. On the other hand, in autologous monocytes 298 
the IL6 locus was found to be in a “poised” conformation, which is a chromatin status 299 
given by the presence of H3K4me1, PU.1 and C/EBPβ already under resting 300 
conditions. Such a chromatin organization influences the kinetics of IL-6 transcription, 301 
which in monocytes is much more accelerated than in neutrophils [47]. The different 302 
kinetics of IL-6 gene expression observed between neutrophils and monocytes is 303 
controlled also by other factors, including: 1) expression of IкBζ, a transcriptional 304 
coactivator that is required for the IL-6 transcription [53], which in monocytes is more 305 
rapidly induced by TLR stimulation than in neutrophils; 2) endogenous production of 306 
IL-10, which occurs only in monocytes [21] and that turns off IL-6 transcription at 307 
delayed time-points[54]; 3) induction of miR187 by endogenous IL-10, occurring only 308 
in monocytes, which regulate IкBζ expression[55]; and 4) the presence of distinct cell-309 
specific enhancers, located at -14 kb and at -49 and -64 kb from the IL-6 TSS in 310 
neutrophils and monocytes, respectively [47].  311 
The importance of epigenetic in regulating cytokine gene expression in human 312 
neutrophils is exemplified by the fact that R848 induces an increase of the chromatin 313 
accessibility at their IL6 locus, and by doing so confers responsiveness to TNFα, which 314 
by itself is not able to trigger IL-6 transcription in resting neutrophils [47]. When the 315 
IL6 locus is accessible, as in TLR8-activated neutrophils, TNFα induces the 316 
recruitment of C/EBPβ and histone acetylation, in turn promoting IL-6 transcription 317 
[47]. Indeed, in the presence of adalimumab and etanercept [56], two TNFα inhibitors, 318 
the mRNA expression and production of IL-6 by TLR8-activated neutrophils 319 
dramatically decreases, indicating that endogenous TNFα plays a crucial role in the 320 
amplification of IL-6 expression [47]. Furthermore, an important role of endogenous 321 
TNFα in amplifying neutrophil-derived IL-6 was recently confirmed by studies using 322 
TLR8-stimulated neutrophils in the presence of IFNα, hence mimicking a potential 323 
situation occurring in systemic lupus erythematosus (SLE) patients [57]. These findings 324 
indicate that TLR8 ligands, IFNα and TNFα, three players often coexisting in many 325 
diseases of viral or autoimmune origin, promote a strong production of IL-6 by human 326 
neutrophils, placing this cell type among potential targets for immunotherapeutic 327 
interventions. 328 
 329 
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330 
Adapted from: Zimmermann, M., et al., Chromatin remodelling and autocrine TNFalpha are 331 
required for optimal interleukin-6 expression in activated human neutrophils. Nat Commun, 6: p. 6061, 332 
2015 [47]. 333 
Figure 4 | R848 induces a reorganization of the chromatin at the IL-6 locus of human 334 
neutrophils. 335 
Scheme illustrating the occupancy of PU.1, NF-кB, C/EBPβ and histone modifications 336 
H3K4me1, H3H4me3 and H3K27Ac, at the regulatory regions of the IL-6 locus of 337 
neutrophils. IL-6 locus in neutrophils is inactive based on the absence of histone modifications 338 
and TF binding. Upon neutrophils treatment with R848, recruitment of PU.1, C/EBPβ, NF-339 
кB and deposition of significant levels of histone marks (H3K4me1, H3H4me3 and 340 
H3K27Ac) occur at various IL-6 locus positions, suggesting an induction of latent regulatory 341 
sites (such as enhancers) leading to IL-6 gene transcription. 342 
 343 
1.1.4 Chemokine expression by neutrophils 344 
Among the cytokines produced by neutrophils, chemokines represent 345 
interesting ones given their ability to recruit selective leukocytes into the site of 346 
inflammation. In this manner, chemokines regulate leukocyte trafficking and immune 347 
system responses, other than influencing B and T cell development and modulating 348 
angiogenesis. As displayed in Figure 2, human neutrophils are a source of many 349 
chemokines, including CXCL1, CXCL8, CXCL10, CCL2, CCL3, CCL4 [58] and, as 350 
more recently described, CCL23 [59]. Interestingly, some of the chemokines released 351 
by neutrophils potently amplify their own recruitment [60]. Furthermore, by releasing 352 
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chemokines, neutrophils orchestrate sequential recruitment and/or activation of 353 
distinct leukocyte types into the inflamed tissue, such as monocytes, dendritic cells 354 
(DCs), natural killer (NK) cells, and T-helper type 1 (Th1) and type 17 (Th17) cells [58, 355 
61].  356 
Neutrophils express many chemokine receptors as well, including CXCR2, 357 
CXCR4 and CCR1, and are the first cell types targeted by chemokines during 358 
inflammation. CXCR4 expression, for example, progressively decreases during the 359 
maturation of neutrophils in the bone marrow, allowing the release of mature 360 
neutrophils into the bloodstream [62]. In this context, a decrease of CXCL12 (the 361 
ligand of CXCR4) and CXCR4 expression by neutrophils can be promoted by G-CSF, 362 
that in this manner further decreases the number of neutrophils that are retained in 363 
the bone marrow. On the contrary, neutrophils increase their CXCR4 expression with 364 
senescence, which favours their return to the bone marrow where they undergo 365 
apoptosis [63]. As already explained on page 16, circulating neutrophils promptly 366 
respond to activated endothelium by binding selectin and integrin ligands, thus rolling 367 
and spreading along the endothelium to finally, transmigrate in response to 368 
chemokines, including CXCL1, CXCL2 and CXCL8. Some of these chemokines are 369 
produced by endothelial cells or other cell types at the infection site, including 370 
neutrophils themselves. Once transmigrated, neutrophils follow chemoattractant 371 
gradients created by chemokines/chemotactic factors to migrate to the inflammation 372 
site and exert their various effector functions. 373 
 374 
1.2 INTERLEUKIN 17 375 
 IL-17 and receptors 376 
The IL-17 family consists of six cytokines, IL-17A (IL-17), IL-17B, IL-17C, 377 
IL-17D, IL-17E (IL-25) and IL-17F (Figure 5). IL-17A and IL-17F are the most 378 
closely related, since IL-17F has 50% sequence identity with IL-17A and its gene is 379 
localized adjacent to the IL-17A gene on human chromosome 6 [64]. IL-17F is often 380 
coproduced with IL-17A and together they can form an IL-17F/IL-17A heterodimer 381 
[65]. Being the most potent one, IL-17A induces the expression of proinflammatory 382 
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mediators, including IL-1, IL-6, TNFα, CXCL8, G-CSF and GM-CSF by epithelial 383 
cells and stromal cells, which together lead to the recruitment and activation of 384 
neutrophils. IL-17B is expressed in various tissues, such as pancreas, small intestine 385 
and brain [66], and has been shown to induce inflammatory cytokines such as IL-1 386 
and TNF by monocyte cell line THP-1 [67] and IL-1, IL-6 and IL-23 by murine 387 
fibroblast cell line 3T3 [68]. IL-17B is present in the rheumatoid arthritis synovium 388 
and was shown to enhance the TNF-induced production of G-CSF and IL-6 in 389 
fibroblasts [69]. Moreover, IL-17B can play an important role in lymphoid tissues by 390 
regulating the trafficking of germinal center B cells by downregulation of the 391 
expression of RGS16 protein [70]. Furthermore, IL-17B has been shown to have 392 
potential roles in the pathogenesis of inflammatory and autoimmune diseases and 393 
tumor progression [66]. Less is known regarding the other IL-17 members. IL-17C has 394 
been shown to bind to IL-17RE and induce the activation of nuclear IkappaB family 395 
member (IкBζ) in Th17 cells, hence leading to a potentiation of IL-17 production [71], 396 
while IL-17E (also known as IL-25) has been correlated with the augmentation of 397 
allergic responses, by enhancing Th2 memory cell function and suppressing the Th17 398 
responses [72]. 399 
The IL-17R group comprises five receptor subunits, IL-17RA, IL-17RB, IL-400 
17RC, IL-17RD and IL-17RE. IL-17RA was the first to be described and is 401 
ubiquitously expressed, particularly in hematopoietic cells (Figure 5). It is by far the 402 
largest member of the family and functions as a common receptor subunit used by at 403 
least four ligands, namely IL-17A, IL-17C, IL-17E and IL-17F[73]. For example, both 404 
IL-17A and IL-17F, as either homodimers or heterodimers, induce signals through the 405 
IL-17RA/IL17RC complex. It is important to note that IL-17RA is unique among the 406 
interleukin receptors because it recruits an adaptor protein known as ACT1 [74, 75]. 407 
Binding of IL-17A to IL-17R leads to the activation of canonical nuclear factor кB 408 
(NF-кB) and mitogen-activated protein kinase (MAPK) pathways, which requires the 409 
recruitment of ACT1 and the presence of TNF receptor associated factor 6 410 
(TRAF6)[76]. Furthermore, IL-17A triggers the activation of the CCAAT/enhancer 411 
binding proteins (C/EBPs) for the transcription of IL-17-target genes [77].  412 
 413 
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414 
Gaffen, S.L., et al., The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev 415 
Immunol, 2014. 14(9): p. 585-600 [78]. 416 
 417 
Figure 5 | Members and related receptors of the IL-17 family.  418 
CBAD, C/EBPβ activation domain; SEFEX, SEFIR extension; SEFIR, SEF/IL-17R. *IL-419 
17RD is also known as SEF. 420 
 421 
 IL-17 and Th17 cells 422 
IL-17A is a cytokine cloned in 1993 that is important in host defence and 423 
inflammation [79]. After the discovery of a subtype of CD4+ T helper (Th) expressing 424 
IL-17A (currently known as Th17 cells), plenty of studies have been published 425 
correlating Th17 with a wide range of physiological and pathological processes. 426 
Although Th17 cells are considered the main sources of IL-17A and IL-17F, other 427 
innate immune cells produce these cytokines, including  T cells, natural killer T cells 428 
(NKT), invariant natural killer cells (iNKT), Paneth cells, TCRβ+ natural Th17 cells, 429 
lymphoid-tissue inducer-like cells (LTi), IL-17-expressing type 3 innate lymphoid cells 430 
(ILC3s) and mast cells [80, 81].  Nonetheless, an exaggerated IL-17A production can 431 
lead to the development of autoimmune diseases, such as psoriasis, multiple sclerosis 432 
and rheumatoid arthritis, as well as cancer progression, which hence makes IL-17 as a 433 
very important target for the development of new therapies [78].   434 
The expression of IL-17 by Th17 cells is regulated by specific transcription 435 
factors and chromatin status. Specifically, the activation of the T cell receptor (TCR) 436 
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signalling pathway leads to the recruitment of pioneering transcription factors, namely 437 
basic leucine zipper transcription factor ATF-like (BATF) and interferon-regulatory 438 
factor 4 (IRF4), which cooperatively make accessible target genes on the chromatin. 439 
When an inflammatory stimuli is present, such as IL-6 or activation of mTOR during 440 
hypoxia, transcription factor signal transducer activator of transcription 3 (STAT3) is 441 
recruited to the accessible chromatin, in turn promoting the transcription of genes 442 
encoding retinoic acid receptor-related orphan receptor-γt (RORγt; encoded by Rorc) 443 
and hypoxia-inducible factor 1 alpha (HIF1α; encoded by Hif1a) leading to lineage 444 
specification of T helper 17 (Th17) cells. A further activation by IL-23 promotes the 445 
recruitment of B lymphocyte-induced maturation protein 1 (BLIMP1) to the RORγt-446 
STAT3 transcriptional complex enhancing the expression of Th17 induced-genes, 447 
such as IL-17A, IL-17F, IL-23R, CSF2 and IL-2 [78]. 448 
Although IL-17A and IL-17F are modest activators of signaling, a notable 449 
feature of these cytokines is their strong synergistic effect with other pro-inflammatory 450 
molecules, in particular with TNF, but also with IFNγ, IL-22, lymphotoxin, IL-1β and 451 
LPS[82]. Such synergistic effect could occur at the level of promoter (for example, Il6 452 
and Lnc2) and/or mRNA stability (for example, CXCL1 and CXCL2) [83, 84]. 453 
Moreover, IкBζ is also upregulated upon IL-17 activation and in turn, promotes the 454 
expression of some target genes [85]. 455 
 456 
 Neutrophils and IL-17 457 
The relationship between human neutrophils and the IL-17 cytokines 458 
indirectly begins with the demonstration that in vitro activated neutrophils release 459 
chemoattractant molecules, including CCL2 and CCL20, that efficiently recruit Th17 460 
cells to the inflamed tissue [86]. Th17 cells further produce IL17A and IL17F on one 461 
side and CXCL8 on the other, which promote, respectively, the release of neutrophil 462 
chemoattractant molecules by epithelial cells and the direct recruitment of neutrophils. 463 
Moreover, activated Th17 cells release cytokines, such as TNF, GM-CSF and IFN, 464 
that positively modulate survival and expression of activation markers by human 465 
neutrophils [40, 87]. However, whether human neutrophils respond to IL-17 or not 466 
appears to be still controversial. In fact, despite of our original data showing that 467 
neutrophils cannot be directly activated by IL-17A and/or IL-17F due to their lack of 468 
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IL-17RC expression[87], confirming previous studies reporting the inability of IL-17 469 
to directly affect neutrophil apoptosis[88], subsequent studies have claimed that IL-470 
17A is instead capable to attenuate the anti-apoptotic effect of GM-CSF [89], as well 471 
as increase the killing rate of pneumococcal when IL-17A is used at high 472 
concentrations (> 1 µg/ml) [90].  473 
While Th17 cells are considered the major producers of IL-17 by far, whether 474 
human neutrophils represent an IL-17 source again appears to be currently an unclear 475 
issue, based on the controversial data reported in the literature. In such regard, our 476 
group reported no detection of IL-17A or IL-17F mRNA/protein 477 
expression/production by highly purified populations (> 99.7 %) of human 478 
neutrophils incubated for up to 20 h with 100 U/ml IFN and/or 100 ng/ml LPS [87, 479 
91-93]. By contrast, diverse studies have reported that neutrophils are capable of 480 
transcribing/producing IL-17A. For instance, in a recent study, Taylor et al. [94] have 481 
reported that a putative subset of human neutrophils express IL-17A mRNA after 1 h 482 
stimulation with 20 µg/mL IL-6 and 2 µg/mL IL-23, as well as produce IL-17A after 483 
3 h [94]. Moreover, neutrophils were shown to express RORt, which upon incubation 484 
with supernatants containing IL-6 and IL-23 that were obtained from PBMCs treated 485 
with Aspergillus fumigatus hyphae that, was found translocated into the nucleus and, 486 
consequently, retained as responsible for the activation of IL-17A gene. When 487 
neutrophils treated with PBMC supernatants were incubated with antibodies against 488 
IL-6 or IL-23, their ability to express IL-17A mRNA vanished [94]. It is important to 489 
note that Taylor et al. [94] have also reported that, in the presence of IL-6, IL-23 and 490 
A. fumigatus hyphae, neutrophils are induced to express surface IL17RC, in turn 491 
proposing that neutrophils can respond to IL-17A in an autocrine fashion, for instance 492 
by producing ROS [94]. The same group has also shown that the  JAK/STAT 493 
signalling pathway activated by IL-6 plus IL-23 plays a very important role in the ROS 494 
production and hyphal killing by neutrophils [95]. In a further study [96], the plasma 495 
of both healthy controls and patients with fungal keratitis was found to contain IL-496 
17A, IL-6 and IL-23, showing no significant differences between them. Peripheral 497 
neutrophils from patients with fungal keratitis were analysed by intracellular flow 498 
cytometry, immunofluorescence and RT-qPCR and found to express IL-17A, 499 
suggesting a possible effect in the corneal inflammation and cytokine production in 500 
response to growing hyphae [96]. Another group has instead recognized a subset of 501 
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peripheral human neutrophils expressing IL-17 during Mycobacterium tuberculosis (MTB) 502 
infection [97]. According to the authors, such IL-17 production by neutrophils is due 503 
to an autocrine activity of the IL-6 and IL-23 production during MTB infection [97]. 504 
Furthermore, IL-6 and IL-23 have also been found in the microenvironment of human 505 
gastric cancer, where neutrophils were, again, found to be IL-17A-, as well as MMP9-506 
, positive by IHC and IF [98]. In the same study, neutrophils (> 96 % pure) isolated 507 
from the whole blood of gastric cancer patients were shown to express IL-17A and 508 
RORt mRNAs when stimulated with 20 µg/ml IL-6 and 2 µg/ml IL-23 [98]. 509 
IL-17-producing neutrophils have been also found to be related with chronic 510 
diseases, such as asthma, psoriasis and rheumatoid arthritis (RA). For instance, 511 
neutrophils (> 95 % pure) isolated from the blood of severe asthma patients stimulated 512 
with IL-21, IL-23, IL-21 plus IL-23 and IL-6 (all used at 20 ng/ml) were found to 513 
express IL-17A and IL-17F mRNA after 4 h by RT-qPCR and after 12 h by 514 
intracellular flow cytometry. In addition, the same authors observed a basal IL-17A 515 
expression in resting neutrophils by western blot, which was further increased upon 516 
stimulation with IL-21, IL-23 and IL-21 plus IL-23 for 18 h [99]. Consistently, a subset 517 
of IL-17-positive neutrophils was found in the whole blood of patients with allergic 518 
asthma, those one being allergic to fungi having a higher percentage of them [100].  519 
IL-17 has become a very interesting target for the development of therapies 520 
towards autoimmune diseases, especially psoriasis, which displays a high infiltration of 521 
neutrophils in the damaged tissue. Immunofluorescence and immunohistochemistry 522 
experiments detected IL-17A in neutrophils present in biopsies from moderate-to-523 
severe psoriasis patients [92]. Since no mRNA expression was observed in neutrophils 524 
isolated from active plaques, the authors suggested that IL-17 might be stored (pre-525 
formed) by neutrophils [92]. Furthermore, because treatment of these patients with 526 
secukinumab, a human monoclonal anti-IL-17A antibody, was found to promote a 527 
clearance of neutrophils in the psoriasis plaques and decrease CXCL8 mRNA 528 
expression, authors proposed that IL-17A may have a role in the cross-talk between 529 
neutrophils and keratinocytes leading to the release of CXCL8 and further neutrophils 530 
recruitment [92]. A different study identified IL-17A-positive neutrophils and mast 531 
cells in psoriasis biopsies by immunofluorescence, leading the authors to state that 532 
both cell types represent the major sources of IL-17 in human skin [81]. Moreover, as 533 
detected by immunofluorescence of psoriasis biopsies, neutrophils and mast cells were 534 
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found to release IL-17A during extrusion of extracellular traps, even though authors 535 
reported that “mRNA from human neutrophils from several subjects showed either low or 536 
undetectable levels of IL-17 using real time RT-PCR and Affymetrix gene array experiments 537 
(M.J.Kaplan, data not shown)”, suggesting, similarly to Reich et al (ref), that IL-17A is pre-538 
formed and stored intracellularly by human neutrophils and mast cells[81]. However, 539 
a recent report by Yamanaka et al. [91] contradicts the notion that human neutrophils 540 
represent the major source of IL-17A in psoriasis. Accordingly, authors show no 541 
evident IL-17A mRNA expression in highly purified populations of neutrophils 542 
isolated from peripheral blood of psoriasis patients [91]. However,  authors show that 543 
IL-17A expression become evident if neutrophils are isolated by gradient 544 
centrifugation only since they are contaminated by CD3+ lymphocytes, which generate 545 
false-positive results for IL-17A mRNA expression[91]. In the case of RA and psoriatic 546 
arthritis (PsA), a study demonstrated the presence of IL-17A expressing–neutrophils, 547 
-mast cells and –T cells within the inflamed synovial membrane from these patients 548 
[101]. Using immunohistochemistry for IL-17A and dual-immunofluorescence 549 
staining for CD15 and IL-17A, authors found that the percentage positivity of IL-17A 550 
was highest in neutrophils[101]. Opposite results were however reported by van 551 
Baarsen et al. [93], who failed to detect a co-localisation of IL-17A with CD15 by dual-552 
immunofluorescence staining of synovial biopsies from RA, PsA and inflammatory 553 
osteoarthritis (OA) patients [93]. The contrasting results between the two latter studies 554 
are likely explained by the different antibodies used, as Moran et al [101] utilized 555 
polyclonal anti-IL-17A (polyclonal goat, R&D systems), while van Baarsen et al. [93, 556 
101] performed the dual-immunofluorescence using a monoclonal antibody from the 557 
same manufacturer. That is not trivial, taking into account in fact Tamarozzi et al.’s 558 
paper [102]. These authors, in fact, initially reported the presence of IL-17A-positive 559 
neutrophils in Wolbachia-positive Onchocerca volvulus nodules by 560 
immunohistochemistry (IHC) [102]. Subsequently, they found that IL-17A protein is 561 
not detectable in highly pure population of neutrophils (99.9 %) using alternative 562 
assays, including western blot and ELISA or RT-qPCR for mRNA expression [102].  563 
Based on these premises, this study has the objective to clarify whether human 564 
neutrophils express and/or produce IL-17. To do so, we have used highly pure 565 
populations of human neutrophils (> 99.7 %) to evaluate the mRNA expression and 566 
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production of IL-17 members and related receptors, in response to various stimuli, 567 
including those supposed to be very effective according to the literature.  568 
569 
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2 MATERIALS AND METHODS 571 
 572 
 Cell purification and culture 573 
Neutrophils were isolated from buffy coats of healthy donors and manipulated 574 
under endotoxin-free conditions. In selected experiments, neutrophils were also 575 
isolated from peripheral blood of patients with severe. After Ficoll-Paque gradient 576 
centrifugation of buffy coats or peripheral blood, followed by dextran sedimentation 577 
of granulocytes and hypotonic lysis of erythrocytes, neutrophils were isolated to reach 578 
99.7 ± 0.2 % purity by positively removing all contaminating cells using the EasySep 579 
neutrophil enrichment kit (StemCell Technologies, Vancouver, Canada) [17]. 580 
Neutrophils were then suspended at 5×106/ml in RPMI 1640 medium supplemented 581 
with 10 % low (< 0.5 EU/ml) endotoxin FBS (BioWhittaker-Lonza, Basel, 582 
Switzerland), incubated with or without 0.2-50 µM R848, 5-50 µM R837, 500 g/ml 583 
particulate -glucan (Invivogen, San Diego, CA, USA), 0.1-100 µg/ml ultrapure LPS 584 
(from E. coli 0111:B4 strain, Alexis, Enzo Life Sciences, Farmingdale, NY, USA), 1 585 
µg/ml Pam3CSK4 (Invivogen), 50 µg/ml poly(I:C) (Invivogen), 1000 U/ml G-CSF 586 
(Myelostim, Italfarmaco Spa, Milano, Italy), 100 U/ml IFN (R&D Systems, 587 
Minneapolis, MN, USA), 10 ng/ml GM-CSF (Miltenyi Biotec), 5 ng/ml TNF 588 
(Peprotech, Rocky Hill, NJ, USA), 2-20 µg/ml IL-6 (R&D Systems), 0.2-2 µg/ml IL-589 
23 (R&D Systems), 100-500 ng/ml IL-17A (R&D Systems), 10 µg/ml anti-IL-17A 590 
neutralizing Abs (secukinumab, Novartis, Basel, Switzerland)  100 nM fMLF, 500 591 
g/ml curdlan (Sigma, Saint Louis, MO, USA), 20 µg/ml phorbol mysistate acetate 592 
(PMA) (Sigma), 1 µg/ml Ionomycin (Sigma), 100 µg/ml CpG oligodeoxynucleotides 593 
(ODN) (Invivogen), 1000 U/ml PEGylated IFNα-2a (Pegasys, Roche, Basel, 594 
Switzerland). Inactivated conidia and hyphae from Aspergillus fumigatus were kindly 595 
provided by prof. Luigina Romani (University of Perugia), and used at a neutrophil-596 
fungi ratio of 1:5 for A. fumigatus conidia and 1:1 for A. fumigatus hyphae, as previously 597 
described [103]. Neutrophils were plated either in 6/24-well tissue culture plates or in 598 
polystyrene flasks (from Greiner Bio-One, Kremsmünster, Austria) for culture at 37°, 599 
5 % CO2 atmosphere. After the desired incubation period, neutrophils were either 600 
processed for chromatin immunoprecipitation (ChIP) experiments, or collected and 601 
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spun at 300 × g for 5 min for other types of assays. In the latter case, cell-free 602 
supernatants were immediately frozen in liquid nitrogen and stored at – 80°, while the 603 
corresponding cell pellets were either extracted for total RNA or lysed for protein 604 
analysis. Th17 clones, kindly provided by prof. Francesco Annunziato (University of 605 
Firenze), were stimulated for up 72 h with anti-CD3 and anti-CD28 mAbs (5µg/ml, 606 
BD Biosciences) essentially as described [104].  607 
 608 
 Flow Cytometry 609 
For flow cytometry, 105 neutrophils were harvested after the desired treatment, 610 
centrifuged and suspended in 100 µL PBS containing 10 % complemented-inactivated 611 
human serum for FcR blocking. Neutrophils were then stained for 15 min at T room 612 
with: APC anti-human IL-17RA/CD217 (clone 424LTS) and APC mouse IgG1к, as 613 
isotype control (clone P3.6.2.8.1) from eBioscience (San Diego, CA, USA); PE anti-614 
human IL-17RC (clone 309822) and mouse PE IgG2B isotype control from R&D 615 
systems; PE-vio770 anti-human CD11b (clone ICRF44), FITC anti-human CD66b 616 
(clone G10F5) and PerCP-Cy5.6 anti-human CD16 (clone 3G8) from Biolegend (San 617 
Diego, California, USA); APC anti-human CD62L (clone 145/15 Miltenyi Biotec), all 618 
at working dilutions specified in the corresponding datasheets. For intracellular 619 
staining, neutrophils were incubated for 20 min in intracellular (IC) fixation buffer 620 
(eBioscience), followed by permeabilization buffer (eBioscience) and 1h incubation 621 
with antibody in the presence of Fc block. Sample fluorescence was then measured by 622 
MACSQuant Analyzer (Miltenyi Biotec), while data analysis performed using FlowJo 623 
software Version 10 from Tree Star (Ashland, OR, USA) [18]. For neutrophils within 624 
the blood of psoriatic patients, 100 µl whole blood were stained with APC anti-human 625 
IL-17RA and PE anti-human IL-17RC Abs in combination with the following mAbs: 626 
VioBlue anti-human CD14 (clone TÜK4), PE anti-human CD56 (clone AF12-7H3), 627 
PE-Vio770 anti-human CD3 (clone BW264/56), APC anti-human CD19 (clone LT19) 628 
from Miltenyi; Brilliant Violet anti-human CD45 (clone 2D1), PerCP-Cy5.5 anti-629 
human CD16 (clone 3G8) and APC-Cy7 anti-human HLA-DR (clone L243) from 630 
Biolegend. After red cells lysis by the ammonium chloride buffer, sample fluorescence 631 
was immediately measured as previously described. 632 
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 Respiratory burst activity 633 
After isolation, neutrophils were suspended at the concentration of 2 x 106 634 
cells/ml in HBSS buffer containing 0.5 mM CaCl2 and 1 mg/ml glucose. Neutrophils 635 
(100 µl/well) were then distributed in a 96-well plate and then incubated for 10 min at 636 
37º prior to the addition of 80 µM cytochrome C, 2 mM NaN3 (Sigma) and the 637 
indicated stimuli, including 20 ng/ml phorbol mysistate acetate (PMA) as control. 638 
Plates were then incubated at 37º in an automated ELx808IU microplate reader 639 
(BioTek Instruments, Inc., Winooski, VT) to record cytochrome C reduction  (via 640 
absorbance at 550 and 468 nm at intervals of 5 min for 90 min. O2
- production was 641 
finally calculated using an extinction coefficient of 24.5 mM [105]. 642 
 643 
 Immunohistochemistry 644 
Cytospin preparations of neutrophils [106] cultured with the indicated stimuli 645 
were stained by ematoxylin and eosin for morphological evaluation. After coverslip 646 
removal, specimens were rehydrated through a scale of alcohols, with endogenous 647 
peroxidase activity blocked by treatment with 0.3 % H202 in methanol for 20 min. Anti-648 
human IL-17A (AF-317-NA) and IL-17B (AF1248) goat IgG pAbs from R&D 649 
Systems were 1:50 diluted, added to specimens for 60 min and then revealed using the 650 
goat HRP-polymer (Biocare Medical, Pacheco, CA, USA) followed by 651 
diaminobenzidine (DAB). Omission of the primary antibody was also performed as 652 
negative control. For IL-17A and IL-17B tissue immunostaining, four-micron tissue 653 
sections from two FFPE cases of pustular psoriasis were deparaffinised and rehydrated 654 
through a scale of alcohols. Endogenous peroxidase activity was then blocked by 655 
treatment with 0.3 % H202 in methanol for 20 min. Epitope retrieval in sections was 656 
performed using a slide steamer in 1.0 mM ethylene diamine EDTA buffer (pH 8.0), 657 
for 40 min at 98º C [107]. IL-17A and IL-17B antibodies were diluted 1:50 and revealed 658 
using goat HRP-polymer (IHC) or horse anti-goat IgG biotinylated antibody (Vector 659 
Laboratories, Peterborough, UK) followed by streptavidin-FITC (Southern Biotech, 660 
Birmingham, AL, USA). DAPI was used for counterstaining. For double IHC, anti-661 
IL-17A and IL-17B Abs were diluted 1:500 and after revelation (as detailed above), 662 
anti-CD66b abs (diluted 1:80 from BioLegend) were added to the sections. Mach4 AP 663 
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polymer was used as secondary antibody followed by Ferangi Blue as chromogen. 664 
Ematoxylin was used for counterstaining. 665 
 666 
 667 
 Enzyme-linked immunosorbent assay 668 
Cytokine concentrations in cell-free supernatants and cell lysates were 669 
measured by commercial enzyme-linked immunosorbent (ELISA) kits specific for: IL-670 
17A (DY317 from R&D systems and 88-7176 from eBioscience), IL-17A/F (88-7117, 671 
eBioscience), IL-17B [ABKA2223 from Abnova (Taipei, Taiwan) and ab171344 from 672 
Abcam (Cambridge, United Kingdom)], IL-17F (887478, eBioscience) and CXCL8 673 
(Mabtech, Nacka Strand, Sweden). ELISA detection limits were 4 pg/ml (eBioscience) 674 
and 15.6 pg/ml (R&D) for IL-17A, 30 pg/ml for IL-17A/F, 24 pg/ml (Abnova) and 675 
10 pg/ml (Abcam) for IL-17B, 16 pg/ml for IL-17F, 8 pg/ml for CXCL8.  676 
 677 
 678 
 Reverse transcription quantitative real-time PCR (RT-qPCR) 679 
Total RNA was extracted from neutrophils by the RNeasy Mini Kit (Qiagen, 680 
Venlo, Limburg, Netherlands) as previously detailed [47]. To completely remove any 681 
possible contaminating DNA, an on-column DNase digestion with the RNase-free 682 
DNase set (Qiagen) was performed during total RNA isolation. Total RNA was then 683 
reverse-transcribed into cDNA using Superscript III (Life Technologies, Carlsbad, 684 
CA, USA) and random hexamer primers (Life Technologies), while qPCR was carried 685 
out using Fast SYBR® Green Master Mix (Life Technologies). Sequences of gene-686 
specific primer pairs (Life Technologies) are listed in Table 1. Data were calculated by 687 
Q-Gene software (http://www.gene-quantification.de/download.html) and expressed 688 
as mean normalized expression (MNE) units after GAPDH normalization [108]. 689 
 690 
 691 
 692 
 693 
 694 
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 695 
 696 
Table 1 | List of human primer sets utilized for RT-qPCR assays 697 
Gene Sequence 
forward primers reverse primers 
GAPDH AACAGCCTCAAGATCATCAGC GGATGATGTTCTGGAGAGCC 
RPL32 AGGGTTCGTAGAAGATTCAAGG GGAAACATTGTGAGCGATCTC 
SOCS3 GGCCACTCTTCAGCATCTC ATCGTACTGGTCCAGGAACTC 
IL-1ra TTCCTGTTCCATTCAGAGACGAT AATTGACATTTGGTCCTTGCAA 
IL-17A CTCATTGGTGTCACTGCTACTG CCTGGATTTCGTGGGATTGTG 
IL-17B ACAACCTGCTGTTTCTTCTTACC ACCATCTCCTCGATGTTCCTC 
IL-17C GCTACTCGGCTGAGGAACTG GTGTCCACACGGTATCTCCA 
IL-17D CTACTGGAGCAGCTGTACG GTCGTAGGAGATTCTGTAGGC 
IL-17E TGGAGATATGAGTTGGACAGAG GCTAAGGAAACACGGTACAG 
IL-17F CTGGAATTACACTGTCACTTGG GAGATGTCTTCCTTTCCTTGAG 
IL-17RA AGACACTCCAGAACCAATTCC TCTTAGAGTTGCTCTCCACCA 
IL-17RC GTCACTGTGGACAAGGTTCTC CTCCAACAGTAGCACATCGTC 
TNFα GAGCACTGAAAGCATGATCC CGAGAAGATGATCTGACTGCC 
CXCL8 CTGGCCGTGGCTCTCTTG CCTTGGCAAAACTGCACCTT 
 698 
 699 
 Immunoblotting experiments 700 
Total neutrophil proteins were recovered from protein-rich ﬂow-through 701 
solutions after the ﬁrst centrifugation step of the RNeasy mini kit (Qiagen) procedure 702 
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used for total RNA extraction, as previously described [47]. Lysates of human cerebral 703 
cortex were kindly provided by Prof. Bruno Bonetti (Department of Neurosciences, 704 
Biomedicine and Movement Sciences, University of Verona) and suspended in RIPA 705 
buffer (100 mM Tris pH 7.5, 600 mM NaCl, 4 % Triton X-100, 4 % sodium 706 
deoxycholate and 0.4 % SDS) supplemented with inhibitors of proteases (5 µg/ml 707 
leupeptin, 5 µg/ml pepstatin and 1 mM PMSF) and phosphatases (1 mM Na3VO4, 20 708 
µM PAO and 50 mM NaF). Protein-rich ﬂow-through from neutrophils and extracts 709 
of cerebral cortex were then immunoblotted by standard procedures using the anti-710 
human IL-17A (AF-317-NA) and IL-17B (AF1248) goat IgG pAbs from R&D 711 
Systems, the anti-human phospho-STAT3 (Tyr705) rabbit pAbs (#9131, Cell 712 
Signaling, Beverly, MA, USA); the anti-human STAT3 rabbit pAbs (sc-482, Santa Cruz 713 
Biotechnology, Dallas, TX, USA) and anti-human β-actin mAbs (A5060 from Sigma). 714 
Blotted proteins were detected by using the Odyssey infrared imaging system (LI-COR 715 
Biosciences, Lincoln, NE, USA) [47]. 716 
 717 
 718 
 Chromatin Immunoprecipitation (ChIP) assays 719 
Protein-DNA cross-linking was achieved by incubating 5 × 106  neutrophils 720 
with 1% formaldehyde for 10 minutes at room T under gentle agitation. Cross-linking 721 
reaction was stopped by adding glycine to a final concentration of 125 mM and 722 
incubating at room T for another 5 minutes. After fixation, cells were washed with ice-723 
cold PBS, collected by scraping, and finally pelleted by centrifugation (5 min, 300 x g, 724 
4 °C). Pellet was resuspended in 900 µl of lysis buffer L1 (50 mM Tris, pH 8.0, 2 mM 725 
EDTA, 0.1% IGEPAL, 10% glycerol) supplemented with proteases (5 µg/ml 726 
leupeptin, 5 µg/ml pepstatin, and 1 mM PMSF) and phosphatases (1 mM Na3VO4, 20 727 
µM PAO, and 50 mM NaF) inhibitors. Resulting nuclei were pelleted at 1000 x g at 4 728 
°C and resuspended in 300 µl lysis L2 buffer (50 mM Tris, pH 8.0, 1% SDS, 5 mM 729 
EDTA) including protease inhibitors. Chromatin was sheared to an average DNA size 730 
of 300-400 bp by sonication [6 pulses of 15 seconds at 50% maximum potency with 731 
15 seconds pause on wet ice using a BANDELIN SONOPLUS ultrasonic 732 
homogenizers HD 2070 (Bandelin, Berlin, Germany). The lysate was then cleared by 733 
centrifugation (10 min, 13,000 x g, 12 °C) to remove debris, and diluted 10 times in 734 
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dilution buffer (50 mM Tris, 5 mM EDTA, 200 mM, 0.5 % IGEPAL). 735 
Immunoprecipitations were carried out overnight at 4°C using 1 μl anti-H3K4me1 736 
(ab8895) and anti-H3K27Ac (ab4729) (Abcam, Cambridge, United Kingdom). Then, 737 
immune complexes were collected by adding 15 µl of protein A sepharose-coupled 738 
magnetics beads (GE Healthcare, Piscataway, NJ, USA) for 1h at 4°C in gentle 739 
rotation. Beads were then immobilized on a magnetic support and, after keeping 5 % 740 
of the supernatant [unbound DNA used to normalize the amount of 741 
immunoprecipitated DNA (specified in the text as “input” DNA)] and washed three 742 
times in washing buffer (20 mM Tris, pH 8.0, 0.1% SDS, 2 mM EDTA, 1% IGEPAL, 743 
500 mM NaCl) and one in TE. The resulting protein complexes were then eluted in 744 
TE containing 2 % SDS and reversed crosslinked by incubation overnight at 65 °C. 745 
The DNA was purified by QiaQuick PCR purification kit (Qiagen) according to the 746 
manufacturer’s instructions and eluted in 50-100 µl. 2 µl of the immunoprecipitated 747 
DNA, which was used in each quantitative PCR (qPCR) reaction, was carried out using 748 
Fast SYBR® Green Master Mix (Life Technologies). To establish the background 749 
levels of ChIP experiments, the precipitation signal was quantified also at the promoter 750 
of prolactin (PRL) since it is completely silent in myeloid cells[109]. The 751 
coimmunoprecipitated material was subjected to qPCR analysis using the following 752 
promoter specific primers (purchased from Life Technologies) listed in the Table 2. 753 
 754 
 755 
 ChIP-seq 756 
Purified DNA from H3K27Ac and H3K4me1 ChIP assays (performed as 757 
described in the previous paragraph) was adapter-ligated and PCR-amplified for 758 
sequencing on HiSeq2000 platform (Illumina, Cambridge, UK) using TruSeq DNA 759 
Library Prep Kit (Illumina). After sequencing, reads were quality-filtered according to 760 
the Illumina pipeline. Single end (51 bp) reads were then mapped to the human 761 
genome (Genome Reference Consortium GRCh37, Feb/2009) using BOWTIE v1.0.0 762 
[110]. Only reads with no more than two mismatches (when compared to the reference 763 
genome) were converted to tag directories using HOMER’s module known as 764 
“makeTagDirectory”, and then converted to BedGraph format using HOMER’s 765 
module known as “makeUCSCfile”, to be finally normalized to 107 total tag counts. 766 
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ChIP-seq signals were visualized using Integrative Genomics Viewer (IGV). For 767 
H3K4me1 and H3K27Ac ChIP-seqs of Th17 cells, 36 bp reads, already filtered and 768 
mapped, were downloaded from database of the “roadmap epigenomics project” 769 
(http://egg2.wustl.edu/roadmap/web_portal/processed_data.html) (NIH 770 
Epigenomics Roadmap Initiative). Aligned reads were then converted to BedGraph 771 
format and normalized to 107 total tag counts. 772 
 773 
Table 2 |List of human primer sets utilized for qPCR of ChIP assays 774 
 775 
 776 
 777 
 Gene Expression Data Set of normal hematopoietic stem and progenitor 778 
cells 779 
Gene expression profiles of cells from normal bone marrow at different stages 780 
of human granulopoiesis were downloaded from Gene Expression Omnibus Database 781 
(GEO number: GSE42519)[111]. Gene expression means and standard errors were 782 
calculated from the values of the biological replicates present in the GEO database.  783 
 784 
 785 
 Statistical analysis 786 
Data are expressed as mean ± SEM. Statistical evaluation was performed by 787 
using, depending on the experiment type, Student’s t test, 1-way ANOVA followed by 788 
ChIP primer 
name 
Location (relative 
to the gene TSS) 
Sequence 
forward primers reverse primers 
IL-17A#1 -30260 to -30119 CACAAAACCGCAGGTACTCAG TCACCACAAAGCCCACAAAG 
IL-17A#2 -177 to -53 TGCCCTTCCCATTTTCCTTC TCCTTCTGTGGTCACTTACG 
IL-17A#3 +704 to +898 TAGCACCAACAGCACTTCTAGC CAGCACATGCATCATTGTCAG 
IL-17F#1 -19472 to -19371 AAGACATGACCCCCAGAGATC GTTTTCCTTGAGAGCAATCGTG 
IL-17F#2 -223 to -132 CAATGGGGGTGGAAGTAGG CCGAAGGGGAACAAAAGGG 
IL-17F#3 +1411 to +1532 CCATTGTTATCCCCACCATAC GGCATAGGCTTTGATGTCAG 
SOCS3 -113 to -45 TCTCTGCTGCGAGTAGTGAC CCGCCCCCCGATTCCTGGA 
PRL +386 to +506 AGGGAAACGAATGCCTGATT GCAGGAAACACACTTCACCA 
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Tukey’s post hoc test or 2-way ANOVA followed by Bonferroni’s post hoc test. P 789 
values < 0.05 were considered as statistically significant. 790 
 791 
 792 
       Study approval 793 
Human samples were obtained following informed written consent by both 794 
healthy donors and psoriatic patients. All experimental protocols were approved by 795 
the Ethic Committee of the Azienda Ospedaliera Universitaria Integrata di Verona 796 
(Italy). The methods were carried out in accordance with the approved guidelines. 797 
798 
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3 RESULTS 800 
 801 
 Human neutrophils incubated with various agonists in vitro do not 802 
express IL-17 members, either at mRNA or at protein levels  803 
 804 
We have previously shown that human neutrophils (> 99.7 % purity), in vitro 805 
incubated with 100 U/ml IFN and/or 100 ng/ml LPS for up to 20 h, neither express 806 
IL-17A or IL-17F mRNA, nor produce IL-17A or IL-17F protein [87]. Additional RT-807 
qPCR experiments not only confirmed our previous data (Figure 6A, left panel), but 808 
also revealed that other agonists, including 5 µM R848 and/or 1000 U/ml IFN 809 
(Figure 6B, left panel), 10 ng/ml GM-CSF, 100 nM fMLF (Figure 6C, left panel), 810 
1000 U/ml G-CSF and 5 ng/ml TNF (Figure 6D, left panel), similarly fail to induce 811 
an accumulation of transcripts encoding IL-17A (Figure 6A-D, left panels), IL-17F 812 
(Figure 6A-D, central panels), IL-17B, IL-17C, IL-17D and IL-17E (data not 813 
shown) in neutrophils. LPS and/or IFN, R848 and/or IFN, GM-CSF or fMLF, 814 
however, were found to modulate the expression of CXCL8 mRNA (Figure 6A-C, 815 
right panels), while G-CSF or TNF modulated that of IL-1ra mRNA (Figure 6D, 816 
right panel), as expected [47, 57, 112]. Consistent with the gene expression data, 817 
neither IL-17A, IL17F (Table 3) nor IL-17A/F and IL-17B (data not shown) 818 
proteins could be detected in supernatants harvested from neutrophils incubated for 819 
20 h with either the stimuli used for the experiments shown in Figure 6, or with 500 820 
µg/ml -glucan, 500 µg/ml curdlan, 1µg/ml Pam3CSK4, 50 µg/ml poly(IC) and 100 821 
µg/ml CpG ODN. Noteworthy, ELISA kits from two different commercial sources 822 
(see M&M) were used for either IL-17A or IL-17B, in both cases giving equivalent 823 
information. On the other hand, stimulus-dependent levels of CXCL8 could be 824 
measured in the same supernatants, indicating that stimuli were effective and 825 
neutrophils fully responsive (Table 3). In any case, validity of both IL-17 primers and 826 
ELISA kits was demonstrated by the detection of either IL-17A, IL-17D, IL-17E and 827 
IL-17F transcripts in human Th17, but not Th1, clones (data not shown), or IL-17A 828 
and IL-17F proteins in supernatants from CD4+ T cells activated with anti-CD3/anti-829 
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CD28 mAbs (data not shown). We could also detect intracellular IL-17B in lysates of 830 
human cerebral cortex (data not shown), as expected [113].  831 
 832 
 833 
Figure 6 | IL-17A, IL-17F, CXCL8 and IL-1ra mRNA expression levels in neutrophils 834 
activated by a variety of stimuli. 835 
Human neutrophils were cultured at 5 × 106/ml for up to 20 h with: A, 100 U/ml IFN and/or 836 
100 ng/ml LPS; B, 1000 U/ml IFN and/or 5 µM R848; C, 10 ng/ml GM-CSF or 100 nM 837 
fMLF; D, 1000 U/ml G-CSF or 5 ng/ml TNF. IL-17A, IL-17F, CXCL8 and IL-1ra mRNA 838 
expression was evaluated by RT-qPCR and data depicted as mean normalized expression 839 
(MNE) units after GAPDH mRNA normalization. The experiments depicted in each 840 
panels (A-D) are representative of at least two ones with similar results. Error bars stand 841 
for standard errors calculated from triplicate qPCR reactions. 842 
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Table 3 | Lack of IL-17A production by neutrophils activated under various 843 
experimental conditions. 844 
neutrophils 
stimuli IL-17A (pg/ml) IL-17F (pg/ml) CXCL8 (ng/ml) 
- nd nd 0,07 ± 0,05 
 500 μg/ml -glucan nd nd 0,41 ± 0,16 * 
500 μg/ml curdlan nd nd 0,49 ± 0,02 *** 
10 ng/ml GM-CSF nd nd 0,30 ± 0,13 * 
100 nM fMLF nd nd 0,33 ± 0,12 * 
5 ng/ml TNF nd nd 1,22 ± 0,90 
1 μg/ml Pam3CyS nd nd 10,31 ± 3,85 ** 
50 μg/ml Poly(I:C) nd nd 0,02 ± 0,02 
100 ng/ml LPS nd nd 0,89 ± 0,22 ** 
5 μM R848 nd nd 9,47 ± 3,35** 
100 μg/ml CpG ODN nd nd 5,57 ± 1,1 *** 
100 U/ml IFN nd nd 0,10 ± 0,04 
100 U/ml IFN +  
100 ng/ml LPS 
nd nd 2,51 ± 1,1 ** 
CD4+ T cells 
- nd nd 2,51 ±  1,1 
5 µg/ml antiCD3/CD28 739,6 ± 56,6 *** 948,9 ± 95,4 *** 172,6 ±  25,1 *** 
Human neutrophils (5 × 106/ml) were cultured for 20 h with the indicated stimuli. CD4+ T 845 
cells were stimulated for up to 72 h with anti-CD3 and anti-CD28 mAbs. Cell-free 846 
supernatants were then harvested and IL-17A, IL-17F and CXCL8 content measured by 847 
specific ELISA. Values are represented as the mean ± SD or as not detected (nd) when the 848 
values were under the detection limit (n = 3). Asterisks stand for significant increases as 849 
compared to untreated cells: *p < 0.05, ** p < 0.01, *** p < 0.001, by Student’s t-test.  850 
 851 
 852 
In other experiments, neutrophils were incubated for 2 h with 20 µg/ml IL-6 853 
plus 2 µg/ml IL-23, in the presence or the absence of inactivated conidia, or hyphae, 854 
from A. fumigatus. These experiments were done with the purpose to mimic, as much 855 
as possible, recently described experimental conditions shown to induce not only IL-856 
17A and IL-17F, but also IL-17RC, mRNA expression [94, 95, 97-99]. Neutrophils 857 
were also incubated with 100-500 ng/ml IL-17A to reinvestigate their eventual 858 
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responsiveness. As shown in Figure 7, neutrophils treated with either IL-17A, or IL-859 
6 plus IL-23 (in the presence or the absence of inactivated A. fumigatus 860 
conidia/hyphae), showed neither induction of IL-17A (Figure 7A), IL-17F (Figure 861 
7B) and IL-17RC (Figure 7C) mRNAs, nor upregulation of the constitutively 862 
expressed IL-17RA transcript levels (Figure 7D). Similar results were obtained when 863 
incubation under identical conditions was prolonged up to 6 h (data not shown). 864 
Elevated levels of IL-17RC mRNAs were however detected in HBECs (data not 865 
shown), used as control cells [87], thus confirming that our primers were correctly 866 
designed. Importantly, the capacity of IL-6 plus IL-23 to stimulate neutrophils was 867 
evidenced by their ability to time-dependently promote STAT3 phosphorylation 868 
(Figure 7E), as well as to upregulate SOCS3 mRNA expression (Figure 7F), such an 869 
effect being potentiated by the presence of inactivated A.fumigatus conidia/hyphae 870 
(Figure 7F). By contrast, IL-17A-treatment influenced neither SOCS3 (Figure 7F), 871 
nor CXCL8 (data not shown) mRNA levels in neutrophils. Finally, no IL-17A 872 
(Figure 8A), IL-17F (Figure 8B) or IL-17AF (data not shown) proteins were 873 
detected either intracellularly in, or in supernatants harvested from, neutrophils 874 
incubated with IL-6 plus IL-23, in the presence or the absence of inactivated A. 875 
fumigatus conidia/hyphae. Under the same experimental conditions, CXCL8 protein 876 
was newly synthesized and released by neutrophils incubated with IL-6 plus IL-23 in 877 
the presence of inactivated A. fumigatus conidia/hyphae, but not in their absence 878 
(Figure 8C). Also using intracellular flow cytometry, consistent with previous findings, 879 
IL-17A expression was not detected in human neutrophils untreated or stimulated with 880 
R848 or IL-6 plus IL-23 (Figure 9). In fact, in all the conditions tested, the 881 
fluorescence signal obtained using the isotype control antibody was higher than that 882 
achieved with specific anti-IL-17A antibodies (Figure 9). Taken together, data extend 883 
our previous findings on the inability of human neutrophils to express IL-17 members 884 
at mRNA and protein levels under various activating conditions. Data also confirm 885 
and extend the inability of IL-17A to directly modify IL-17A, IL-17F, IL-17RA, IL-886 
17RC, SOCS3 and CXCL8 gene expression in human neutrophils [87]. 887 
 888 
 889 
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 890 
 891 
Figure 7| No induction of IL-17A, IL-17F and IL-17RC mRNA expression in 892 
neutrophils incubated with IL-6 plus IL-23 in combination with inactivated 893 
A.fumigatus hyphae or conidia 894 
Neutrophils (5 × 106/ml) were incubated either with 100 ng/ml  rIL-17A for 2 h, or with or 895 
without 20 µg/ml IL-6 plus 2 µg/ml IL-23 for 1 h, prior to adding or not inactivated A. 896 
fumigatus conidia (1:5 neutrophils/conidia ratio) and hyphae (1:1 neutrophils/hyphae ratio) for 897 
additional 1 h. Cells were then harvested for mRNA extraction to evaluate IL-17A (A), IL-898 
17F (B), IL-17RC (C), IL-17RA (D) and SOCS3 (F) mRNA expression by RT-qPCR. Gene 899 
expression data are depicted as mean normalized expression (MNE) units after GAPDH 900 
mRNA normalization (means ± SEM, n = 4). Asterisks stand for significant differences as 901 
compared to untreated cells: * p < 0.05, ** p < 0.01, by Student’s t-test. (E) Immunoblot 902 
displaying STAT3 tyrosine phosphorylation in neutrophils, either untreated or cultured for 15 903 
or 60 min with 20 µg/ml IL-6 plus 2 µg/ml IL-23 (representative experiment, n = 2). 904 
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 905 
Figure 8 | Lack of IL-17A and IL-17F production by human neutrophils activated by 906 
IL-6 plus IL-23 in a combination with inactivated A.fumigatus hyphae or conidia 907 
Neutrophils (5 × 106/ml) were incubated with or without 20 µg/ml IL-6 plus 2 µg/ml IL-23 908 
and then cultured for 3 more hours in the presence or not of inactivated A. fumigatus conidia 909 
and hyphae (used 1:5 and 1:1 respectively). After incubation, IL-17A (A), IL-17F (B) and 910 
CXCL8 (C) levels were determined in cell-free supernatants and in corresponding cell pellets 911 
by specific ELISA. Values are depicted as the mean ± SD or as not detected (nd) when values 912 
were under the detection limit (n = 3). Asterisks stand for significant differences as compared 913 
to untreated cells: * p < 0.05, ** p < 0.01, by Student’s t-test. 914 
 915 
 916 
 917 
 918 
 919 
Figure 9| No induction of intracellular IL-17A expression in CD66b+ neutrophils 920 
Expression of intracellular IL-17A by flow cytometry in CD66b+ neutrophils cultured for 1 h 921 
without or with 5 µM R848 or 20 µg/ml IL-6 plus 2 µg/ml IL-23. Graphs depict a 922 
representative experiment out of three independent ones with similar results. . Filled and empty 923 
histograms show staining with IL-17A specific Abs and isotype control Abs, respectively. 924 
 925 
 926 
 927 
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 Human neutrophils incubated with IL-6 plus IL-23, in the presence or the 928 
absence of inactivated A.fumigatus hyphae or conidia, do not express IL-929 
17RC. 930 
 931 
Flow cyometry experiments confirmed [87] that neutrophils, either freshly 932 
isolated (Figure 10A), or incubated for 3 h in the absence (Figure 10B) or the presence 933 
of IFN plus LPS (Figure 10C), display only surface IL-17RA, but not IL-17RC. No 934 
IL-17RC surface levels were also observed in neutrophils incubated with either R848 935 
(Figure 10D), or IL-6 plus IL-23 (Figure 10E-H), in the latter case either in the 936 
absence (Figure 10E) or in the presence of inactivated A.fumigatus conidia/hyphae 937 
(Figure 10F and G), or of IL-17A (Figure 10H). IL-17RA surface levels were 938 
downregulated in neutrophils treated with IFN plus LPS (Figure 10C), R848 (Figure 939 
10D) and IL-6 plus IL-23 with IL-17A (Figure 10H). In these experiments, HBEC 940 
were used again as positive control for both IL-17RA and IL-17RC surface expression 941 
(data not shown) [87]. It should be pointed out that, for the investigation of surface 942 
IL-17RC, we have been using the same anti-IL-17RC antibody used in Taylor et al.’s 943 
study [94] directly PE-conjugated, other than the anti-IL-17RC biotin-conjugated 944 
antibodies that necessitate PE-conjugated streptavidin for detection [87], without 945 
noticing any difference between them. By the way, IFN plus LPS (Figure 10C) and 946 
R848 (Figure 10D), as well as IL-6 plus IL-23, either alone (Figure 10E), or in the 947 
presence of either inactivated A.fumigatus conidia/hyphae (Figure 10F and G), or of 948 
IL-17A (Figure 10H), variably modulated the expression of both CD11b and CD62L. 949 
All in all, data illustrate that, in our hands, IL-6 plus IL-23, regardless of their 950 
combination with inactivated A.fumigatus conidia/hyphae, and despite their capacity to 951 
upregulate SOCS3 mRNA expression (Figure 7F), are unable to induce the expression 952 
of IL-17RC, thus leaving human neutrophils unresponsive to IL-17.  953 
 954 
 52 
 
 955 
 956 
Figure 10 | IL-17RA, IL-17RC, CD62L and CD11b surface expression in neutrophils 957 
activated under various experimental conditions. 958 
Expression of surface IL-17RA, IL-17RC, CD62L and CD11b was evaluated by flow 959 
cytometry in neutrophils either freshly isolated (A), or cultured for 3 h without (B) or with 100 960 
U/ml IFN plus 100 ng/ml LPS (C), 5 µM R848 (D), 20 µg/ml IL-6 plus 2 µg/ml IL-23 alone 961 
(E) or in the presence of inactivated A. fumigatus conidia (F), A. fumigatus hyphae (G) and 500 962 
ng/ml rIL-17A (H). Graphs depict a representative experiment out of three independent ones 963 
with similar results. Filled and empty histograms show staining with specific and isotype 964 
control Abs, respectively. 965 
 966 
 967 
 968 
 O2- production by neutrophils stimulated with inactivated A. fumigatus 969 
hyphae after preincubation with IL-6 plus IL-23 is not modified by either 970 
exogenous IL17A or IL-17A inhibitors 971 
We then measured the capacity to release O2
- by neutrophils pretreated with or 972 
without IL-6 plus IL-23 for one h, and then incubated for one more h with inactivated 973 
A.fumigatus hyphae, in the presence or the absence of either IL-17A or anti-IL-17A 974 
neutralizing Abs (Figure 11). As control, neutrophils were also stimulated with either 975 
inactivated A.fumigatus hyphae alone or 20 ng/ml PMA (Figure 11). As shown in 976 
Figure 11, inactivated A.fumigatus hyphae were found to trigger a remarkable O2
- 977 
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production by neutrophils, even though lower than PMA. However, such O2
- release 978 
was not potentiated by the preincubation with IL-6 plus IL-23 (which, by themselves, 979 
did not trigger any O2
- production by neutrophils) (Figure 11). Under the latter 980 
experimental conditions, addition of either IL-17A or anti-IL-17A neutralizing Abs 981 
(IL-17A Abs) did not influence the effect of inactivated A.fumigatus hyphae on 982 
neutrophil-derived O2
- (Figure 11).  983 
 984 
 985 
Figure 11 | Superoxide anion production by neutrophils stimulated by inactivated 986 
hyphae from A.fumigatus in combination with IL-6 plus IL-23, IL-17A or 987 
secukinumab. 988 
Neutrophils (5 × 106/ml) were preincubated with or without 20 µg/ml IL-6 plus 2 µg IL-23 989 
for 1 h and then treated for 1 more hour with inactivated hyphae from A. fumigatus, in 990 
combination or not with 500 ng/ml IL-17A or 10 µg/ml anti-IL-17A neutralizing mAb 991 
(secukinumab). As control, neutrophils were also stimulated with 20 ng/ml PMA for 1 h. 992 
Graphs depict a representative experiment out of three independent ones with similar results. 993 
 994 
 995 
 996 
 997 
 Chromatin organization at the IL-17A and IL-17F promoters and 998 
enhancers in human neutrophils 999 
 1000 
Signatures of histone posttranslational modifications at a specific gene locus 1001 
provide indicative elements to predict whether such a gene can be transcribed or not 1002 
[29, 114]. Therefore, we evaluated the presence of histone marks associated to active 1003 
(e.g. H3K27Ac) and poised (e.g. H3K4me1) genomic regulatory elements [115] at the 1004 
IL17A and IL17F loci of human neutrophils. Genome-wide ChIP-seq assays 1005 
 54 
 
demonstrated that, in freshly isolated neutrophils, the entire genomic region containing 1006 
IL-17A and IL-17F loci is completely devoid of H3K27Ac and H3K4me1 (Figure 12). 1007 
By contrast, based on data available from the NIH Epigenomics Roadmap Initiative 1008 
[116], multiple H3K4me1 peaks are present in the same genomic regions of 1009 
PMA/Ionomcyin-stimulated Th17 cells, while H3K27Ac peaks localize at the IL-17A 1010 
locus only (Figure 12). To validate the previous data, we performed H3K27Ac and 1011 
H3K4me1 qPCR ChIPs using neutrophils incubated for 1 h either with or without 20 1012 
µg/ml IL-6 plus 2 µg/ml IL-23, as well as Th17 clones (Figure 13). Based on the 1013 
H3K4me1 peaks from the ChIP-seqs of Th17 cells [116] (Figure 12), we designed 1014 
specific primers amplifying potential regulatory regions at the IL-17A and IL-17F 1015 
genomic loci, namely IL-17A#1 and IL-17F#1 for enhancers, and IL-17A#2, IL-1016 
17A#3 and IL-17F#2 for promoters (Figure 13A and B). As expected, Th17 clones, 1017 
used as positive controls, displayed constitutively bound H3K4me1 at their IL-17A 1018 
and IL-17F promoters and enhancers (Figure 13A and B, left panels). We also 1019 
detected high levels of H3K27Ac at the IL-17A and IL-17F promoters and enhancer 1020 
of Th17 clones (Figure 13A and B, right panels), in line with their constitutive 1021 
expression of both IL-17A and IL-17F mRNA (data not shown). By contrast, we did 1022 
not observe any H3K4me1 or H3K27Ac at the IL17A and IL17F loci of neutrophils, 1023 
either under resting conditions (thus confirming the ChIP-seq data shown in Figure 1024 
12), or after incubation with IL-6 plus IL-23 (Figure 13A and B). In fact, the 1025 
H3K3me1 and H3K27Ac levels at the IL-17A and IL-17F enhancers in neutrophils 1026 
were similar to those ones present at the PRL promoter, a genomic region with a closed 1027 
chromatin conformation in myeloid cells herein used to determine the signal 1028 
background (Figure 13A and B). Notably, measurable amounts of H3K3me1 and 1029 
H3K27Ac were found at the SOCS3 promoter of neutrophils under resting conditions, 1030 
as well as of Th17 clones (Figure 13C). Interestingly, H3K27Ac levels tended to 1031 
increase in neutrophils incubated with IL-6 plus IL-23 (Figure 13C), in accordance 1032 
with a supposed STAT3-dependent induction of SOCS3 mRNA [117]. Taken 1033 
together, data indicate that the organization of the IL17A and IL17F loci in human 1034 
neutrophils is characterized by the absence of poised chromatin marks, unlike that of 1035 
IL17A- and IL17F-producing Th17 clones. Data also indicate that human neutrophils 1036 
do not reorganize the chromatin of the IL17A and IL17F loci in response to IL-6 plus 1037 
IL-23, consistent with their inability to de novo accumulate IL-17A and IL-17F mRNA. 1038 
 55 
 
 1039 
 1040 
 1041 
 1042 
Figure 12 | ChIP-Seq profiles of H3K4me1 and H3K27Ac at the IL17A and IL17F loci 1043 
in human neutrophils and Th17 cells. 1044 
Representative snapshots depicting H3K4me1 and H3K27Ac ChIP-seqs at the IL17A and 1045 
IL17F genomic loci in freshly isolated human neutrophils or, as retrieved from NIH 1046 
Epigenomics Roadmap Initiative [116], in PMA/ionomcyin-stimulated Th17 cells. 1047 
 1048 
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 1049 
Figure 13 | H3K4me1 or H3K27Ac levels at the IL-17A, IL-17F and SOCS3 genomic 1050 
loci of Th17 cells and resting/ IL-6 plus IL-23-activated neutrophils. 1051 
Enrichment levels of H3K4me1 (left panels) and H3K27Ac (right panels) at the IL-17A (A), 1052 
IL-17F (B) and SOCS3 (C) genomic loci by ChIP analysis in human Th17 clones and 1053 
neutrophils incubated for 1 h with or without 20 µg/ml IL-6 plus 2 µg/ml IL-23. (A-C) A 1054 
scheme illustrating the positions of the designed primer pairs amplifying promoter and 1055 
potential enhancer regions of IL-17A, IL-17F and SOCS3 for ChIP analysis are 1056 
depicted at the top of each panel. Co-immunoprecipitated DNA samples were expressed 1057 
as percent of the total input. Panels in (A-C) depict a representative experiment out of two 1058 
independent ones with similar results. Error bars represent standard errors calculated from 1059 
triplicate qPCR reactions. 1060 
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 1061 
Figure 14 | IL-17A, CXCL8, TNF and SOCS3 mRNA expression, as well as IL-17R 1062 
surface expression, in neutrophils from patients with psoriasis 1063 
(A) Neutrophils isolated from healthy donors (n = 3) or psoriatic patients (n = 3) were cultured 1064 
for 20 h with 100 U/ml IFNγ plus 1 µg/ml LPS, 5 µM R848 or 500 ng/ml IL-17A to evaluate 1065 
IL-17A, IL-17F, IL-17RA, IL-17RC, CXCL8, TNFα and SOCS3 mRNA expression by RT-1066 
qPCR. Gene expression data are depicted as mean normalized expression (MNE) units after 1067 
GAPDH mRNA normalization. (B) Surface IL-17RA and IL-17RC expression evaluated by 1068 
flow cytometry in human neutrophils from healthy donors or psoriatic patients Values 1069 
represent the mean ± SEM (n = 3). For the data of panels A and B, no significant differences 1070 
between healthy donors or psoriatic patients were observed by 2-way ANOVA followed by 1071 
Bonferroni’s post-test.  1072 
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 Human neutrophils from patients with psoriasis do not express/produce 1073 
IL-17A and/or IL-17F 1074 
We subsequently investigated whether neutrophils isolated from patients with 1075 
active psoriasis could express IL-17A, IL-17F and/or IL-17RC mRNA, either 1076 
constitutively or upon incubation for 20 h with either IFNγ plus LPS, R848 or IL-17A. 1077 
As shown in Figure 14A, the latter was not the case, as they behaved similarly to 1078 
neutrophils from healthy donors. Psoriatic neutrophils did not also respond to IL-17A 1079 
(Figure 14A), due to their lack of surface IL-17RC expression (Figure 14B). 1080 
Nonetheless, psoriatic neutrophils fully responded to either R848 or IFNγ plus LPS, 1081 
as they accumulated CXCL8, TNF and SOCS3 transcripts at levels comparable to 1082 
those of healthy donors neutrophils (Figure 14A).  1083 
 1084 
 1085 
 1086 
 Commercial anti-IL-17A antibodies stain cytospins of resting and 1087 
activated neutrophils but not their corresponding lysates 1088 
 1089 
In additional experiments, cytospins of resting and R848-stimulated 1090 
neutrophils were incubated with anti-human IL-17A goat antibodies (AF-317-NA) 1091 
previously shown to stain neutrophils pathological tissues [81, 92, 101, 118-136], as 1092 
also confirmed by our IHC/IF staining of inflamed psoriatic tissue (Figure 15A). 1093 
Consistently, neutrophils became strongly IL-17A-positive, yet with no difference 1094 
between the two experimental conditions (Figure 15B). By contrast, immunostaining 1095 
of the same cytospins with anti-human CXCL8 Abs showed a positivity only in R848-1096 
treated neutrophils (Figure 15B), thus excluding methodological arctifacts. Not 1097 
surprisingly, once processed for RT-qPCR analysis and ELISA, the correspondingly 1098 
neutrophils samples were found totally negative for both IL-17A mRNA expression 1099 
and IL-17A production (data not shown). The detection by IHC of IL-17A positive 1100 
neutrophils, in the absence of IL-17A mRNA, could be explained by the fact that the 1101 
cytokine is synthesized in bone marrow neutrophil precursors, at the stages when 1102 
granule proteins, such as myeloperoxidase (MPO), elastase and azurocidin 1, are 1103 
formed [137]. However in transcriptomes generated from cells isolated at different 1104 
stages during granulopoiesis [111], we do not identified IL-17A mRNA accumulation 1105 
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(Figure 16). In the same database, we not even detected IL-17RC and IL-10 mRNA 1106 
(Figure 16), consistent with the inability of mature neutrophils to express them [29, 1107 
87]. By contrast, we did find MPO, elastase and azurocidin 1 mRNA expression only 1108 
in transcriptomes of neutrophil precursors, as expected [137], thus validating the 1109 
reliability of the database [111] (Figure 16). 1110 
In line with the latter data, immunoblots performed with AF-317-NA revealed 1111 
that whole lysates prepared from neutrophils do not show any positive signal in 1112 
correspondence of rhIL-17A molecular weight (Figure 15C). In these experiments, 1113 
neutrophils were either freshly isolated (D1 and D2 in Figure 15C), or cultured for 3 1114 
h with or without R848, 2 µg/ml IL-6 plus 0.2 µg/ml IL-23 (low IL-6 plus IL-23 in 1115 
Figure 15C), or 20 µg/ml IL-6 plus 2 µg/ml IL-23 (high IL-6 plus IL-23 in Figure 1116 
15C). By contrast, AF-317-NA strongly reacted in correspondence of neutrophil 1117 
proteins displaying higher MW than that of rIL-17A, with no difference in signals 1118 
among fresh isolated, stimulated or untreated neutrophils (Figure 15C). While these 1119 
data confirm the observations reported by Tamarozzi et al [102], who also used mouse 1120 
anti-IL-17A mAbs (#41802, from R&D) in addition to AF-317-NA, they are in 1121 
contrast with Lin et al’s findings [81] illustrating a constitutive IL-17A (but not IL-17F) 1122 
expression in neutrophil lysates, as revealed by immunoblotting with #41802. Halwani 1123 
et al [99] too found constitutive IL-17A amounts in lysates of neutrophils from 1124 
asthmatic patients, even increasing upon cell incubation with IL-21 and/or IL-23 for 1125 
18 h, as revealed by immunoblotting with unspecified antibodies from R&D. However, 1126 
since only portions of the immunoblots are shown in Halwani et al [99] and Lin et al 1127 
[81] paper, it is not known whether additional proteins were recognized by antibodies 1128 
used. Whatever the case is, our experiments suggest that the positive staining of 1129 
neutrophils detected by IHC and IF using AF-317-NA on cytospins and, possibly, 1130 
tissue slides, stands for an IL-17A-unrelated binding(s) to neutrophils.  1131 
 1132 
 1133 
 1134 
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 1135 
Figure 15 | Staining human neutrophils by anti-IL-17A (AF-317-NA) polyclonal 1136 
antibodies 1137 
(A) Immunofluorescence (top panels) and immunohistochemistry (lower panels) staining of 1138 
two FFPE cases of human pustular psoriasis using anti-IL-17A (AF-317-NA) and anti-CD66b 1139 
antibodies (as labeled). Top panels show DAPI, FITC channel and merge in order to recognize 1140 
neutrophil shape; lower panels show different magnification of IHC and double IHC to 1141 
characterize IL-17A+ cells with the neutrophil marker CD66b. (B) Cytospins of neutrophils, 1142 
either untreated (top panels) or treated with 5 µM R848 (bottom panels) for 3 h, were stained 1143 
with anti-IL-17A (AF-317-NA, left panels) and anti-CXCL8 (right panels) Abs. Original 1144 
magnification 200x (first row in A, and left image in third row, scale bar 100 m) and 400x 1145 
(second row in A, center/right images in third row in A, as well as in B, scale bar 50 m). 1146 
Images of the second row in A represent magnifications of images in first row. (C) AF-317-1147 
NA immunoblot of lysates from neutrophils either freshly isolated (T0, from 2 donors) or 1148 
incubated for 3 h with or without 2 µg/ml IL-6 plus 0.2 µg/ml IL-23 (low), 20 µg/ml IL-6 1149 
plus 2 µg/ml IL-23 (high) or 5 µM R848. Recombinant human IL-17A (rhIL-17A) was used 1150 
as positive control. Panels B and C display representative experiments out of two independent 1151 
ones with similar results.   1152 
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 1153 
 1154 
Figure 16 | IL-17A, IL-17B, IL-17F, IL-10, IL-17RC, IL-17RA azurocidin, neutrophil 1155 
elastase and MPO mRNA expression levels at different stages of neutrophil 1156 
maturation. 1157 
mRNA expression data derive from Gene Expression Omnibus database (accession 1158 
number GSE42519) [111]. (A) IL-17A, IL-17B, IL-17F, IL-10, IL-17RC and IL-17RA 1159 
or (B) azurocidin (AZU1), neutrophil elastase (ELANE) and MPO mRNA expression 1160 
levels were measured in the following cell types: hematopoietic stem cells (HSCs) 1161 
multipotent progenitors (MPPs), common myeloid progenitors (CMPs), granulocyte-1162 
macrophage progenitors (GMPs), early and late promyelocytes (PMs), myelocytes 1163 
(MYs), metamyelocytes (MMs), band cells (BCs), and bone marrow 1164 
polymorphonuclear neutrophil granulocytes (PMNs). Values represent the mean ± 1165 
SEM as calculated from data of the biological replicates present in the database. 1166 
 1167 
 1168 
 1169 
 1170 
 1171 
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 Human neutrophils do not express/produce IL-17B 1172 
 1173 
In a separate set of experiments, we also tested goat anti-IL-17B (AF1248) Abs 1174 
that, in recent publications, has been shown to positively stain, by IHC and IF, 1175 
neutrophils present in tissue samples from rheumatoid arthritis (RA) [69] and colon 1176 
carcinoma (CCR) [138] patients. Consistently, we found that also neutrophils present 1177 
in inflamed psoriatic tissue were strongly detectable by IHC and IF staining with 1178 
AF1248 (Figure 17A). AF1248 stained neutrophils isolated from the blood of healthy 1179 
donors and incubated for 3 h with or without 5 M R848 in an equivalent manner 1180 
(Figure 17B). However, by immunoblotting, AF1248 did not recognize any protein 1181 
corresponding to the MW of rhIL-17B in whole lysates prepared from neutrophils 1182 
treated with R848 or IL-6 plus IL-23, as previously described (Figure 17C). These 1183 
negative observations were also confirmed by measurement of intracellular as well as 1184 
released IL-17B by two commercial ELISA (see M&M). Accordingly, no antigenic IL-1185 
17B could be measured in supernatants and whole lysates from neutrophils incubated 1186 
with 5 µM R848 with or without 1000 U/mL IFNα, 100 µg/ml LPS with or without 1187 
100 U/ml IFNγ, 2/20 µg/ml IL-6 plus 2 µg/ml IL-23, (data not shown), in agreement 1188 
with the lack of IL-17B mRNA induction. Detectable IL-17B levels were however 1189 
measured in lysates of human cerebral cortex [113], demonstrating that our two IL-1190 
17B ELISA kits were sensitive enough. Altogether, our data indicate that, similarly to 1191 
the case of AF-317-NA, the positive staining of neutrophils in cytospin slides and, 1192 
possibly, tissue samples by AF1248, likely stand for an IL-17B-unrelated, non-specific, 1193 
recognition occurring in human neutrophils. 1194 
 1195 
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 1196 
Figure 17 | Staining human neutrophils by anti-IL-17B (AF1248) antibodies 1197 
(A) Immunofluorescence (top panels) and immunohistochemistry (lower panels) staining of 1198 
two FFPE cases of human pustular psoriasis using anti-IL-17B (AF1248) and CD66b 1199 
antibodies (as labeled). Top panels show DAPI, FITC channel and merge in order to recognize 1200 
neutrophil shape; lower panels show different magnification of IHC and double IHC to 1201 
characterize IL-17A+ cells with the neutrophil marker CD66b. (B) Cytospins of neutrophils 1202 
incubated without (top panel) or with 5 µM R848 (bottom panel) for 3 h. Original 1203 
magnification 200x (first row in A, and left image in third row, scale bar 100 m) and 400x 1204 
(second row in A, center/right images in third row in A, as well as in B, scale bar 50 m). 1205 
Images of the second row in A represent magnifications of images in first row. (C) AF1248 1206 
immunoblot of lysates from neutrophils either freshly isolated (T0, from 2 donors) or 1207 
incubated for 3 h with or without 2 µg/ml IL-6 plus 0.2 µg/ml IL-23 (low), 20 µg/ml IL-6 1208 
plus 2 µg/ml IL-23 (high) or 5 µM R848. Recombinant human IL-17B (rhIL-17B) was used 1209 
as positive control. Panels B and C display representative experiments out of two independent 1210 
ones with similar results.  1211 
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 1212 
  1213 
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4 DISCUSSION AND CONCLUSION 1214 
 1215 
In this study, we have reinvestigated in-depth whether human neutrophils 1216 
produce IL-17A or IL-17B, IL-17F and IL-17A/F in vitro. According to the literature, 1217 
in fact, information on such an issue appears discordant, as the majority of papers 1218 
sustain that human neutrophils do express/produce IL-17A [81, 92, 94-101, 118-136, 1219 
139-145], while a minority fail to detect it [87, 91, 93, 102, 146, 147]. This issue is even 1220 
more critical if one takes into account that also the capacity of murine neutrophils to 1221 
produce IL-17A, shown in a variety of mouse models of infectious and autoimmune 1222 
inflammation [94, 95, 97, 148-152], has been recently questioned [153, 154]. Preclinical 1223 
models evidencing neutrophil-derived IL-17 as pathogenic in diseases might be, in fact, 1224 
prematurely taken as proof-of-concept for immediate translational applications in 1225 
humans.  1226 
Herein, by using multiple methodological approaches (RT-qPCR, ChIP, ChIP-1227 
seq, ELISA, intracellular staining and immunoblotting), we confirm and greatly extend 1228 
our previous 2010 findings [87] showing that highly purified (> 99.7 %) populations 1229 
of human neutrophils, either resting, or activated by a variety of stimulatory conditions, 1230 
including TLR and dectin ligands, fungal PAMPs and cytokines, used singly or in 1231 
combinations, neither express IL-17A, IL-17F, IL-17B, IL-17C, IL-17D and IL-17E 1232 
mRNA, nor produce IL-17A, IL-17F, IL-17A/F and IL-17B in vitro. Similarly, we show 1233 
that also neutrophils isolated from patients with active psoriasis do not express IL-1234 
17A, IL-17F, IL-17B, IL-17C, IL-17D and IL-17E as well as IL-17RC mRNA when 1235 
activated by R848, IFN plus LPS, and IL-17A in vitro. In such regard, RNA-Seq 1236 
experiments made by Tamarozzi et al [102], using neutrophils isolated by negative-1237 
selection (> 99.9 % pure) from healthy donors or RA patients (as we do), then treated 1238 
for 1 h with a range of inflammatory cytokines (TNF, GM-CSF, G-CSF, IL-6, IL-1239 
1β, CXCL8, IFN, IFNγ), also failed to detect any of the mRNA for IL-17 cytokine 1240 
family. By contrast, Yamanaka et al [91] have been recently reported the presence of 1241 
constitutive IL-17A transcripts in neutrophils from healthy donors and psoriasis 1242 
patients isolated by density gradient cell separation (92 % purity). However, when the 1243 
same cell populations were further purified by magnetic sorting (reaching a 99 % 1244 
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purity), they were found totally devoid of IL-17A mRNA [91], indicating that 1245 
contaminating monocytes/lymphocytes were actually responsible for the IL-17A 1246 
mRNA expression in unsorted “neutrophils”. Needless to say that Yamanaka et al’s 1247 
observations [91] are example of a notion that we have been always recommending in 1248 
our studies [17, 18, 21], namely the requirement of using highly purified cell 1249 
populations if one wants to obtain correct results when examining neutrophil gene 1250 
expression or neutrophil-derived cytokines.   1251 
Interestingly, other studies confirm that human neutrophils do not 1252 
constitutively contain IL-17A transcripts [81, 92, 94, 95, 97, 98, 102, 141], including 1253 
those ultimately showing a concurrent IL-17A protein positivity, as revealed by 1254 
intracellular flow cytometry [94, 95, 97], ELISA [94, 97], confocal microscopy [94] or 1255 
IHC [98]. Some authors [81, 92] speculated that the absence of IL-17A mRNA in 1256 
mature neutrophils indicates that the cytokine is synthesized in bone marrow 1257 
neutrophil precursors, at the stages when granule proteinase formed [137]. However, 1258 
we would exclude such a hypothesis as our analysis of transcriptomes generated from 1259 
all types of bone marrow cell populations [111] failed to identify an IL-17A mRNA 1260 
accumulation at any stage of neutrophil maturation. 1261 
We were unable to detect IL-17A and IL-17F mRNA/production/release even 1262 
by human neutrophils incubated with IL-6 plus IL-23, in contrast to what repeatedly 1263 
found [94, 95, 97-99]. In our experiments, neutrophils did however respond to IL-6 1264 
plus IL-23 in terms of STAT3 phosphorylation and SOCS3 mRNA induction, 1265 
indicating that the two cytokines are effectively stimulatory for neutrophils. It is 1266 
intriguing that, apart from Halwani et al. [99], who found that either 20 ng/ml IL-6 or 1267 
20 ng/ml IL-23, singly used, directly induced IL-17A mRNA and protein in a fraction 1268 
of neutrophils from asthmatic patients, other groups highlighted the necessity to use 1269 
at least 20 µg/ml IL-6 plus 2 µg/ml IL-23 [94, 95, 98] (as we did). In this context, the 1270 
paper by Hu et al [97], based on the use of neutralizing antibodies and pharmacological 1271 
inhibitors, identified endogenous IL-6 and IL-23 as indirect inducers of IL-17A 1272 
expression in a fraction of neutrophils either infected with Mycobacterium tuberculosis 1273 
(MTB), or stimulated with LPS or Pam3CSK4. In this latter study, however, IL-6 and 1274 
IL-23 levels corresponded to 1 ng/ml at the best. Herein, we failed to detect IL-17A 1275 
mRNA expression and production in neutrophils incubated with either LPS or 1276 
Pam3CSK4, even if it is true that they produce IL-6 [47] and IL-23 (our unpublished 1277 
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observations). Whether stimulation of neutrophils with MTB effectively promotes 1278 
IL-17A expression via endogenous IL-6 and IL-23 remains to be verified. However, 1279 
no IL-17A, IL-17B, IL-17C or IFNγ secretion from Mycobacterium bovis Bacille-1280 
Calmette Guerin (BCG)-stimulated neutrophils was recently reported [146]. In 1281 
addition, we failed to detect intracellular IL-17A expression by intracellular flow 1282 
cytometry using the same protocol and the same reagents reported by Taylor 2014 [94]. 1283 
The fact that isotype control give higher fluorescence signal respect to specific anti-1284 
IL-17A Abs indicates that results obtained by other groups using this method could 1285 
be due to non-specific binding of the antibody to intracellular protein. It should be 1286 
also remarked that the purity of neutrophils in the studies showing their IL-17 1287 
production in response to IL-6 plus IL-23 [94, 95, 98, 99], reported to be > 96 % at 1288 
the best [98], does not sufficiently secure fully genuine results at least in our opinion. 1289 
Nevertheless, we investigated potential mechanisms helping to clarify whether 1290 
human neutrophils respond to IL-6 plus IL-23 in terms of IL-17A expression or not. 1291 
ChIP assays revealed that, in resting, as well as in IL-6 plus IL-23-stimulated, 1292 
neutrophils, but not in Th17 cell lines, the IL-17A locus does not contain any H3Kme1 1293 
and H3K27Ac, which are two histone marks that are usually present in those genomic 1294 
regions that act as active enhancers [155]. On the other hand, the levels H3K27Ac 1295 
were found increased at the SOCS3 promoter of neutrophils incubated with IL-6 plus 1296 
IL-23, consistent with the potentially inducible SOCS3 mRNA transcription. Notably, 1297 
the complete absence of H3K4me1 at the IL-17A locus of neutrophils is particularly 1298 
informative, since such a histone modification is known to precede very early, but 1299 
time-consuming [48], events necessary for the assembly of the transcriptional 1300 
machinery, including nucleosomal depletion, H3K27Ac deposition and enhancer 1301 
activation [155]. Based on our data, it appears that the chromatin at the IL-17A locus 1302 
of human neutrophils likely displays a closed conformation, inaccessible to 1303 
transcription factors and, consequently, RNA polymerase, ultimately preventing IL-1304 
17A mRNA transcription in resting as well as stimulated neutrophils. It is thus very 1305 
unlikely that H3K4me1 modification could be induced within one hour, e.g., the time-1306 
point at which IL-17 mRNA expression in IL-6 plus IL23-stimulated neutrophils has 1307 
been observed [94, 95, 98]. Obviously, this does not exclude that there could exist 1308 
given stimulatory conditions able to modify the chromatin at the IL17A or IL17F loci 1309 
of human neutrophils.  1310 
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A variety of studies report the presence of IL-17A+-neutrophils in sample 1311 
tissues from many diseases, including psoriasis [81, 92, 120, 123, 126, 135], skin 1312 
inflammation [124], bullous pemphigoid [125], hidradenitis suppurativa [136], fungal 1313 
keratitis [96], RA [69, 101], ankylosing spondylitis [118], systemic lupus erythematosus 1314 
(SLE) [129, 144], human ANCA-associated glomerulonephritis [133], cystic fibrosis 1315 
[119, 128, 141], nasal polips [145], chronic obstructive pulmonary disease (COPD) 1316 
[122], lung tissues during bacterial pneumonia [142], alcoholic liver diseases [134], 1317 
acute renal allograft rejection [130], atherosclerotic plaques [121], cutaneous T cell 1318 
lymphoma lesions [132], gastric cancer [98], cervical cancer [127] and prostate cancer 1319 
[143], as revealed by IHC, IF or intracellular flow cytometry using various commercial 1320 
anti-IL-17A antibodies. Not surprisingly, results occasionally appear discordant. For 1321 
example, while Moran et al [101] reported IL-17A-positive synovial tissue neutrophils 1322 
using the AF-317-NA, van Baarsen et al [93] show that synovial tissue neutrophils from 1323 
arthritis patients are not stained by #41802. By IHC experiments using AF-317-NA, 1324 
we too detected IL-17A+-neutrophils not only in skin sections of psoriasis patients, 1325 
but also in cytospin slides of neutrophils isolated from healthy donors and incubated 1326 
for 3 h with or without R848, at similar levels. By contrast, we found that whole lysates 1327 
of the same neutrophil populations displayed major signals at levels of proteins having 1328 
MW not corresponding to that of IL-17A when immunoblotted with AF-317-NA. 1329 
Our findings substantially confirm the observations previously made by Tamarozzi et 1330 
al [102] who also did not detect any IL-17A expression in highly pure populations of 1331 
neutrophils (99.9 %) by using a variety of assays including RT-qPCR, RNA-seq, 1332 
western blot and ELISA, despite of finding IL-17A+-neutrophils in Wolbachia 1333 
Onchocerca volvulus-positive nodules by IHC. Notably, by immunoprecipitation 1334 
experiments followed by mass spectrometry, Tamarozzi et al [102] also uncovered that 1335 
both AF-317-NA and #41802 bind to several proteins expressed in granules (including 1336 
myeloperoxidase, lactoferroxin and lysozyme C) and cytoskeleton (such as keratin and 1337 
profilin) of neutrophils, while other anti-human IL-17A antibodies (sc-6077 from 1338 
Santa Cruz, and PRS4877 from Sigma) were found to recognize multiple non-specific 1339 
bands in neutrophil immunoblots [102]. All in all, data suggest that the IL-17A-1340 
positivity of human neutrophils detected by AF-317-NA and #41802 is, at least in vitro, 1341 
likely an artifact. Whether these or other anti-IL-17A antibodies, including sc-7927 1342 
(from Santa Cruz) [127, 131], ab9565 (from abcam) [139], ab136668 (from Abcam) 1343 
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[142], 500-P07 and 500-P07G (from Peprotech) [131] and eBio64Dec17 (from 1344 
eBioscience) [96, 120, 131], are instead reliable in specifically detecting IL-17A+-1345 
neutrophils in tissue samples should be more convincingly established. For instance, 1346 
in models of skin inflammation resembling psoriasis [124], accumulated neutrophils 1347 
stained by AF-317-NA were shown to express IL-17 mRNA transcripts. In other 1348 
studies, tissue neutrophil staining by AF-317-NA was blocked after antibody pre-1349 
adsorption with rIL-17A [118, 133], or confirmed by costaining of the same section by 1350 
eBio64DEC17 [133]. It is worth recalling that neutrophils express high levels of IL-1351 
17RA [87] that could in theory bind exogenously-derived IL-17A, consequently leading 1352 
to a positive signal in IHC or IF experiments without actual intracellular IL-17 1353 
production [156], as observed in the case of mast cells [157]. Whatever the case is, we 1354 
would recommend to always validate by multiple IL-17A-investigation methods an 1355 
eventual detection of IL-17A-positive neutrophils by exclusively IHC, or IF or 1356 
intracellular flow cytometry [100, 118, 119, 121, 122, 125-128, 130, 131, 134-136, 139, 1357 
140, 143, 144]. 1358 
Similar concerns can be made for the, to date, reported IL-17B expression by 1359 
human neutrophils. Accordingly, IL-17B has been detected in neutrophils infiltrating 1360 
the synovial membrane of RA patients [69] and the stroma of colon carcinoma cancer 1361 
[138] by IHC/IF, as well as in freshly isolated neutrophils by immunoblotting [69], in 1362 
all cases using #AF1248 antibodies. We also detected IL-17B-positive neutrophils in 1363 
psoriasis plaques and cytospin slides of freshly isolated neutrophils by IHC using 1364 
#AF1248. However, we could not measure any IL-17B in lysates of freshly 1365 
isolated/activated neutrophils either by using two different commercial ELISA, or by 1366 
#AF1248 immunoblotting. In the latter experiments, many proteins with MW 1367 
different from that of rIL-17B were recognized by #AF1248, thus invalidating at least 1368 
the cytospin results. Intriguingly, Kouri et al [69] did detect IL-17B protein in lysates 1369 
of neutrophils (95 % pure), by both ELISA and immunoblotting using #AF1248. 1370 
However, these authors showed only a portion of the western blot [69], thus rendering 1371 
impossible to know whether additional major proteins were recognized by #AF1248. 1372 
Curiously, we, Tamarozzi et al [102] and Kouri et al. [69], all found that human 1373 
neutrophils do not transcribe IL-17B mRNA under resting or activating condition. 1374 
Furthermore, no IL-17B secretion from BCG-stimulated neutrophils was recently 1375 
shown [146]. In such regard, Koury et al [69] suggested that IL-17B is synthesized only 1376 
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at the promyelocyte and myelocyte stage in the bone marrow, disappearing in mature 1377 
neutrophils. However, our analysis of transcriptomes generated from all types of bone 1378 
marrow cell populations [111] revealed that, similarly to IL-17A, also IL-17B is never 1379 
transcribed during the different stages of neutrophil maturation. Altogether, data 1380 
suggest that human neutrophils do not express IL-17B in vitro. They also suggest that 1381 
the positive staining of neutrophils by IHC using AF1248 is likely due to a nonspecific, 1382 
IL-17B-independent, binding of these antibodies.  1383 
In conclusion, data shown in this study are consistent with the notion that 1384 
human neutrophils are unable to express and produce IL-17A, IL-17B or IL-17F in 1385 
vitro. 1386 
 1387 
 1388 
 1389 
  1390 
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6 APPENDICES 1743 
 1744 
During my PhD studies, I have been involved in some research projects 1745 
ongoing in Prof. M.A. Cassatella’s lab, focused on the regulation of neutrophil-derived 1746 
cytokines under different stimulatory conditions. One of them is presented in this 1747 
thesis and was recently published in Frontiers of Immunology Journal[158]. The other 1748 
projects are described below followed by the respective publications. 1749 
 1750 
In the first study, entitled “IFN enhances the production of IL-6 by 1751 
human neutrophils activated via TLR8”[57], we have demonstrated that interferon 1752 
alfa (IFN), a cytokine that is crucial for innate antiviral defences, strongly upregulates 1753 
IL-6 production in neutrophils incubated with TLR8 ligands, which mimic infection 1754 
by RNA viruses. We have proved that the increased IL-6 production is independent 1755 
from a presumed TLR7 induction by IFN, but rather mediated by an upregulated 1756 
synthesis and release of TNF acting autocrinally. By performing chromatin 1757 
immunoprecipitation assays (ChIPs), we have also shown that the molecular 1758 
mechanisms underlying the activation of IL-6 mRNA expression in IFN plus R848-1759 
treated neutrophils occur through an increased recruitment of C/EBP, but not 1760 
STAT1 or IRF1, to the IL-6 promoter. Finally, we have shown that highly purified 1761 
neutrophils from systemic lupus erythematosus (SLE) patients, displaying an IFN-1762 
induced gene expression signature (hence with active disease state), produce increased 1763 
amounts of both IL-6 and TNF in response to R848 as compared to healthy donors, 1764 
thus corroborating our in vitro observations. Data from this study have uncovered a 1765 
novel effects that type I IFN exerts in activated neutrophils, which enlarge our 1766 
knowledge on the various biological actions that type I IFN orchestrates during 1767 
infectious and autoimmune diseases. 1768 
 1769 
In the second study, entitled “The importance of being “pure” 1770 
neutrophils”[17], we performed experiments with the purpose to compare different 1771 
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isolation methods of human neutrophils. Since one-step isolation kits were recently 1772 
designed for isolation of neutrophils from whole blood, we decided to compare them 1773 
with our usual isolation procedure, which allows the isolation of > 99.6 % pure 1774 
neutrophils from either whole blood or buffy coats. We investigated the precise purity 1775 
of wbNeuM (MACSexpress® Neutrophil isolation kit) wbNeuE (EasySep™ direct 1776 
human neutrophil isolation kit) and Neu (our conventional procedure) by flow 1777 
cytometric analysis focusing on thirteen different cell markers. While Neu confirmed 1778 
to be 99.7 % pure, both wbNeuM and wbNeuE, although 98.9 ± 0.5 % and 97.5 ± 1 1779 
% pure, respectively, were found to be reproducibly contaminated by eosinophils (0.29 1780 
± 0.37 % for wbNeuM and 0.53 ± 0.61 % for wbNeuE) and slan+CD16+-monocytes 1781 
(0.33 ± 0.16 % for wbNeuM and 0.22 ± 0.19 % for wbNeuE). Because slan+CD16+-1782 
monocytes display a well-known capacity to produce elevated amounts of cytokines 1783 
when stimulated by TLR ligands, we set up a protocol to remove them from wbNeuM 1784 
and wbNeuE. Notably, wbNeuM completely lost the capacity to produce IL-10, as 1785 
well as to express IFIT1 and ISG15 mRNA in response to either R848 or poly(I:C) 1786 
after slan+CD16+-monocyte removal. In addition, both wbNeuM and wbNeuE lost 1787 
the capacity to express or produce IL-6 when stimulated with R848 for 4 h, again after 1788 
slan+CD16+-monocyte depletion. On the other hand, slan+CD16+-monocyte-1789 
depletion was less effective for wbNeuE, particularly for IFIT1 and ISG15 1790 
transcription, indicating that other contaminating cells are responsible for the mRNA 1791 
expression of IFN stimulated genes. These findings support the notion that is 1792 
absolutely mandatory to use highly purified populations of neutrophils when gene 1793 
expression and/or neutrophil-derived cytokines are investigated 1794 
 1795 
In the third study, entitled “Human neutrophils produce CCL23 in response 1796 
to various TLR-agonists and TNF”[59], we showed that human neutrophils in 1797 
addition to release CCL2, CCL3 and CCL4, are able to produce another CCR1-binding 1798 
chemokine, namely CCL23, which selectively recruits resting T lymphocytes and 1799 
monocytes, inhibits proliferation of myeloid progenitor cells and promotes 1800 
angiogenesis. Other CCR1-binding chemokines, including CCL5, CCL7, CCL13, 1801 
CCL14, CCL15 and CCL16 were found as not induced at the mRNA level in 1802 
neutrophils, at least after R848-treatment. Surprisingly, the amounts of CCL23 1803 
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produced by neutrophils incubated with R848 for 24 h were comparable to those made 1804 
by the same number of autologous R848-treated monocytes. This finding is quite 1805 
unusual because, on a per cell basis, activated monocytes usually produce higher 1806 
cytokine/chemokine levels than autologous neutrophils, although some other 1807 
exceptions exist, for instance CCL19/MIP3β. Moreover, activated neutrophils may 1808 
represent major sources of CCL23, even in consideration of the fact that, during 1809 
bacterial or viral infections, neutrophils often outnumber mononuclear leukocytes by 1810 
one to two orders of magnitude. Furthermore, we also report that the production of 1811 
CCR1-binding chemokines by R848-activated neutrophils is differentially modulated 1812 
by IFNα. In fact, while production of CCL3 and CCL4 was not affected by the addition 1813 
of IFNα to neutrophils, that of CCL23 was strongly inhibited. By contrast, CCL2 1814 
production was strongly enhanced in neutrophils incubated with R848 in the presence 1815 
of IFNα. Given the potent effect of TLR8 agonists in inducing neutrophil-derived 1816 
CCL23, and its negative regulation by IFNα, data also contribute to extend our 1817 
knowledge on the complex role of neutrophils to both host defense and disease in 1818 
response to viral infections. 1819 
 1820 
 1821 
 1822 
 1823 
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IFNα enhances the production 
of IL-6 by human neutrophils 
activated via TLR8
Maili Zimmermann1, Fabio Arruda-Silva1, Francisco Bianchetto-Aguilera1, Giulia Finotti1, 
Federica Calzetti1, Patrizia Scapini1, Claudio Lunardi2, Marco A. Cassatella1 & Nicola Tamassia1
Recently, we reported that human neutrophils produce biologically active amounts of IL-6 when 
incubated with agonists activating TLR8, a receptor recognizing viral single strand RNA. In this study, 
we demonstrate that IFNα, a cytokine that modulates the early innate immune responses toward viral 
and bacterial infections, potently enhances the production of IL-6 in neutrophils stimulated with R848, 
a TLR8 agonist. We also show that such an effect is not caused by an IFNα-dependent induction of TLR7 
and its consequent co-activation with TLR8 in response to R848, but, rather, it is substantially mediated 
by an increased production and release of endogenous TNFα. The latter cytokine, in an autocrine 
manner, leads to an augmented synthesis of the IkBζ co-activator and an enhanced recruitment 
of the C/EBPβ transcription factor to the IL-6 promoter. Moreover, we show that neutrophils from 
SLE patients with active disease state, hence displaying an IFN-induced gene expression signature, 
produce increased amounts of both IL-6 and TNFα in response to R848 as compared to healthy donors. 
Altogether, data uncover novel effects that type I IFN exerts in TLR8-activated neutrophils, which 
therefore enlarge our knowledge on the various biological actions which type I IFN orchestrates during 
infectious and autoimmune diseases.
Neutrophils are the first and the most numerous innate immune cells recruited to the sites of infection, where 
they play a crucial role in destroying and eliminating invading pathogens1 . Because of their powerful microbi-
cidal equipment, neutrophils are often depicted as harmful cells that can cause damage to the surrounding tissues 
during acute inflammation1. Nonetheless, extensive research performed in the last decades has recognized neu-
trophils as highly versatile and sophisticated cells displaying an important role in linking the innate and adaptive 
arms of the immune response, as well as a significant synthetic capacity2,3. For instance, neutrophils produce and 
release a wide range of cytokines having pro-inflammatory, anti-inflammatory and immunoregulatory actions as 
a result of their interactions with microbes and other environmental substances3. Ligands for Toll-like receptors 
(TLR) or other pattern recognition receptors (PRR) function, in fact, as very powerful stimuli for cytokine expres-
sion in neutrophils4–7. In this context, we have recently reported that human neutrophils can de novo express and 
produce biologically active amounts of IL-68; however, they do so only after an overnight incubation, and more 
significantly in response to engagement of TLR8– which commonly recognizes single strand RNA (ssRNA) of 
viral origin9. Accordingly, we have shown that the induction of IL-6 production by neutrophils primarily occurs 
because TLR8 agonists are able to trigger a sequence of time-dependent molecular events, which, ultimately, 
remodel the chromatin at the IL-6 genomic locus from an “inactive” to an “active” configuration8. Most of these 
events were found to be sustained and amplified by endogenous TNFα (also produced in abundant amounts in 
response to TLR8 activation) and include, among others: the de novo expression of the co-activator Iκ Bζ , which is 
required to drive IL-6 transcription10; the induction of a latent enhancer located 14 kb upstream of the IL-6 tran-
scriptional start site (TSS); the CCAAT/enhancer binding protein-β (C/EBPβ ) recruitment to, as well as histone 
acetylation induction at, IL-6 regulatory regions8. Notably, the identification of neutrophils as potential source 
of IL-6, as well as the molecular mechanisms specifically regulating such a function, has definitively clarified 
controversial literature in the field11. Moreover, in light of findings demonstrating that neutrophils produce IL-6 
upon incubation with respiratory syncytial virus (a single-stranded RNA virus)12, recognize HIV-1 via TLR813, 
and express a broad repertoire of functional PRR involved in the recognition of nucleic acids of viral origin6,7, 
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our data have further corroborated the notion that neutrophils should be included among the cells responding 
to viral infections14.
Type I interferon (IFN) is known to mediate the early innate immune responses to viral infections, acting 
either directly, by inhibiting viral replication, or indirectly, by activating and potentiating effector functions 
exerted by immune cells15. Interestingly, type I IFN targets also human neutrophils, for instance by prolonging 
their survival16, or by inducing the expression of CXCL10 mRNA17, and the production of biologically active 
TNF-related apoptosis-inducing ligand (TRAIL)18. There is also evidence that type I IFN potentiates the expres-
sion of IL-6, for example in double strand RNA (dsRNA)-stimulated HeLa cells19, or in circulating PBMCs of 
chronic hepatitis C patients20. Besides, an uncontrolled production of type I IFN is involved in the pathogenesis 
of autoimmune diseases, including systemic lupus erythematosus (SLE) or rheumatoid arthritis21.
Based on these premises, herein we investigated whether type I IFN modulates the production of IL-6 by 
TLR8-activated neutrophils and, if so, at which molecular level. To validate the biological significance of in vitro 
results, we also investigated whether neutrophils isolated from patients with active SLE, hence displaying the 
“IFN-signature”, produce altered levels of IL-6 in response to activation via TLR8.
Results
IFNα potentiates the production of IL-6 by human neutrophils incubated with R848. To inves-
tigate the effect of type I IFN on the production of IL-6 by TLR8-stimulated neutrophils, we incubated highly 
purified neutrophils (99.7 ± 0.2 % purity)22 with or without 5 μ M R8488, in the presence or absence of 1000 U/ml 
IFNα 18, for up to 20 h. We found that IFNα , while not triggering per se any IL-6 production (Fig. 1a, left panel) 
or mRNA expression (Fig. 1a, middle panel), enhanced the yields of IL-6 recovered in supernatants from neu-
trophils incubated with R848, as well as the accumulation of the related mRNA (Fig. 1a, middle panel). Such a 
potentiation was significantly evident only after 20 h of cell incubation (Fig. 1a, left and middle panels), and not 
due to an enhanced secretion of an intracellularly stored pool of IL-6 (Fig. 1a, right panel). Under the same exper-
imental conditions, IFNα neither triggered the expression of CXCL8, nor influenced the stimulatory effect of 
R848 on the CXCL8 production and mRNA accumulation (Fig. 1b), while it potently induced the accumulation 
of IFIT1 mRNA (Fig. 1c), a classical interferon-dependent gene23. Taken together, these data demonstrate that 
IFNα greatly enhances the production of IL-6 by neutrophils stimulated with R848.
IFNα does not induce the expression of TLR7 in human neutrophils. To identify the mech-
anisms whereby IFNα augments the production of IL-6 in R848-treated neutrophils, we initially investigated 
whether an IFNα -mediated de novo induction of TLR7 and its consequent co-activation with TLR8 could occur. 
In this regard, we have recently shown that resting mature neutrophils do not express TLR78. However, ear-
lier observations have reported that SLE-serum treated neutrophils express TLR7 and respond to its specific 
ligand, R83724, by producing augmented levels of CXCL825. Such an acquisition to express TLR7 mRNA and, 
in turn, respond to R837, was suggested to be caused by the presence of type I IFN in SLE serum, also because, 
in vitro, 1000 U/ml IFNα were shown to induce TLR7 mRNA expression in neutrophils from healthy donors25. 
Figure 1. IFNα enhances the production of IL-6 in R848-treated neutrophils. Neutrophils (5 × 106/ml), 
isolated from the peripheral blood of healthy donors, were cultured with or without 5 μ M R848, 1000 U/ml 
IFNα or IFNα plus R848 for 6, 12 and 20 h to evaluate: released (a, left panel) and cell-associated (a, right panel) 
IL-6, as well as released CXCL8 (b, left panel), by ELISA; IL-6 (a, central panel), CXCL8 (b, right panel), and 
IFIT1 (c) mRNA expression, by RT-qPCR. ELISA values stand for the mean ± SEM (n = 3–11). Gene expression 
data (mean ± SEM, n = 3–9) are depicted as mean normalized expression (MNE) units after GAPDH mRNA 
normalization. Asterisks indicate a significant enhancement by IFNα : ***p < 0.001, by 2-way ANOVA followed 
by Bonferroni’s post-test.
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In the same study, IRS-661 (a specific TLR7 inhibitor) was found to inhibit the upregulation of CD83 in plasma-
cytoid dendritic cells (pDCs) treated with supernatants harvested from SLE neutrophils previously incubated 
with anti-ribonucleoprotein antibodies, the latter being shown to trigger neutrophil extracellular trap release via 
TLR725. In our populations of highly purified neutrophils incubated for 20 h with 1000 U/ml IFNα , either alone 
or in combination with either R848 or R837, no induction of TLR7 mRNA was, however, detected (Fig. 2a, left 
panel). Similarly, IFNα did not influence the expression of TLR8 mRNA (Fig. 2a, right panel), which, instead, was 
found to be remarkably upregulated by R848 (Fig. 2a, right panel). Control experiments confirmed26 that TLR7, 
but not TLR8, mRNA is expressed in human pDCs under resting conditions, TLR7 being upregulated upon pDC 
incubation with R837 or IFNα (Fig. 2b).
Consistent with the lack of TLR7 mRNA expression, no IL-6 production was observed in neutrophils stimu-
lated for 20 h by up to 50 μ M R837, either in the absence or in the presence of IFNα (Fig. 2c, left panel). On the 
other hand, we could confirm that R837 stimulates the production of CXCL8 by neutrophils (Fig. 2c, right panel), 
but only at elevated concentrations (e.g., 25–50 μ M) and, once again, without being influenced by the IFNα 
co-addition (Fig. 2c, right panel). Such R837-induced CXCL8 production occurred in a TLR7-independent man-
ner (Fig. 2d), as it was not abrogated by the pretreatment of neutrophils with BafilomycinA1 (BafA1), a potent 
inhibitor of endosomal acidification that is a required condition for efficient TLR7 and TLR8, but not TLR4, 
signaling27 (Fig. 2d). Altogether, data prove that the enhanced IL-6 production by neutrophils co-treated with 
IFNα and R848 is not mediated by the co-activation of TLR8 with newly induced TLR7. Data also indicate that 
neutrophil-derived CXCL8 in response to R837 is independent of endosomal TLR7 (as well as TLR8), and, likely, 
occurs via other, not yet identified mechanisms.
Endogenous TNFα partially mediates the upregulatory effect of IFNα on the R848-stimulated 
IL-6 production. Additional experiments uncovered that also the production of TNFα is significantly 
Figure 2. TLR7 is not expressed in human neutrophils incubated with IFNα. (a) TLR7 (left panel) and TLR8 
(right panel) mRNA expression either in (a), neutrophils cultured with or without 5 μ M R848, 5 and 25 μ M 
R837, in the presence or absence of 1000 U/ml IFNα for 20 h, or (b), pDCs cultured for 5 h with or without 
5 μ M R837 or 1000 U/ml IFNα . In (a), no significant effect by IFNα was found by 2-way ANOVA followed by 
Bonferroni’s post-test. (c) IL-6  and CXCL8 levels detectable in supernatants from neutrophils treated for 20 h 
with or without 1–50 μ M R837, in the presence or absence of 1000 U/ml IFNα . (d) CXCL8 mRNA expression 
in neutrophils pretreated with 25 nM Bafilomycin A1 (BafA1) for 30 min and then incubated for 5 h with 
100 ng/ml LPS, 5 μ M R848 or 50 μ M R837. Values in panels (a,c,d) stand for the mean ± SEM (n = 5), while 
panel (b) depicts a representative experiment out of three independent ones with similar results. Asterisks in 
panel (c,d) indicate a significant increase with respect to untreated cells, while # symbols in panel (d) indicate 
a significant inhibition exerted by BafA1: *p < 0.05, *** and ###p < 0.001, by 2-way ANOVA followed by 
Bonferroni’s post-test.
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augmented by IFNα in neutrophils incubated with R848 for 20 h (by approximately three-fold, Fig. 3a, left 
panel). Interestingly, no significant changes of the TNFα transcript accumulation were observed in IFNα plus 
R848-treated neutrophils as compared to cells treated with R848 only (Fig. 3a, right panel), indicating that IFNα 
enhances the production of TNFα likely by acting at the translational level. Therefore, at the light of our recently 
published observations, briefly described in the introduction8, we investigated the contribution of endogenous 
TNFα in mediating the enhancement of IL-6 expression in neutrophils treated with IFNα plus R848. To do so, 
we used two TNFα neutralizing drugs, namely adalimumab (ADA) and etanercept (ETA)28, and compared the 
grade of their inhibitory effects on the production of IL-6 by neutrophils incubated for 20 h with R848 only versus 
neutrophils incubated with IFNα and R848. As shown in left panel of Fig. 3b, the release of IL-6 by neutrophils 
treated with IFNα and R848 was inhibited to a slightly higher extent than in neutrophils treated with R848 only 
(61.1 ± 3.7 % versus 55.7 ± 2.1 in the case of ADA; by 58.4 ± 3.9 % versus 50.5 ± 2.0 % in the case of ETA, n = 5), 
indicating that endogenous TNFα is crucial for the IFNα -dependent IL-6 enhancement. Yet, neither ADA, nor 
ETA, reduced the production of IL-6 by neutrophils co-treated with IFNα and R848 to the levels detected in 
supernatants harvested from neutrophils treated with R848 only. Nonetheless, in IFNα plus R848-treated neu-
trophils, ADA reduced the accumulation of IL-6 transcripts only after 20, but not 6, h of incubation (Fig. 3c). 
Furthermore, that endogenous TNFα greatly contributes to mediate the upregulatory effect of IFNα on the pro-
duction of IL-6 was further supported by the western blot experiment displayed in Fig. 3d. The latter, in fact, 
shows that ADA inhibits the enhanced expression of Iκ Β ζ protein that is detectable in neutrophils treated with 
IFNα plus R848 as compared to cells treated with R848 only. Notably, results shown in right panel of Fig. 3b also 
show that TNFα neutralizing drugs do not suppress all cytokines produced by neutrophils treated with R848 and/
or IFNα . In fact, blocking the activity of autocrine TNFα did not significantly influence the release of IL-1ra by 
neutrophils incubated with R848, IFNα , or IFNα plus R848, the latter combination triggering a synergistic IL-1ra 
production. All in all, data indicate that the increased production of TNFα occurring in neutrophils co-treated 
with IFNα and R848, with respect to neutrophils incubated with R848 only, largely mediates their enhanced 
production of IL-6.
IFNα potentiates the R848-induced recruitment of C/EBPβ to the IL-6 genomic locus. Results 
from primary transcript (PT) experiments (Fig. 4a), as well as from ChIP of Polymerase II (Pol II) recruitment 
to the IL-6 TSS (Fig. 4b, left panel), indicated that the potentiation of IL-6 expression in neutrophils co-treated 
with IFNα and R848 for 20 h occurred at the transcriptional level. At the light of these data, we subsequently 
investigated whether IFNα , directly or indirectly, activates transcription factors (TFs) able to transactivate IL-6 
gene expression, including C/EBPβ 29. In this context, it has been recently shown that type II IFN/IFNγ , known to 
potently upregulate cytokine production in neutrophils30, also increases the transcription of IL-6 in human and 
murine macrophages stimulated with TLR ligands, via induction of a sustained signal transducer and activator 
of transcription 1 (STAT1) and IRF-1 occupancy at the IL-6 locus31. However, no recruitment of either STAT1 
(Fig. 4c) or IRF-1 (data not shown) to the promoter (Fig. 4c) or enhancers (data not shown) of the IL-6 locus was 
detected in neutrophils treated with IFNα , either alone or in combination with R848. Conversely, an evident Pol 
II (Fig. 4b, right panel) and STAT1 (Fig. 4c, right panel) recruitment at the IFIT1 promoter occurred in response 
to IFNα , at both the 6 and 20 h time-points. Instead, in neutrophils co-treated with IFNα plus R848 we detected 
an increased recruitment of C/EBPβ to the IL-6 promoter with respect to neutrophils treated with R848 only 
(Fig. 4d), which, interestingly, was measured already after 6 h of incubation. Notably, the increased recruitment 
of C/EBPβ to the IL-6 promoter of neutrophils treated for 20 h with IFNα plus R848 was partially, but not com-
pletely, reduced by ADA to the levels reached in neutrophils treated with R848 only, similarly to what observed in 
the case of IL-6 release (Fig. 3b) and IL-6 mRNA (Fig. 3c). Taken together, data demonstrate that, in R848-treated 
neutrophils, IFNα increases IL-6 transcription in a STAT1/IRF1-independent manner. Data also demonstrate 
that, under the same experimental conditions, IFNα augments the recruitment of C/EBPβ to the IL-6 promoter 
induced by R848 in a manner partially dependent on endogenous TNFα .
IFNα does not increase the prosurvival effect that R848 exerts on neutrophils. Given the 
well-known tendency of neutrophils to undergo apoptosis once cultured in vitro32, the observation that both 
IL-6 and TNFα are produced at maximal levels after an overnight incubation with IFNα plus R848 might appear 
intriguing. It should be, however, mentioned that TLR8 ligands have been already shown to delay neutrophil 
apoptosis33–35, as also confirmed by our flow cytometric analysis by Vybrant DyeCycle violet/Sytox stain (Fig. 5a). 
Because also IFNα delays neutrophil apoptosis36,37, we next investigated whether potential factors whereby R848 
delays neutrophil apoptosis also favor the production of IL-6, and whether IFNα had a positive effect on them, 
to ultimately enhance IL-6 expression. Since, R848-treated neutrophils produce, in addition to TNFα , also high 
amounts of G-CSF (Fig. 5b), and given that both G-CSF and TNFα delay neutrophil apoptosis32,38, we initially 
asked whether endogenous G-CSF and/or TNFα could play a role in mediating the prosurvival effect of R848. In 
the case of G-CSF, we found that G-CSF-blocking antibodies did not change the viability of neutrophils observed 
after 20 h of culture in the presence of R848 (Fig. 5c), even though they significantly decreased the prosurvival 
effect of exogenous G-CSF (Fig. 5c). Consistently, G-CSF neutralization did not have any effect on the induced 
IL-6 or CXCL8 mRNA accumulation in R848-treated neutrophils (Fig. 5d), while it almost completely abolished 
the induction of SOCS3 mRNA in response to exogenous G-CSF (Fig. 5d). Notably, neutrophil-derived G-CSF 
was biologically active, as supernatants harvested from R848-activated neutrophils (R848-SN in Fig. 5e) triggered, 
in 60 min, a G-CSF-dependent STAT3 tyrosine phosphorylation in freshly isolated heterologous neutrophils 
(Fig. 5e). Interestingly, the inability of R848-treated neutrophils to respond to endogenous G-CSF was found to 
likely rely on a complete downregulation of G-CSFR (Fig. 5f). Conversely, ADA, as well as ETA (data not shown), 
significantly decreased the prosurvival effect exerted by R848 in neutrophils (by 25 ± 4% at 20 h, n = 6) (Fig. 5g). 
Nonetheless, despite of the fact that it potently upregulates the production of TNFα in R848-treated neutrophils 
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Figure 3. Role of endogenous TNFα in mediating the enhancing effect of IFNα on the production of 
IL-6 by R848-treated neutrophils. (a) Neutrophils (5 × 106/ml), isolated from the peripheral blood of healthy 
donors, were cultured with or without 5 μ M R848, 1000 U/ml IFNα or IFNα plus R848 for 6, 12 and 20 h to 
evaluate: released (n = 3–11) (left panel), TNFα , as measured by ELISA, and TNFα mRNA expression (right 
panel), by RT-qPCR (n = 3–8). Asterisks indicate significant increase: **p < 0.01, by 2-way ANOVA followed 
by Bonferroni’s post-test. (b) IL-6 (left panel) and IL-1ra (right panel) levels in supernatants from neutrophils 
pretreated for 30 min with or without 10 μ g/ml ADA or 10 μ g/ml ETA and then incubated for further 20 h with 
1000 U/ml IFNα and/or 5 μ M R848. Values represent the mean ± SEM (n = 5). (c) IL-6 mRNA expression in 
neutrophils pretreated for 30 min with or without 10 μ g/ml ADA and then incubated for further 6 (left panel) or 
20 h (right panel) with 1000 U/ml IFNα and/or 5 μ M R848. Values represent the means ± SEM (n = 5). In (b,c), 
asterisks indicate significant inhibition by ADA: *p < 0.05, **p < 0.01, by 1-way ANOVA followed by Tukey’s 
post-test. (d) Iκ Bζ antigen expression (by western blot analysis) in neutrophils pretreated for 30 min with or 
without 10 μ g/ml ADA and then incubated for further 20 h with 1000 U/ml IFNα and/or 5 μ M R848. Samples 
were run on the same gel, but lanes were noncontiguous. A representative experiment out of two independent 
ones with similar results is shown (left panel). The graph (right panel) illustrates the relative densitometric 
quantification of Iκ Bζ levels (normalized by actin).
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(Fig. 3a), IFNα  did not exert any additional prosurvival effect on top of that promoted by R848 alone (Fig. 5h). 
All in all, data demonstrate that R848-induced viability is partially dependent on endogenously produced TNFα . 
Data, however, exclude that IFNα amplifies the production of IL-6 by R848-treated neutrophils simply because 
it enhances neutrophil survival.
R848-treated neutrophils do not express type I IFNs but produce increased levels of IL-6 when 
coincubated with type II IFN. Next, we ruled out any autocrine action of potential endogenous type I IFN 
in regulating IL-6 production by TLR8-activated neutrophils. RT-qPCR experiments, in fact, failed to detect any 
mRNA accumulation for both IFNβ (Fig. 6a, left panel) and IFNα , in the latter case as measured using primers 
recognizing all IFNα transcripts (IFNα 1–13, Fig. 6a, central panel), or specifically IFNα 2 (Fig. 6a, right panel). 
Lack of IFNα production was also confirmed at the protein level, as revealed by ELISA testing supernatants har-
vested from neutrophils treated for 20h, not only with R848, but also with various CpG preparations (CpG-ODN 
2006 and 2216) (Fig. 6b, left panel), which are known to activate TLR939. As expected39, pDCs incubated for 20 h 
with either CpG-ODN 2216, or R848, were found to release significant amounts of IFNα (data not shown). On 
the other hand, neutrophils released significant amounts of CXCL8 in response to CpG-ODN 2006 and R848 
(Fig. 6b, right panel), indicating that they were properly activated.
In other experiments, and supporting previous findings obtained in murine macrophages31, we observed that 
also type II IFN/IFNγ remarkably enhances the production of IL-6 by neutrophils incubated with R848. The latter 
phenomenon was observed to occur after 20 h of neutrophil incubation (Fig. 6c, left panel), concomitantly with 
an upregulation of IL-6 transcripts (Fig. 6d, left panel). Similarly to IFNα , while IFNγ did not exhibit any effect 
on CXCL8 mRNA expression (Fig. 6c, right panel) and protein production in R848-treated neutrophils (Fig. 6d, 
right panel), its effect on the increased IL-6 mRNA expression was accompanied by an enhanced C/EBPβ recruit-
ment to the IL-6 promoter (Fig. 6e).
Production of IL-6 in response to TLR7 and/or TLR8 agonists by SLE neutrophils. In a final 
series of experiments, we investigated whether highly purified neutrophils from SLE patients with active disease 
(SLEDAI > 5, see Table 1 for patient characterization), thus constitutively displaying remarkably elevated lev-
els of IFN-dependent genes, such as IFIT1, LGP2, IGS15, OASL and MDA5 (Fig. 7a), produce more IL-6 than 
neutrophils from healthy donors (HD) in response to TLR8 and/or TLR7 agonists. We found that SLE neutro-
phils treated with 5 μ M R848 produced twice as much IL-6 than control neutrophils (Fig. 7b). SLE neutrophils 
Figure 4. Effect of IFNα on Pol II, STAT1 and C/EBPβ recruitment to the IL-6 promoter in R848-treated 
neutrophils. (a) Neutrophils (5 × 106/ml), isolated from the peripheral blood of healthy donors, were cultured 
with or without 5 μ M R848, 1000 U/ml IFNα or IFNα plus R848 for 6, 12 and 20 h to evaluate IL-6 primary 
transcript (PT) expression by RT-qPCR (n = 3–8). Asterisks indicate a significant increase: **p < 0.01, by 2-way 
ANOVA followed by Bonferroni’s post-test. Evaluation of Pol II (b) and STAT1 (c) binding to the IL-6 (b,c, 
left panel) or to the IFIT1 (b,c, right panel) promoters by ChIP analysis in neutrophils incubated for 6 h and 
20 h with or without 1000 U/ml IFNα and/or 5 μ M R848. (d) Neutrophils were pretreated for 30 min with or 
without 10 μ g/ml ADA and then incubated for further 6 or 20 h with 1000 U/ml IFNα and/or 5 μ M R848 to be 
processed for ChIP analysis using C/EBPβ Abs. In panels b–d, the co-immunoprecipitated DNA samples were 
amplified using specific primer pairs and expressed as percent of the total input. Panel b depicts a representative 
experiment out of two ones with similar results while values in panels c,d stand for the mean ± SEM (n = 3). 
Asterisks in panel (c,d) indicate a significant increase with respect to untreated cells while # symbols indicate a 
significant inhibition exerted by ADA: * and #p < 0.05, ** and ##p < 0.01 and ***p < 0.001, by 1-way ANOVA 
followed by Tukey’s post-test.
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also released significantly more TNFα in response to R848 (Fig. 7b), and, interestingly, showed a tendency to 
release more CXCL8 than HD neutrophils (Fig. 7b). However, no increase of IL-1ra could be observed under 
the same experimental conditions (Fig. 7b), in line with the proinflammatory status of these SLE neutrophils40. 
By contrast, SLE neutrophils neither produced IL-6 or TNFα , nor significantly upregulated their IL-1ra produc-
tion in response to 5–50 μ M R837 (Fig. 7b), in accordance with their lack of TLR7 mRNA expression (Fig. 7a). 
Nonetheless, CXCL8 was released in a dose-dependent manner by both control and SLE neutrophils, yet at simi-
lar levels (Fig. 7b). Finally, no IFNα expression/production was observed under R848 or R837 stimulation (data 
not shown). The fact that neutrophils isolated from patients with active SLE – thus constitutively displaying 
the so-called IFN signature (Fig. 7a) – produce higher levels of both IL-6 and TNFα in response to R848 than 
HD neutrophils is consistent with the in vitro effects of IFNα  on the same cytokines (Figs 1a and 3a). It is also 
plausible that factors other than type I IFN might control the cytokine-producing capacity of neutrophils in SLE 
patients, as suggested by their different behavior to release CXCL8 and IL-1ra in response to R848 as compared to 
HD neutrophils incubated with IFNα and R848.
Discussion
IL-6 is a multifunctional cytokine involved in regulation of the immune system. As a potent pro-inflammatory 
cytokine, IL-6 plays a pivotal role in host defense against pathogens and acute stress41. Nonetheless, IL-6 plays 
Figure 5. The enhanced viability of R848-treated neutrophils is partially dependent on endogenous TNFα, 
but not G-CSF. (a) Neutrophils were cultured with or without 5 μ M R848 for up to 20 h, to be processed for 
viability evaluation by flow cytometry analysis. The percentage of alive cells was defined as Vybrant/Sytox 
double negative cell population (grey boxes). (b) G-CSF levels in supernatants from neutrophils cultured with 
or without 5 μ M R848 for up to 20 h. (c,g,h), viability of neutrophils after culture for 20 h with 5 μ M R848 
(c,g,h), 1000 U/ml G-CSF (c), 10 ng/ml TNFα (g), in the presence or not of, respectively, 10 μ g/ml mAbs 
neutralizing G-CSF (c), 10 μ g/ml ADA (g), or 1000 U/ml IFNα (h). Data are expressed as mean ± SEM (n = 3 
for panel c, n = 6 for panels g and h), while asterisks indicate a significant inhibition (for panels c,g) or increase 
(for panel h), as it follows: *p < 0.05, **p < 0.01, ***p < 0.001, by 2-way ANOVA followed by Bonferroni’s 
post-test. (d) IL-6, CXCL8 and SOCS3 mRNA expression in neutrophils pretreated for 30 min with or without 
10 μ g/ml neutralizing G-CSF mAbs and then incubated for further 20 h with 5 μ M R848 or 1000 U/ml G-CSF. 
Error bars represent the SEM calculated from triplicate qPCR reactions. A representative experiment out of 
three independent ones with similar results is shown. (e) STAT3 tyrosine phosphorylation in freshly isolated 
neutrophils, either untreated or cultured for 60 min with 5 μ M R848, 1000 U/ml G-CSF or supernatants from 
allogenic neutrophils incubated for 20 h with 5 μ M R848 (R848-SN), in the presence or absence of 10 μ g/ml 
neutralizing G-CSF mAbs (representative experiment, n = 2). The graph in the lower panel displays the relative 
densitometric quantification of p-STAT3 levels (normalized by total STAT3). (f) Neutrophils cultured for 20 h 
with or without 5 μ M R848 were analysed by flow cytometry for G-CSFR membrane expression using an anti-
G-CSFR (filled histogram) or matched isotype control (empty histogram) mAbs.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:19674 | DOI: 10.1038/srep19674
also a role in the pathogenesis of inflammatory and autoimmune diseases41. Recently, we demonstrated that upon 
activation of TLR8 by specific imidazoquinolines exerting antiviral activities, including R848 and CL075, neutro-
phils display the capacities to produce IL-6 in biologically active amounts8. Since neutrophils outnumber other 
immune cells under diverse inflammatory conditions, a detailed knowledge on how their production of IL-6 is 
regulated is of notable interest. In such regard, very crucial cytokines that, amongst others, modulate cytokine 
expression of immune cell and consequently also innate immune responses, are type I IFNs15. While being 
protective during acute viral infections, type I IFNs can also have deleterious roles in bacterial infections and 
Figure 6. R848-treated neutrophils do not express type I IFN but produce higher levels of IL-6 when 
coincubated with IFNγ. (a) Neutrophils were cultured with or without 5 μ M R848, 1000 U/ml IFNα or IFNα 
plus R848 for 6, 12 and 20 h to evaluate IFNβ , IFNα 1–13 and IFNα 2 mRNA expression by RT-qPCR (n = 3–8). In 
panel (b) neutrophils were cultured with or without 5 μ μ M R848, 2 μ M CpG ODN 2006 and 2 μ M CpG ODN 
2216 for 20 h and then IFNα (left panel) and CXCL8 (right panel) release were measured by specific ELISA. In 
panel (c–e) neutrophils were cultured with or without 5 μ M R848, 100 U/ml IFNγ or IFNγ plus R848 for 20 h 
(c), or 6 and 20 h (d,e), to evaluate: i) IL-6 (c, left panel) and CXCL8 (c, right panel) production by ELISA; ii) 
IL-6 (d, left panel) and CXCL8 (d, right panel) mRNA expression by RT-qPCR; iii) C/EBPβ binding to the IL-6 
and PRL promoters by ChIP analysis (e). Panels (d,e) depict a representative experiment out of two ones with 
similar results. ELISA values in panel (b,c) stand for the mean ± SEM (n = 5). Asterisks indicate a significant 
increase over control (b), or enhancement by IFNγ (c): *p < 0.05, **p < 0.01, ***p < 0.001, by 1-way ANOVA 
(b) or 2-way ANOVA (c).
Patient 
code Age Ethnicitya Gender
Disease state 
(SLEDAI) Symbolb
SLE # 1 36 C F 6 Δ 
SLE # 2 68 C F 8 ο 
SLE # 3 23 C F 5 □ 
SLE # 4 27 H F 14 ◊
SLE # 5 48 C F 12 ∇
SLE # 6 42 C F 11 *
Table 1. Characteristics of SLE patients. aH = Hispanic; C = Caucasian. bSymbols refer to Fig. 7a.
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autoimmune diseases42, including pathologies in which neutrophils are involved, such as sepsis43, pediatric SLE25 
and rheumatoid arthritis44. In this study, we show that TLR8-activated neutrophils produce approximately three 
times more IL-6 when cultured for 20 h in the presence of IFNα than in its absence, a phenomenon controlled 
at the level of both mRNA transcription and accumulation. Similarly, we report that neutrophils isolated from 
SLE patients with active disease produce significantly higher levels of IL-6 than neutrophils from healthy donors, 
when stimulated in vitro with R848 for 20 h. Because neutrophils from SLE patients displayed a strong “IFN sig-
nature”, it is tempting to speculate that their increased capacity to produce IL-6 likely depends on previous in vivo 
exposures to circulating type I IFN, thus consistent with in vitro experiments. Instead, no direct effect of IFNα on 
IL-6 gene expression could be detected. Also type II IFN/IFNγ was found to remarkably enhance the production 
of IL-6 by neutrophils treated with R848, further highlighting the capacity of these cells to fully respond to the 
interferon-induced signals during viral and autoimmune diseases.
In the attempt to clarify the molecular bases of such an IFNα -dependent enhancement of neutrophil-derived 
IL-6 we could exclude that IFNα does so simply by increasing the viability of neutrophils. In fact, even though 
we confirmed that TLR8 activation potently prolongs the survival of neutrophils12,33–35, viability of neutrophils 
incubated in the presence of both IFNα and R848 did not differ from that measured in neutrophils incubated in 
the presence of R848 only. Notably, under the latter experimental conditions, neutrophils were found to release 
remarkable amounts of biologically active G-CSF, as demonstrated by the capacity of supernatants harvested 
from R848-treated neutrophils to trigger a G-CSF-dependent STAT3 phosphorylation in heterologous neutro-
phils. However, contrary to our expectations, endogenous G-CSF was ineffective in R848-treated neutrophils, 
as surface G-CSFRs were completely downregulated. The biological meaning of such a G-CSFR disappearance 
in R848-treated neutrophils is unknown, but it has been observed to occur also in LPS-, TNFα -, fMLF- and 
C5a-treated cells45 as well as in vivo, after intravenous injection of LPS46. By contrast, we uncovered that the 
Figure 7. Gene expression profile and IL-6, TNFα, CXCL8 and IL-1ra production by neutrophils isolated 
from SLE patients. (a) IFIT1, LGP2, ISG15, OASL, MDA5, TLR7 and TLR8 mRNA expression in neutrophils 
freshly isolated from the peripheral blood of SLE patients with high SLEDAI (n = 6, each symbol identifying a 
different patient, see Table 1) and healthy donors (n = 10). Asterisks (***p < 0.001, by Student’s t test) indicate 
a significant difference between the two groups. (b) Amounts of IL-6, TNFα , CXCL8 and IL-1ra produced by 
peripheral neutrophils isolated from SLE patients (n = 6) and healthy donors (n = 6) cultured for 20 h in the 
presence of 5 μ M R848 and 5–50 μ M R837. Asterisks indicate a significant increase: *p < 0.05, by 2-way ANOVA 
followed by Bonferroni’s post-test.
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extended survival of R848-treated neutrophils partially depends on endogenous TNFα . Whether the enhanced 
viability mediated by endogenous TNFα also helps to sustain IL-6 production in R848-treated neutrophils 
remains to be demonstrated.
We also excluded that the IFNα -dependent enhancement of neutrophil-derived IL-6 is caused by an induc-
tion of TLR7 and its consequent co-activation with TLR8 in response to R848. Under our experimental condi-
tions, neither neutrophils from healthy donors incubated with IFNα , nor SLE neutrophils, were found to express 
TLR7 or respond to the TLR7-specific agonist R837 in terms of IL-6 production. These findings are in partial con-
tradiction with the results of a previous publication reporting that neutrophils isolated from juvenile SLE patients 
express TLR7 mRNA, as well as that, in vitro, 1000 U/ml IFNα could induce TLR7 mRNA expression in neutro-
phils from HDs25. While it should be kept in mind that juvenile and adult SLE are two clinically distinct diseases47, 
in which circulating neutrophils may be likely exposed to different mediators and, eventually, function diversely, 
other factors might explain the differences between our results and those by Garcia-Romo and collegues25. For 
instance, knowing that PBMCs express discrete levels of TLR748, it is plausible to hypothesize that potential con-
taminating PBMCs might have influenced the data outcome in the work by Garcia-Romo and collegues25; in fact, 
while neutrophils are isolated at a purity level greater than 99.7% in our hands8,49, in the study by Garcia-Romo 
and collegues25 neutrophils were stated greater than 98 % pure. On the same line, other studies, in which no 
precaution for completely removing all possible contaminating leukocytes were undertaken, have reported that 
resting neutrophils isolated from the blood could express low levels of TLR7 mRNA33,50,51. By contrast, no TLR7 
mRNA expression was detected when neutrophils were isolated to high levels of purity, in particular in terms of 
contaminating eosinophils52,53. How critical is the purity of neutrophils to obtain genuine and reliable results in 
the context of gene expression studies has been already evidenced3,54.
Interestingly, we found that both neutrophils from healthy donors and SLE patients similarly respond to R837 
in terms of CXCL8 production, but only if the TLR7 agonist was used at 25–50 μ M. In this latter case, our obser-
vations confirm the results by Garcia-Romo et al.25, who also showed that juvenile SLE neutrophils produce 
CXCL8 in response to 36 μ M R83725. However, since in our experiments CXCL8 produced by R837-treated neu-
trophils was not abrogated by the pretreatment of neutrophils with BafilomycinA1, it is our opinion that it likely 
occurs via other, not yet identified, TLR7-independent mechanism. Our observations are, in any case, consistent 
with previous findings demonstrating that chemotaxis and H2O2 release induced by R837 in human neutrophils 
occur in an IRAK4-independent manner, thus without activating a canonical, TLR-activated MyD88-dependent 
signaling pathway55. In this study, we also demonstrate that the augmentation of IL-6 production by IFNα in 
R848-treated neutrophils largely coincides with an enhanced production and release of TNFα , which, in turn, 
appears to substantially mediate it. Even neutrophils from SLE patients with active disease were found to pro-
duce greater TNFα amounts than healthy controls in response to R848, further supporting our in vitro results 
on the effects of IFNα on TNFα expression as well. Consistent with the role of endogenous TNFα in mediating 
the effects of IFNα on IL-6 gene expression, we demonstrated an enhanced recruitment of C/EBPβ to the IL-6 
promoter in IFNα plus R848-treated neutrophils8. Although the notion that endogenous TNFα may mediate 
the enhanced IL-6 production exerted by IFNα in TLR8-activated neutrophils is not so surprising at the light of 
our recently published data8, it nonetheless emphasizes how important is TNFα for neutrophil physiopathology. 
This is further highlighted in studies showing that the interferon gene expression signature in neutrophils from 
rheumatoid arthritis patients correlates with a good response to anti-TNF therapy44, once again indicating that 
IFN activity is mediated via TNFα induction.
Concomitantly, we failed to detect any expression of type I IFN in neutrophils incubated with IFNα and/or 
R848, thus excluding an autocrine action by endogenous type I IFN in regulating the production of IL-6. In our 
hands, lack of IFNα production was also observed in neutrophils treated with CpG-ODN 2006 and 2216, namely 
under experimental conditions previously shown by Lindau and colleagues56 to induce neutrophil-derived IFNα 
at greater levels than R848. In the latter study56, neutrophils were stated to be approximately 99.8 % pure, thus 
excluding the presence of contaminating cells likely producing IFNα . Moreover, that our neutrophil preparations 
were properly activated was demonstrated by the fact that they released significant amounts of CXCL8 in response 
to CpG-ODN 2006. Therefore, we do not know how to explain why we failed to detect type I IFN in neutrophils. 
One possible explanation is that we might have found, by chance, “non-responder donors”, as also occurred to 
Lindau and colleagues themselves56. In summary, our data uncover that TLR8 ligands, IFNα and TNFα , three 
players often coexisting in many diseases of viral or autoimmune origin, promote a strong production of IL-6 in 
human neutrophils placing this cell type among potential targets for immunotherapeutic interventions.
Materials and Methods
Cell purification and culture. Granulocytes were isolated from buffy coats of healthy donors or, for selected 
experiments, from peripheral blood of SLE patients (see below) and as previously described, manipulated under 
endotoxin-free conditions57. Briefly, buffy coats or peripheral blood was centrifuged on Ficoll-Paque PLUS gra-
dient (1078 g/ml density, GE Healthcare, Little Chalfont, United Kingdom) at 400 × g for 30 min, at room T, at a 
1:1 ratio. Then, granulocytes were obtained by dextran sedimentation followed by hypotonic lysis of erythrocytes. 
Finally, neutrophils were isolated to reach 99.7 ± 0.2 % purity by positively removing all contaminating cells 
using the EasySep neutrophil enrichment kit (StemCell Technologies, Vancouver, Canada)8,22. Neutrophils were 
then suspended at 5 × 106/ml in RPMI 1640 medium supplemented with 10 % low endotoxin FBS (< 0.5 EU/ml; 
from BioWhittaker-Lonza, Basel, Switzerland), treated or not with 1000 U/ml pegylated IFNα -2a (Pegasys, 
Roche, Basel, Switzerland), 100 U/ml IFNγ (R&D Systems, Minneapolis, MN, USA) 5 μ M R848, 5–50 μ M 
R837, 2 μ M CpG ODN 2006 and 2 μ M CpG ODN 2216 (Invivogen, San Diego, CA, USA), 10 ng/ml TNFα 
(Peprotech, Rocky Hill, NJ, USA), 100 ng/ml ultrapure LPS from E. coli 0111:B4 strain (Alexis, Enzo Life Sciences, 
Farmingdale, NY, USA), 1000 U/ml G-CSF (Myelostim, Italfarmaco Spa, Milano, Italy), and then plated either in 
6/24-well tissue culture plates or in polystyrene flasks (from Greiner Bio-One, Kremsmünster, Austria) for culture 
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at 37°C, 5% CO2 atmosphere. In selected experiments, neutrophils were preincubated for 30 min with 10 μ g/ml 
adalimumab (Humira, Abbott Biotechnology Limited, Barceloneta, Puerto Rico), 10 μ g/ml etanercept (Enbrel, 
Amgen, Thousand Oaks, CA, USA), or 5 μ g/ml anti-human G-CSF (Clone 3316, R&D Systems), prior to stimula-
tion. After the desired incubation period, neutrophils were either processed for Chromatin Immunoprecipitation 
(ChIP) experiments, or collected and spun at 300 × g for 5 min, for other assay types. In the latter case, cell-free 
supernatants were immediately frozen in liquid nitrogen and stored at − 80 °C, while the corresponding cell pel-
lets were either extracted for total RNA or lysed for protein analysis. pDCs were isolated as previously described58 
using the BDCA-4 Diamond Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
ELISA. Cytokine concentrations in cell-free supernatants and cell-lysates were measured by commercially 
available ELISA kits, specific for human IL-6 (eBioscience, San Diego, CA, USA), TNFα (eBioscience), G-CSF 
(R&D Systems), IL-1ra (R&D Systems), CXCL8 (Mabtech, Nacka Strand, Sweden) and IFNα (Mabtech). 
Detection limits of these ELISA were: 8 pg/ml for IL-6 and IFNα , 4 pg/ml for TNFα , 40 pg/ml for IL-1ra, 16 pg/ml 
for G-CSF and CXCL8.
Flow cytometry. Phenotypic studies were performed exactly as previously described8. For G-CSFR staining, 
105 neutrophils, incubated with or without 5 μ M R848 for the indicated times, were harvested and stained for 
15 min at room T with 1:20 PE anti-human CD114 (G-CSF-R) mAb (clone LMM741, Biolegend, San Diego, CA, 
USA), or with 1:20 PE control mouse IgG1 (BD Biosciences, San Jose, CA, USA). Then, cells were washed and 
stained for Vybrant DyeCycleTM (Life Technologies, Carlsbad, CA, USA) to discriminate cells that were alive, as 
described below. Sample fluorescence was measured by a seven-color MACSQuant Analyzer (Miltenyi Biotec), 
while data analysis was performed by using FlowJo software Version 8.8.6 (Tree Star, Ashland, OR, USA).
Neutrophil viability. After an overnight treatment with the agonists indicated above, 105 neutrophils were 
centrifuged at 300 × g for 5 min, medium removed and ultimately suspended in 100 μ l HBSS buffer containing 
10 nM Vybrant DyeCycleTM Violet stain (Life Technologies) and 5μ M SYTOX AADvanced (Life Technologies). 
Cells were then put on ice for 30 min, protected from light. Cell viability was defined as the percentage of cells that 
were double negative for both stains (Vybrant/Sytox, respectively).
Reverse transcription quantitative real-time PCR (RT-qPCR). Total RNA was extracted from neu-
trophils after lysis by RNeasy Mini Kit (Qiagen, Venlo, Limburg, Netherlands), according to the manufactur-
er’s instructions. To completely remove any possible contaminating DNA, an on-column DNase digestion with 
the RNase-free DNase set (Qiagen) was performed during total RNA isolation. Purified total RNA was then 
reverse-transcribed into cDNA using Superscript III (Life Technologies) and random hexamer primers (Life 
Technologies) while qPCR was carried out using Fast SYBR® Green Master Mix (Life Technologies)59. Sequences 
of gene-specific primer pairs (Life Technologies) are available in the public database RTPrimerDB (www.rtprim-
erdb.org) under the following entry codes: GAPDH (3539), TNFα (3551), CXCL8 (3553), IL-6 (3545), PT-IL-6 
(8687), IFNα 1–13 (3541), IFNα 2 (8955), IFN-β (3542), G-CSF (8615), SOCS3 (3828), TLR7 (8684), TLR8 (8685), 
IFIT1 (3540), MDA5 (3917), ISG15 (3547), LGP2 (3918) and OASL (3550). Data were calculated by Q-Gene soft-
ware (http://www.gene-quantification.de/download.html) and expressed as mean normalized expression (MNE) 
units after GAPDH normalization.
Immunoblots. Whole-cell proteins were recovered from protein-rich flow-through solutions after the first 
centrifugation step of the RNeasy Mini Kit (Qiagen) used for total RNA extraction, as previously described8. 
Proteins were then immunoblotted by standard procedures using the following antibodies: anti-Iκ Bζ rabbit pAb 
(#9244) and anti-phospho-STAT3 (Tyr705) rabbit pAb (#9131) from Cell Signaling (Beverly, MA, USA); rab-
bit pAb anti-STAT3 (sc-482, Santa Cruz Biotechnology, Dallas, TX, USA); rabbit pAb anti-actin (A5060) from 
Sigma. Blotted proteins were detected and quantified by using the Odyssey infrared imaging system (LI-COR 
Biosciences, Lincoln, NE, USA). Densitometry values were calculated by subtracting, for each lane, the respective 
background levels.
Chromatin Immunoprecipitation (ChIP) experiments. ChIP experiments were performed exactly 
as previously described8. Briefly, nuclear extracts from 5 × 106 or 107 neutrophils (for ChIP targeting, respec-
tively, H3K27Ac or STAT1, IRF1, C/EBPβ and PolII) were immunoprecipitated with 1 μ l anti-H3K27Ac (ab4729) 
(Abcam, Cambridge, United Kingdom), 25 μ l anti-STAT1 (sc-346), 25 μ l anti-IRF1 (sc-497), 20 μ l anti- C/EBPβ 
(sc-150), 20 μ l anti-PolII (sc-899) (Santa Cruz Biotechnology). To establish the background levels of ChIP experi-
ments, the precipitation signal was quantified also at the promoter of prolactin (PRL) since it is completely silent in 
myeloid cells. The coimmunoprecipitated material was subjected to qPCR analysis using the following promoter 
specific primers (purchased from Life Technologies): IL-6 forward: 5′ -TAGCCTCAATGACGACCTAAG-3′ ; IL-6 
reverse: 5′ -GTGGGGCTGATTGGAAACCT-3′ ; IFIT1 forward: 5′ -GGCAGCAATGGACTGATGTTC-3′ ; IFIT1 
reverse: 5′ -GGAAACCGAAAGGGGAAAGTG-3′ ; and PRL forward: 5′ -AGGGAAACGAATGCCTGATT-3′ ; 
PRL reverse: 5′ -GCAGGAAACACACTTCACCA-3′ . Data from qPCR were expressed as percentage over input 
DNA and are displayed as means ± SEM.
Statistical analysis. Data are expressed as mean ± SE. Statistical evaluation was performed using Student’s 
t test, 1-way ANOVA followed by Tukey’s post hoc test or 2-way ANOVA followed by Bonferroni’s post hoc test. 
Values of P < 0.05 were considered as statistically significant.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:19674 | DOI: 10.1038/srep19674
Study approval. Human samples were obtained following informed written consent by both healthy donors 
and SLE patients. Clinical evaluation of SLE diseases activity was assessed by the SLEDAI60 at the moment of the 
venipuncture. As reported in Table 1, only patients with moderate or severe flare (e.g., SLEDAI higher than 5) 
were recruited for our analysis. All experimental protocols were approved by the Ethic Committee of the Azienda 
Ospedaliera Universitaria Integrata di Verona (Italy). The methods were carried out in accordance with the 
approved guidelines.
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neutrophilsTo the Editor:
The identification of polymorphonuclear neutrophils as
cellular source of cytokines prompts researchers in the field to
investigate whether the production of neutrophil-derived cyto-
kines can be altered in human diseases.1 For such a purpose, we
developed a simple procedure that allows the isolation of more
than 99.6% pure neutrophils (here defined as Neu) from either
whole blood or buffy coats.2 Our procedure includes a densitygradient centrifugation step of whole blood/buffy coats over
Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, United
Kingdom), dextran sedimentation, and red cell osmotic lysis
of the granulocyte pellet, and a final immunomagnetic negative
selection step using the ‘‘EasySep Human Neutrophil Enrich-
ment Kit’’2 (StemCell Technologies, Vancouver, British
Columbia, Canada). By doing so, we have recently reported
that Neu incubated with 5 mM R848 (a TLR8 ligand) produce
IL-6 and TNF-a starting from 6 hours, and at maximal levels
after an overnight incubation (up to 200 pg/mL/
5 3 106 cells).2 Under the same experimental conditions, how-
ever, Neu neither express mRNA encoding IL-102 or interferon-
stimulated genes (ISGs) such as interferon-induced protein with
tetratricopeptide repeats 1 (IFIT1) and ISG15,E1 nor produce
IL-10.3
Recently, 1-step kits specifically designed to guarantee a rapid
isolation of ‘‘unstressed,’’ highly pure, neutrophils from the blood,
skipping any density gradient centrifugation step, have been
released into the market. These kits include the ‘‘MACSxpress
Neutrophil isolation kit’’ (Miltenyi Biotec, Bergisch Gladbach,
Germany) and the ‘‘EasySep direct Human Neutrophil Isolation
Kit,’’ the resulting neutrophils defined here as wbNeuM and
wbNeuE, respectively. To our surprise, both wbNeuM and
wbNeuE incubated with R848 for 20 hours were found to express
remarkable levels of IL-10, IFIT1, and ISG15 mRNA (Fig 1, A),
as well as to release detectable amounts of IL-10 (Fig 1, B).
Furthermore, although both wbNeuM and wbNeuE accumulated
IFIT1 and ISG15 transcripts also upon incubation with
50 mg/mL poly(I:C) (a TLR3 ligand) for 20 hours (Fig 1, A),
Neu did not, consistent with the notion that human neutrophils
lack TLR3.4,E2 R848-treated wbNeuM and wbNeuE were also
induced to accumulate and release elevated levels of IL-6
mRNA (Fig 1, A) and IL-6 protein (Fig 1, B), respectively, already
after 4 hours of incubation, unlike Neu.2 Similarly, TNF-a and
CXCL8 mRNA expression (Fig 1, A) and production (Fig 1, B)
were much higher in wbNeuM and wbNeuE than in Neu. In
contrast, wbNeuM, wbNeuE, and Neu did not show remarkable
differences upon incubation with 10 ng/mL TNF-a, in terms of
either CXCL8 mRNA accumulation and production, or other
cytokine expression (Fig 1).
Given these unexpected results, we evaluated the precise purity
of wbNeuM, wbNeuE, and Neu by flow cytometric analysis,
using a panel of 13 markers allowing the identification of
the most representative leukocyte types in the blood. Neu
was confirmed to be 99.77% 6 0.15% pure,2 whereas
both wbNeuM and wbNeuE, although reaching a purity of
98.86%6 0.25% and 97.46%6 1.06%, respectively (confirming
what is declared in their related kit datasheets), were found
to be reproducibly contaminated by eosinophils and
slan1CD161-monocytes5 (also known as slanDCsE3), the
latter cells representing the majority of the wbNeuM- and
wbNeuE-copurified CD161-monocytes (see Table E1 in this
article’s Online Repository at www.jacionline.org). However,
eosinophil contamination was found irrelevant because
neutrophils isolated by Ficoll-Paque followed by dextran
sedimentation and erythrocyte lysis (here defined as NeuF),
although containing 1.52% 6 1.12% eosinophils, did not differ
from Neu in terms of CXCL8 production, IL-6 and TNF-a
mRNA expression in response to R848, or IFIT1 and
ISG15 mRNA expression in response to either R848 or
poly(:C) (see Fig E1 in this article’s Online Repository at
FIG 1. Patterns of gene expression and cytokine production by Neu,wbNeuM, andwbNeuE incubated with
R848, poly(I:C), or TNF-a. Neu, wbNeuM, and wbNeuE were incubated with 5 mM R848, 50 mg/mL poly(I:C),
or 10 ng/mL TNF-a for mRNA expression analysis by RT-quantitative PCR (A) and cytokine production by
ELISA (B). Analysis of IL-6 and TNF-a was performed after 4 hours of incubation, whereas that of CXCL8,
IL-10, IFIT1, and ISG15 was performed after 20 hours. Panels A and B display representative experiments
out of 3 performed with similar results. MNE, Mean normalized units; n.d., not done.
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quently hypothesized as most likely responsible for the abnormal
cytokine-producing response by wbNeuM and wbNeuE, given
their well-known capacity to produce remarkably elevated
amounts of cytokines when stimulated by R848 or other TLR
ligands.E4 Our prediction appeared to be correct as, after
depletion of slan1CD161-monocytes by saturating amounts of
aM-DC8–linked microbeads (see Fig E2 in this article’s Online
Repository at www.jacionline.org), wbNeuM completely lost
the capacity to produce IL-10 (Fig 2, A), as well to express
IFIT1 and ISG15 mRNA in response to either R848 or poly(I:C)
(Fig 2, B). The effect of slan1CD161-monocyte-depletion wasless effective in the case of wbNeuE, particularly for IFIT1 and
ISG15 mRNA expression (Fig 2, B). Nonetheless, both wbNeuM
and wbNeuE depleted of slan1CD161-monocytes lost the
capacity to express IL-6, and produced TNF-a at much lesser
levels than did untouched wbNeuM and wbNeuE, after incubation
with R848 for 4 hours (Fig 2, A and B). Notably, that
slan1CD161-monocytes, but not neutrophils, were the cells
actually producing IL-10 in response to R848 was clearly
evidenced by a specific ‘‘IL-10 secretion assay’’ showing that
only slan1CD161-monocytes stained positive for IL-10
within wbNeuE (see Fig E3 in this article’s Online Repository
at www.jacionline.org) or wbNeuM (data not shown).
FIG 2. Effects of the removal of various contaminating leukocyte subtypes from wbNeuM and wbNeuE.
Percentages of decrease in cytokine production (A) and gene expression (B-D), observed in wbNeuM (Fig
2, A and B) and wbNeuE (Fig 2, A-D) depleted of slan1CD161-monocytes, alone (Fig 2, A and B) (n 5 2-5),
or together with B cells, natural killer cells, or pDCs (Fig 2, C and D) (n 5 3). Analysis of IL-6 and TNF-a
mRNA expression/production was performed after 4 hours, whereas that of IL-10, IFIT1, and ISG15 was
performed after 20 hours of incubation (Fig 2, C and D). *P < .05 by 1-way ANOVA followed by Tukey
posttest.
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slan1CD161-monocytes, could be responsible for IFIT1 and
ISG15 mRNA expression in wbNeuE treated with either R848
or poly(I:C), we performed additional depletion experiments
also targeting B cells, or natural killer cells, or plasmacytoid
dendritic cells (pDCs) (see Fig E4 in this article’s Online Repos-
itory at www.jacionline.org). As shown in Fig 2, C, depletion of
both slan1CD161-monocytes and pDCs from wbNeuE treated
with R848 almost completely abolished the expression ofIFIT1 and ISG15 mRNAs, consistent with the capacity of
pDCs to produce IFN-a in response to R848 stimulation and,
in turn, express ISGs.E5 In the case of poly(I:C) stimulation,
removal of slan1CD161-monocytes together with either natural
killer cells or pDCs slightly, but not significantly, decreased the
expression of IFIT1 and ISG15 mRNAs in wbNeuE (Fig 2, D),
whereas removal of slan1CD161-monocytes together with
B cells was irrelevant. The latter findings indicate that other
leukocyte subtypes, or combination of them, are responsible
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wbNeuE.
Taken together, our data demonstrate that the profile of
cytokines derived from the stimulation of wbNeuM and wbNeuE
may appear profoundly altered as a consequence of their
contamination with very small percentages of slan1CD161-
monocytes (0.1% to 0.6%), alone or in combination with pDCs
or other leukocyte subtypes. Such an inconvenience becomes,
in fact, evident if wbNeuM and wbNeuE are stimulated with
TLR ligands, but not with TNF-a. These findings support what
we have been always recommending,1,6 namely, that it is abso-
lutely mandatory to use highly purified populations of neutrophils
when gene expression and/or neutrophil-derived cytokines are
investigated. Hence, based on the data presented here, the use
of commercial kits aimed at rapidly purifying neutrophils is
certainly advisable, provided that these kits are used after a round
of blood density gradient centrifugation. Without this step, which
ensures the elimination of most PBMCs from granulocytes, in
turn favoring an optimal negative selection of contaminating cells
by these specific kits, researchers may inadvertently obtain
false-positive results: these may include the detection of either
cytokines/genes made by contaminating cells,7 or unusually
high amounts of neutrophil-derived cytokines, as shown here or
elsewhere.8,9,E6 Moreover, although it has been unequivocally
demonstrated that, in human neutrophils, the IL-10 locus is in
an inactive state and cannot be remodeled in response to TLR
ligands,3 articles reporting the detection of IL-10 in supernatants
from TLR-activated neutrophils7 continue to be, since then,
published. Given that wbNeuM or neutrophils with unascertained
purity were used in these reports,7 caution should be undertaken
on their reliability based on the data presented here.
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expression via the extracellular
signal-regulated kinase and signal
transducer and activator of
transcription–dependent pathwaysTo the Editor:
Volatile organic compounds (VOCs) can be an important
environmental risk factor in the development and/or aggravation
of atopic dermatitis (AD). A previous study reported that xylene
and formaldehyde intensified allergic inflammation in an
experimental mouse model.1 In a prospective study to evaluate
the clinical effects of air pollution including VOCs on skin
symptoms in children with AD,2 concentrations of total VOCs
were higher on days when the patients had symptoms of AD
than on days without symptoms. A significant increase in
transepidermal water loss after exposure to VOCs was also
reported.3 Although these accumulated data show an association
between exposure to VOCs and aggravation of AD, the molecular
effects of VOCs on the aggravation of AD are still unclear.
Filaggrin is a key regulator in epidermal barrier function. The
pathogenesis of AD may be proposed as an epidermal barrier
defect that leads to diminished epidermal defense mechanisms.3
In a cohort study, filaggrin mutations were associated with the
predilection sites of AD that are exposed areas of the body such
as hands and cheeks, whereas there were no predilection sites in
persons with the wild-type gene.4 These sites are typically
exposed to environmental factors including irritants, air pollution,
and chemicals. This suggests that persons with mutations in genes
encoding proteins of the skin barrier are susceptible to AD when
exposed to environmental triggers. On the basis of these reports,
we investigated the effects of toluene, a typical VOC that usually
occurs in indoor air from the use of common household products
(paints, paint thinners, adhesives, synthetic fragrances, and nail
polish) and cigarette smoke, on filaggrin-mediated epidermal
barrier dysfunction.
After toluene exposure, the expression of filaggrin mRNA and
protein decreased (Fig 1, A and B). Furthermore, to determine
whether toluene affects the expression of other keratinocyte
differentiation-associated markers (eg, involucrin, loricrin, keratin
10, and keratin 5), we measured the mRNA levels of each of these
molecules after toluene treatment. The present study demonstrated
that toluene did not significantly affect the expression of involucrin,
loricrin, keratin 10, and keratin 5 (data not shown). Fluorescence
microscopy analysis also showed that filaggrin levels were lower
in toluene-treated human skin equivalent models than in untreated
human skin equivalent models (Fig 1,C). In addition, we evaluated
the filaggrin breakdown products such as natural moisturizing
factor (NMF) associated with transepidermal water loss.
Pyrrolidone carboxylic acid and urocanic acid are known as the
main components of NMF. As a result, levels of NMF components
METHODS
Cell purification and culture
Neutrophils from the same donors were isolated by different methods, as
follows: (1) by density gradient centrifugation of whole blood over
Ficoll-Paque PLUS (GE Healthcare), dextran sedimentation, and erythrocyte
osmotic lysis (NeuF); (2) similarly to NeuF, but with an additional
immunomagnetic negative selection step, using the ‘‘EasySep Human
Neutrophil Enrichment Kit’’ (StemCell Technologies) (Neu); (3) directly
isolated from whole blood, by the ‘‘MACSxpress Neutrophil isolation kit’’
(Miltenyi Biotec) (wbNeuM); and (4) directly isolated from whole blood by
the ‘‘EasySep direct Human Neutrophil Isolation Kit’’ (StemCell Technolo-
gies) (wbNeuE). In selected experiments, 8 3 106 wbNeuM or wbNeuE
were incubated with or without 30 mL of aM-DC8 microbeads (Miltenyi
Biotec) for 20 minutes on ice, and then slan1CD161-monocytes were
removed by separation via MACS LD column (Miltenyi Biotec). In other
experiments, wbNeuE were stained by a combination of 10 mL of aM-DC8-
fluorescein isothiocyanate (FITC) (Miltenyi Biotec) with or without 20 mL
of aCD19-FITC (Miltenyi Biotec) or 20 mL of aCD56-FITC (Miltenyi Bio-
tec) or 10 mL of aCD303-FITC (Miltenyi Biotec) for 20 minutes on ice.
Removal of stained cells was then achieved by incubation with 20 mL of
anti-FITC microbeads for 20 minutes on ice and subsequent passage through
MACSLD column. Neutrophils were suspended at 53 106/mL in RPMI 1640
medium supplemented with 10% low-endotoxin FBS (<0.5 EU/mL, from
Sigma, St Louis, Mo), treated with 5 mMR848 (Invivogen, San Diego, Calif),
50 mg/mL poly(I:C) (Invivogen), and 10 ng/mL TNF-a (Peprotech, Rocky
Hill, NJ), and finally plated in 48-well tissue culture plates (Greiner Bio-
One, Kremsm€unster, Austria) for culture at 378C, 5% CO2 atmosphere. After
4 or 20 hours, neutrophils were collected and spun at 300g for 5 minutes.
Cell-free supernatants were immediately frozen in liquid nitrogen and stored
at 2808C, while the corresponding pellets were extracted for total RNA.
ELISA
Cytokine concentrations in cell-free supernatants were measured by
ELISA kits specific for IL-6 (eBioscience, San Diego, Calif), IL-10
(eBioscience), TNF-a (eBioscience), and CXCL8 (Mabtech, Nacka Strand,
Sweden). Detection limits of these ELISAs were 8 pg/mL for IL-6, 4 pg/mL
for IL-10 and TNF-a, and 8 pg/mL for CXCL8.
RT-quantitative real-time PCR
Total RNA (0.1 mg) extracted by the RNeasy mini kit (Qiagen, Venlo,
Limburg, The Netherlands) from 1 3 106 neutrophils was reverse
transcribed for RT-quantitative PCR using gene-specific primer pairs (Life
Technologies, Carlsbad, Calif) available in the public database RTPrimerDB
(www.rtprimerdb.org) under the following entry codes: glyceraldehyde-3-
phosphate dehydrogenase (3539), TNF-a (3551), CXCL8 (3553), IL-6
(3545), IL-10 (8230), IFIT1 (3540), and ISG15 (3547). Data were calculated
by Q-Gene software (http://www.genequantification.de/download.html)
and expressed as mean normalized expression units after glyceraldehyde-
3-phosphate dehydrogenase normalization.
Phenotype assessment by flow cytometry
A total of 105 freshly isolated neutrophil populations were suspended
in 50 mL PBS containing 10% complement-inactivated human serum (for
Fcg receptor blocking). Neutrophils were then stained for 15 minutes at
room temperature with different combinations of the following regents:
aCD14-Vioblue (clone T€UK4), aCD3-PE-Vio770 (clone BW 264156),
aCD19-APC (clone LT19), aCD56-PE (clone REA196), aM-DC8-FITC
(clone DD1), aCD11c-Vioblue (clone MJ4-27G12), aCD303-FITC (clone
AC144), aCD141-APC (clone AD5-14H12), aFCeR1a-PE (clone CRA1)
antibodies from Miltenyi Biotec; aCD1c-Alexa488 (clone L161), aCD45
brilliant Violet 510 (clone H130), aCD16-PerCP-Cy5.5 (clone 3G8), and
aHLA-DR-APC-CY7 (clone L243) antibodies from Biolegend (Sa Diego,
Calif) and aCD123-PE (clone 9F5) antibodies from BD Bioscience (San
Jose, Calif). After washings, sample fluorescence was measured by an
8-color MACSQuant Analyzer (Miltenyi Biotec), for which at least
40,000 cells were acquired. Data analysis was performed using FlowJo
software Version 8.8.6 (Tree Star, Ashland, Ore).
IL-10 secretion assay
A total of 2 3 106 neutrophils were treated with or without 5 mM R848 or
10 ng/mL of TNF-a for 14 hours at 378C, then washed, incubated for 5 minutes
with IL-10–catching reagent (Miltenyi Biotec) on ice, immediately diluted with
warm medium, and then left for 45 minutes at 378C on constant rotation to let
IL-10 secretion proceed. After extensive washings, cells were stained on ice
withaIL-10PE,aM-DC8-FITC, andaHLA-DRAPC-Cy7Abs. Vybrant Violet
(Life Technologies)was used as cell viability reagent.Neutrophilswere gated as
high SSChigh/Vybrant-negative cells, whereas slan1CD161-monocytes were
gated as M-DC8/HLA-DR1, Vybrant-negative cells. A total of 800,000 cells
per sample were acquired, as average, by MACSQuant Analyzer.
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FIG E1. CXCL8 production and gene expression patterns in Neu and NeuF incubated with R848 or poly(I:C).
Neu andNeuFwere incubated for 20 hwith either 5 mMR848 or 10 ng/ml TNFa for CXCL8 release (A), or with
either R848 or 50 mg/ml poly(I:C) for IL-6 and TNFa (B), or IFIT1 and ISG15 (C), mRNA expression analysis, by
RT-qPCR, performed after 4 and 20 h of incubation, respectively. Panel A reports themean of 2 experiments,
while panels B and C display representative experiments out of 3 performed with similar results.
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FIG E2. Assessment of slan1CD161-monocyte removal from wbNeuM and wbNeuE. After wbNeuM and
wbNeuE neutrophils isolation, slan1CD161-monocytes were removed by separation using aM-DC8-linked
microbeads viaMACS column. Flow cytometry analysis was then used to assess the levels of contaminant
slan1CD161-monocytes present in neutrophils preparations. Accordingly, contaminating PBMCs were first
identified by SSClow/CD45 positivity (left panels, black gate), and then slan1CD161-monocytes were
selected among them, as M-DC8/CD16 double positive cells (right panels, red gate) and overlayed (red
dots) on total CD45 cells.
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FIG E3. IL-10 secretion assay. 2 x 106WbNeuEwere treated with or without 5 mMR848 or 10 ng/mL TNFa for
14 h and then assayed for IL-10 secretion. Histograms, displaying 1 representative experiment out of 2 with
similar results, show that only slan1CD161-monocytes (right panel), but not neutrophils (left panel), secrete
IL-10. Similar results were obtained using WbNeuM.
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FIG E4. Assessment of slan1CD161-monocyte, B cell, NK cell and pDC removal from wbNeuE. After
isolation, wbNeuE were stained with FITC-conjugated antibodies towards M-DC8 (for slan1CD161-
monocytes) alone or in combination with CD19 (for B cells), CD56 (for NK cells) or CD303 (for pDCs). Panels
show that removal of stained cells was efficiently achieved by anti-FITC microbeads via MACS column
separation. In fact, contaminating PBMCs were first gated by SSClow/CD45 positivity (upper panels, black
gate), and then slan1CD161-monocytes (red dots), B cells (light blue dots), NK cells (green dots) and
pDCs (purple dots) were identified, using specific CD markers overlaid on HLA-DR/CD123 dot plots.
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TABLE E1. Cellular composition of the neutrophil populations isolated from human blood by various procedures
Cell type
Neu (Ficoll and
Easysep kit) (n 5 5)
WbNeuM
(MACSxpress kit) (n 5 5)
WbNeuE
(Easysep direct kit) (n 5 7)
NeuF (Ficoll-Paque)
(n 5 3)
Neutrophils* 99.77 6 0.15 98.86 6 0.25 97.46 6 1.06 96.17 6 2.66
Eosinophils 0.07 6 0.06 0.29 6 0.37 0.53 6 0.61 1.52 6 1.12
CD141-monocytes 0.00 6 0.00 0.02 6 0.02 0.04 6 0.04 0.03 6 0.03
Total CD161-monocytes§ 0.00 6 0.00 0.38 6 0.20 0.25 6 0.18 0.00 6 0.00
slan1CD161-monocytes{ 0.00 6 0.00 0.33 6 0.16 0.22 6 0.19 0.00 6 0.00
CD1c DCsk 0.00 6 0.00 0.00 6 0.00 0.00 6 0.00 0.00 6 0.00
CD141 DCs# 0.00 6 0.00 0.01 6 0.00 0.02 6 0.02 0.00 6 0.01
pDCs** 0.00 6 0.00 0.00 6 0.00 0.06 6 0.03 0.00 6 0.00
T cells 0.05 6 0.09 0.09 6 0.05 0.13 6 0.30 1.95 6 1.81
B cells 0.00 6 0.00 0.02 6 0.02 0.33 6 0.16 0.00 6 0.01
NK cells§§ 0.01 6 0.01 0.11 6 0.08 0.25 6 0.18 0.27 6 0.46
Values are in %. Cell percentages were calculated on the basis of total CD451 cells. The various leukocyte populations were identified by flow cytometry analysis using the
following criteria/surface markers: *SSChi/CD161 cells 5 neutrophils; SSChi/CD162 cells 5 eosinophils; CD141/CD162 cells 5 CD141-classical monocytes; §CD161/
HLA-DR1/CD562 cells 5 total CD161-monocytes; {CD161/HLA-DR1/M-DC81/CD14dim/neg cells 5 slan1CD161-monocytes; kCD1c1/FcεR11/HLA-DR1 cells 5 CD1c
DCs; #CD1411/HLA-DR1/CD11cdim cells 5 CD141 DCs; **CD3031/CD1231 cells 5 pDCs; CD31 cells 5 T lymphocytes; CD191/HLA-DR1 cells 5 B lymphocytes;
§§CD561 cells 5 NK cells.
DC, Dendritic cell; NK, natural killer.
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CCL23, also known as myeloid progenitor inhibitory factor (MPIF)-1, macrophage
inflammatory protein (MIP)-3, or CKβ8, is a member of the CC chemokine subfamily
exerting its effects via CCR1 binding. By doing so, CCL23 selectively recruits resting
T lymphocytes and monocytes, inhibits proliferation of myeloid progenitor cells and
promotes angiogenesis. Previously, we and other groups have reported that human
neutrophils are able to produce chemokines upon appropriate activation, including
CCR1-binding CCL2, CCL3, and CCL4. Herein, we demonstrate that human neutrophils
display the capacity to also express and release CCL23 when stimulated by R848
and, to a lesser extent, by other pro-inflammatory agonists, including LPS, Pam3CSK4,
and TNFα. Notably, we show that, on a per cell basis, R848-activated neutrophils
produce higher levels of CCL23 than autologous CD14+-monocytes activated under
similar experimental conditions. By contrast, we found that, unlike CD14+-monocytes,
neutrophils do not produce CCL23 in response to IL-4, thus indicating that they express
CCL23 in a stimulus-specific fashion. Finally, we show that the production of CCL23 by
R848-stimulated neutrophils is negatively modulated by IFNα, which instead enhances
that of CCL2. Together, data extend our knowledge on the chemokines potentially
produced by neutrophils. The ability of human neutrophils to produce CCL23 further
supports the notion on the neutrophil capacity of orchestrating the recruitment of different
cell types to the inflamed sites, in turn contributing to the control of the immune response.
Keywords: neutrophils, CCL23, R848, CCR1, IFN
INTRODUCTION
Neutrophils are known to perform a series of effector functions, including phagocytosis,
discharge of constitutively stored proinflammatory molecules, generation of massive amounts
of superoxide anion, and active release of neutrophil extracellular traps (NETs), that are all
crucial for innate immunity responses toward infections (Scapini et al., 2013). In addition to
their defensive functions, neutrophils display the capacity to synthesize and secrete a variety of
cytokines, including many chemokines (Tecchio and Cassatella, 2016). For instance, depending
Arruda-Silva et al. CCL23 Production by Human Neutrophils
on the stimulatory conditions, human neutrophils have been
shown to produce both CXC chemokines, such as CXCL1
(GROα), CXCL3, CXCL5 (ENA78), CXCL6, CXCL8 (IL-8),
CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC), and CC
chemokines, including CCL2 (MCP-1), CCL3 (MIP-1α), CCL4
(MIP-1β), CCL17, CCL18, CCL19 (MIP-3β), and CCL20 (MIP-
3α) (reviewed by Tecchio and Cassatella, 2016). Given that these
chemokines recruit leukocytes associated to either the innate
[including neutrophils themselves, monocytes, macrophages,
dendritic cells (DCs), and natural killer (NK) cells] or the
acquired (such as T cell subsets) immune responses (Viola and
Luster, 2008; Griffith et al., 2014), it is plausible to speculate
that neutrophils are in the position to orchestrate leukocyte
trafficking during the entire course of specific responses to
invading pathogens or other antigens (Tecchio and Cassatella,
2016).
In this context, CCL23, also known as myeloid progenitor
inhibitory factor (MPIF)-1, macrophage inflammatory protein
(MIP)-3, or CKβ8, is a recently identified CCL, which, similarly to
CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, and CCL16, binds
CCR1 (Youn et al., 1998; Viola and Luster, 2008). Also CCL4 and
CCL2 have been shown to bind CCR1: the former one, however,
after natural truncation of its two NH2-terminal amino acids
(Guan et al., 2002), the latter one with lower affinity as compared
to its binding to CCR2 (Menten et al., 2002). Similarly to other
CCR1 binding chemokines, CCL23 exerts chemotactic activities
on monocytes, DCs and resting T lymphocytes (Patel et al., 1997;
Youn et al., 1998; Nardelli et al., 1999), as well as on endothelial
cells to ultimately induce tube formation (Hwang et al., 2005;
Son et al., 2006). Moreover, CCL23 has been reported to play a
role in bone formation, for its potent chemoattractant action on
osteoclast precursors, but not for fully differentiated osteoclasts
or osteoblasts (Votta et al., 2000). Amore precise characterization
of CCL23 function is however hindered by the fact that CCL23 is
a gene with no mouse ortholog (Viola and Luster, 2008), which
thus prevents the employment of loss-of-function strategies
in experimental animal models. While CCL23/MPIF-1 cDNA
was originally isolated from a human aortic endothelial library
(Patel et al., 1997), subsequent analysis made on various cell
lines has shown that CCL23 mRNA is readily detectable in
myelomonocytic cell lines (Patel et al., 1997). Expression of
CCL23 mRNA was then found in monocytes stimulated with
IL-1β (Forssmann et al., 1997) and it is now established that
IL-4-treated monocytes produce remarkable amounts of CCL23
(Nardelli et al., 1999; Novak et al., 2007). CCL23 can be detected
in synovial fluids from rheumatoid arthritis patients (Berahovich
et al., 2005), as well as in serum of systemic sclerosis patients
(Yanaba et al., 2011). More recently, eosinophils freshly isolated
from blood were found to express CCL23 mRNA and, in turn,
secrete antigenic CCL23 upon incubation with IL-5 or GM-CSF
(Matsumoto et al., 2011).
Since no information was present in the literature on an
eventual expression/production of CCL23 by neutrophils, we
decided to investigate such a possibility. As a result, we herein
show that also human neutrophils produce CCL23 in vitro, yet
upon incubation with selected stimuli and in a fashion regulated
by endogenous TNFα and exogenous IFNα.
MATERIALS AND METHODS
Cell Purification and Culture
Granulocytes and autologous CD14+-monocytes were isolated
from buffy coats of healthy donors, under endotoxin-free
conditions as previously described (Davey et al., 2011). Briefly,
buffy coats were stratified on Ficoll-Paque PLUS gradient (GE
Healthcare, Little Chalfont, United Kingdom) at a 1:1 ratio, and
then centrifuged at 400 × g for 30min at room T. Granulocytes
were then collected and subjected to dextran sedimentation
followed by hypotonic lysis to remove erythrocytes. Finally,
neutrophils were isolated from granulocytes (to reach a
99.7 ± 0.2% purity) by positively removing all contaminating
cells using the EasySep neutrophil enrichment kit (StemCell
Technologies, Vancouver, Canada; Calzetti et al., 2017). CD14+-
monocytes were instead isolated from PBMCs, obtained after
Ficoll-Paque gradient centrifugation, by anti-CD14 microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) to reach a
purity of ∼98%. Cells were then suspended at 5 × 106/ml in
RPMI 1640 medium supplemented with 10% low endotoxin
FBS (<0.5 EU/ml; from BioWhittaker-Lonza, Basel, Switzerland)
and then plated either in 6/24-well tissue culture plates or
in polystyrene flasks (from Greiner Bio-One, Kremsmünster,
Austria) for culture at 37◦C, 5% CO2 atmosphere, in the
presence or the absence of: 0.2–50µM R848, 5–50µM R837,
1µg/ml Pam3CSK4 (Invivogen, San Diego, CA, USA), 10 ng/ml
TNFα (Peprotech, Rocky Hill, NJ, USA), 0.1–10µg/ml ultrapure
LPS from E. coli 0111:B4 strain (Alexis, Enzo Life Sciences,
Farmingdale, NY, USA), 1,000U/ml pegylated IFNα-2a (Pegasys,
Roche, Basel, Switzerland), 100 U/ml IFNγ (R&D Systems,
Minneapolis, MN, USA), 10 ng/ml GM-CSF (Miltenyi Biotec),
1,000 U/ml G-CSF (Myelostim, Italfarmaco Spa, Milano, Italy),
10–100 ng/ml IL-18 (MBL International, Nagoya, Japan), 10–
100 ng/ml IL-33 (Peprotech), 10 nM fMLF (Sigma, Saint Louis,
MO, USA), 500µg/ml particulate β-glucan (InvivoGen), or
500µg/ml curdlan (Sigma). In some experiments, neutrophils
were preincubated for 30min with either 10 µg/ml adalimumab
(Humira, Abbott Biotechnology Limited, Barceloneta, Puerto
Rico) or 10µg/ml etanercept (Enbrel, Amgen, Thousand Oaks,
CA, USA), prior to further incubation with stimuli. After
the desired incubation period, neutrophils and monocytes
were collected and spun at 300 × g for 5min. Cell-free
supernatants were immediately frozen in liquid nitrogen
and stored at −80 ◦C, while the corresponding cell pellets
were either extracted for total RNA or lysed for protein
analysis.
ELISA
Cytokine concentrations in cell-free supernatants and cell-
lysates were measured by commercially available ELISA
kits, specific for human: CXCL8 (Mabtech, Nacka Strand,
Sweden), CCL23 (R&D Systems, Minneapolis, MN, USA),
CCL2 (R&D Systems), CCL3 (eBioscience, San Diego, CA,
USA), and CCL4 (eBioscience). Detection limits of these
ELISA were: 7.8 pg/ml for CCL23, 7.8 pg/ml for CCL2,
16 pg/ml for CCL3, 4 pg/ml for CCL4, and 16 pg/ml for
CXCL8.
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Reverse Transcription Quantitative
Real-Time PCR (RT-qPCR)
Total RNA was extracted from neutrophils and monocytes by
the RNeasy Mini Kit (Qiagen, Venlo, Limburg, Netherlands),
according to the manufacturer’s instructions. An on-column
DNase digestion with the RNase-free DNase set (Qiagen) was
also performed during total RNA isolation to completely remove
any possible contaminating DNA. Purified total RNA was
then reverse-transcribed into cDNA using Superscript III (Life
Technologies) and random hexamer primers (Life Technologies),
while qPCR was carried out using Fast SYBR R© GreenMasterMix
(Life Technologies) (Tamassia et al., 2014). Sequences of the gene-
specific primers (Life Technologies) used in this study are the
following: GAPDH, forward AACAGCCTCAAGATCATCAGC
and reverse GGATGATGTTCTGGAGAGCC; CXCL8 forward
CTGGCCGTGGCTCTCTTG and reverse CCTTGGCAAAAC
TGCACCTT; IL-1ra forward TTCCTGTTCCATTCAGAGACG
AT and reverse AATTGACATTTGGTCCTTGCAA; CCL2
forward GTCTCTGCCGCCCTTCTGT and reverse TTGCAT
CTGGCTGAGCGAG; CCL3 forward AGCCCACATTCCGTC
ACCTG and reverse CGTGTCAGCAGCAAGTGATG; CCL4
forward CGCCTGCTGCTTTTCTTACAC and reverse CAG
ACTTGCTTGCTTCTTTTGG; and CCL23 forward GTACTT
CTGGACATGCTCTGG and reverse CTGAACTTGCTTATC
ACTGGG. Data were calculated by Q-Gene software (http://
www.gene-quantification.de/download.html) and expressed as
mean normalized expression (MNE) units after GAPDH
normalization.
RNA Sequencing (RNA-seq)
Total RNA extracted from neutrophils (50 × 106/condition)
was quality checked by Agilent 2100 Bioanalyzer (Agilent
Technologies). RNA integrity (RIN) was routinely found to
be ≥7.0. RNA-seq libraries were prepared by oligo-dT selection
using the TruSeq RNA sample preparation kit (Illumina,
San Diego, CA, USA) and sequenced on an Illumina HiSeq
2000. After quality filtering according to the Illumina pipeline,
FIGURE 1 | Expression of CCR1-binding chemokine mRNAs in human
neutrophils incubated with R848. Human neutrophils were incubated with
or without 5µM R848 for 24 h, and then total RNA was extracted and
processed for RNA-seq experiments. Data are presented as FPKM (fragment
per kilobase of exons per million fragments mapped) from two independent
experiments (mean ± SEM).
51-base-pair (bp) reads were aligned to the hg19 assembly
(Genome Reference Consortium GRCh37) as well as the human
transcriptome reference (UCSC annotation), using TopHat
(Trapnell et al., 2013). We allowed up to two mismatches and
specified a mean distance between pairs (–r) of 250 bp. The
reference sequence and annotation files were downloaded from
iGenomes repository at the following website: http://support.
illumina.com/sequencing/sequencing_software/igenome.html.
Read counts per gene were obtained from the aligned reads using
“htseq-count” command from the HTSeq framework version
FIGURE 2 | Kinetics of CCL23, CCL2, CCL3, and CCL4 mRNA
expression in neutrophils and autologousCD14+-monocytes incubated
with R848. Neutrophils and autologous CD14+-monocytes were cultured
with or without 5µM R848 for up to 24 h to evaluate their CCL23 (A), CCL2
(B), CCL3 (C), and CCL4 (D) mRNA expression by RT-qPCR. Gene
expression is depicted as mean normalized expression (MNE) units after
GAPDH mRNA normalization (mean ± SEM, n = 5). Asterisks stand for
significant increase: *P < 0.05, **P < 0.01, ***P < 0.001, by two-way ANOVA
followed by Bonferroni’s post-test.
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0.6.1p1 (Anders et al., 2015), with the following parameters:
“–f bam –r name –m union –s no –t exon –i gene id”. Count
normalization was performed using the Bioconductor/R
packages DESeq2 (Love et al., 2014). Transcript abundance
was indicated as Fragments Per Kilobase of transcript sequence
per Million of mapped fragments (FPKM), using the “fpkm”
function of DESeq2.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical evaluation was
performed by the Student’s t-test, one-way ANOVA followed
by Tukey’s post-hoc test or two-way ANOVA followed by
Bonferroni’s post-hoc test. Values of p < 0.05 were considered as
statistically significant.
Study Approval
This study was carried out in accordance with the
recommendations of “Ethic Committee of the Azienda
Ospedaliera Universitaria Integrata di Verona (Italy)” with
written informed consent from all subjects. All subjects gave
written informed consent in accordance with the Declaration of
Helsinki.
RESULTS
Human Neutrophils Incubated with R848
Accumulate CCL23 Transcripts
We have recently reported that R848 represents a very
powerful inducer of IL-6, TNFα, G-CSF, IL-12-p40, and CXCL8
production by human neutrophils (Zimmermann et al., 2015,
2016). We recall here that R848 is an imidazoquinoline
compound that potently activates the signaling of both TLR7 and
TLR8 (Jurk et al., 2002), but that in human neutrophils activates
only TLR8 (Janke et al., 2009; Zimmermann et al., 2015) as these
cells do not express TLR7 (Hayashi et al., 2003; Janke et al., 2009;
Berger et al., 2012; Zimmermann et al., 2015). Moreover, results
from RNA-seq experiments to discover unidentified molecules
eventually generated by human neutrophils incubated for 24
h with 5µM R848 indicated that, among the various CCR1-
binding chemokines (Griffith et al., 2014), neutrophils express
the mRNA for CCL2, CCL3, CCL4, and CCL23, but not CCL5,
CCL7, CCL8, CCL13, CCL14, CCL15, and CCL16 (Figure 1).
Figure 1 further shows that, in R848-stimulated neutrophils, the
levels of CCL3 and CCL4 mRNAs are remarkably higher than
those of CCL2 and CCL23 mRNAs. While neutrophil expression
of CCL2, CCL3, and CCL4 mRNA is well-established (Kasama
et al., 1993, 1994; Cassatella, 1999; Yamashiro et al., 1999), that of
CCL23 has been never described before.
To validate and extend these preliminary findings,
neutrophils, as well as autologous CD14+-monocytes, incubated
with R848 were subjected to RT-qPCR experiments in which the
kinetics of CCL23, CCL2, CCL3, and CCL4 mRNA expression
were compared. As shown in Figure 2, CCL23 mRNA expression
in neutrophils started to be detected after 3 h, peaked at the
12 h-time point and slowly declined thereafter (Figure 2A, left
panel). Similarly to CCL23, also CCL2 mRNA started to be
accumulated in neutrophils later than 3 h, but then steadily
increased up to 24 h (Figure 2B, left panel). By contrast, CCL3
and CCL4 mRNAs were induced by R848 as early as after 1 h, but
then followed a time-course pattern similar to CCL23 mRNA
(Figures 2C,D, left panels). Interestingly, maximum expression
levels of both CCL23 and CCL2 mRNAs in R848-treated
neutrophils were similar (Figures 2A,B, left panels), but much
lower than those of CCL3 and CCL4 mRNAs (Figures 2C,D, left
panels). Notably, expression levels, as well as kinetics of CCL23
(Figure 2A, right panel), CCL2 (Figure 2B, right panel), CCL3
(Figure 2C, right panel), and CCL4 (Figure 2D, right panel)
mRNAs in R848-treated monocytes strikingly differed from
those in neutrophils. For instance, the peak of CCL2, CCL3,
and CCL4 mRNA expression in R848-treated monocytes was
found to occur earlier than in neutrophils (Figures 2B,C), unlike
that of CCL23 mRNA, which was found to take place later,
consistent with the increase of CCL23 transcripts starting not
before 12 h of incubation (Figure 2A). Moreover, while CCL2
and CCL3 mRNAs accumulated in R848-treated monocytes at
higher levels than in neutrophils (Figures 2B,C), the opposite
was observed in the case of CCL23 and CCL4 transcripts
(Figures 2A,D). Altogether, data demonstrate that neutrophils
incubated with R848 genuinely express CCL23 mRNA, yet in
a different fashion as compared to CCL2, CCL3, and CCL4
FIGURE 3 | Production of CCL23 by neutrophils and monocytes incubated with R848. Neutrophils and CD14+-monocytes were cultured at 5 × 106 cells/ml
with or without 5µM R848 for up to 48 h to evaluate their capacity to produce and release CCL23, as detected by ELISA (n = 4–19) (A). In (B), neutrophils were
cultured with or without 5µM R848 for 24 h and then further incubated for 4 h with or without 10 nM fMLF or 10 ng/ml TNFα to evaluate released and cell-associated
CCL23 (n = 4). Asterisks stand for significant increases: ***P < 0.001 by two-way ANOVA followed by Bonferroni’s post-test.
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genes, or to CCL23 mRNA expression induced in autologous
monocytes.
Human Neutrophils Incubated with R848
Produce Discrete Levels of CCL23
Next, we analyzed whether R848-treated neutrophils are able
to synthesize and release CCL23 and found that they actually
do so. CCL23 protein was, in fact, detected in neutrophil-
derived supernatants, but starting only after 12 h of cell
incubation with R848, and with peak levels reached after 24 h
(211.1 ± 34.2, n = 4–13) (Figure 3A, left panel). This is
consistent with the delayed induction of CCL23 mRNA by
FIGURE 4 | Effect of IL-4 on the production of CCL23 by monocytes
and neutrophils. CD14+-monocytes and neutrophils were cultured at 5 ×
106 cells/ml with or without 20 ng/ml IL-4 for 24 and 48 h to evaluate their
CCL23 (A) and IL-1ra (B) mRNA expression by RT-qPCR, as well as their
CCL23 release (C) by ELISA (n = 4). Gene expression data are depicted as
MNE units after GAPDH mRNA normalization (mean ± SEM). Asterisks stand
for significant increases: *P < 0.05, ***P < 0.001 by two-way ANOVA followed
by Bonferroni’s post-test.
R848, which, by the way, is also known to prolong neutrophil
survival (Zimmermann et al., 2016). Moreover, previous dose-
response experiments revealed that 5µM R848 correspond to
the most effective concentrations to induce the production of
CCL23 (data not shown). We also observed that, of the total
CCL23 synthesized by R848-treated neutrophils, ∼15% remains
cell-associated (Figure 3B), indicating that CCL23 is almost
completely released. And in fact, two potent secretagogues,
namely fMLF or TNFα, were found unable to mobilize the
small quote of intracellular CCL23 accumulated in R848-treated
neutrophils (Figure 3B).
Monocytes too were found to release CCL23 in response
to R848 (Figure 3A, right panel), surprisingly at lower levels
(87.1 ± 28.5, n = 11) than neutrophils, but consistent with
the gene expression data (Figure 2A). However, monocytes
incubated with IL-4 for up to 48 h were found to accumulate and
release remarkable levels of CCL23 mRNA and protein (308.6 ±
149.2 pg/ml, n = 4) (left panels in Figure 4A and Figure 4C,
respectively), confirming previous data (Novak et al., 2007).
By contrast, IL-4-treated neutrophils did not express/produce
any CCL23 mRNA and protein (right panels in Figure 4A
and Figure 4C, respectively), even though they accumulated IL-
1ra mRNA (right panel in Figure 4B), as previously described
(Crepaldi et al., 2002). Altogether, data prove that neutrophils
genuinely produce CCL23 in response to R848 but not
to IL-4.
Effect of IFNα on CCL23 Production by
R848-Treated Neutrophils
Given the recently reported capacity of IFNα to potently increase
IL-6 and TNFα mRNA and protein expression in R848-treated
FIGURE 5 | IFNα downregulates the production of CCL23 by
R848-treated neutrophils Neutrophils (5 × 106/ml) were cultured with or
without 1,000U/ml IFNα and/or 5µM R848. After 24 h, supernatants were
collected and subjected to CCL23, CCL2, CCL3, and CCL4 measurement by
ELISA. Data are depicted as mean ± SEM (n = 3–19). Asterisks stand for
significant increases: **P < 0.01, ***P < 0.001, by two-way ANOVA followed
by Bonferroni’s post-test.
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FIGURE 6 | Other agonists, besides R848, trigger the production of
CCL23 by human neutrophils. Neutrophils (5 × 106/ml) were cultured with
or without 5–50µM R837, 5µM R848, 5µM CL075, 0.1–10µg/ml LPS,
1µg/ml Pam3CSK4, 10 ng/ml TNFα, 10 nM fMLF, 10 ng/ml G-CSF, 10 ng/ml
GM-CSF, 500µg/ml β-Glucan, 500µg/ml Curdlan, 100 ng/ml IL-18, and
100 ng/ml IL-33 for 24 h. Then, extracellular supernatants were collected to
evaluate CCL23 (A) and CXCL8 (B) production by ELISA (mean ± SEM,
n = 3–5). Asterisks stand for significant increases as compared to untreated
cells: *P < 0.05,
(Continued)
FIGURE 6 | Continued
**P < 0.01, ***P < 0.001, by Student’s t-test. (C) Neutrophils (5 × 106/ml)
were pretreated for 30min with 10µg/ml adalimumab (ADA) or 10µg/ml
etanercept (ETA), to be subsequently incubated for further 24 h with 5µM
R848. Cell-free supernatants were then collected to evaluate CCL23
production by ELISA (mean ± SEM, n = 3–5). Asterisks stand for significant
inhibition: *P < 0.05, by one-way ANOVA followed by Tukey’s post-test.
neutrophils (Zimmermann et al., 2016), we investigated IFNα-
mediated effects on neutrophil-derived CCL23 and other CCR1-
binding chemokines. As displayed in Figure 5, we found that,
while IFNα strongly downregulates the production of CCL23
by neutrophils incubated with R848 for 24 h, it significantly
upregulates that of CCL2, but does not influence CCL3 and CCL4
release. Interestingly, Figure 5 also illustrates that the amounts
of CCL3 and CCL4 released by R848-stimulated neutrophils are
higher than those of CCL2 and CCL23, in accordance with the
gene expression data (Figure 2). Taken together, data provide
evidence that IFNα negatively modulates CCL23, but not CCL2,
CCL3, and CCL4 production by R848-treated neutrophils.
Other TLR Agonists, as well as TNFα,
Trigger the Production of CCL23 by Human
Neutrophils
In a final series of experiments, we investigated whether other
agonists could induce the production of CCL23 by human
neutrophils. We found that, in addition to R848 (the most
potent one), also 5µM CL075 (another ligand for TLR8),
1µg/ml Pam3CSK4 (a ligand for TLR2), 10µg/ml ultrapure
LPS (a ligand for TLR4), and 10 ng/ml TNFα promoted the
production of remarkable amounts of CCL23 by neutrophils
(respectively, 108.6 ± 59.3, 61.8 ± 13.2, 88.8 ± 1.3, and 65.1
± 28.2 pg/ml, n = 3–5) (Figure 6A). By contrast, 5–50 µM
R837 (a ligand for TLR7), 500µg/ml β-glucan and 500 µg/ml
curdlan (both ligands for Dectin-1), 10 nM fMLF, 10 ng/ml GM-
CSF, and 1,000U/ml G-CSF, all failed to trigger any extracellular
CCL23 production by neutrophils (Figure 6A), albeit able to
stimulate the production of CXCL8 (Figure 6B). Finally, 100
ng/ml IL-18 and IL-33, two cytokines having potential roles
in Th2-responses, resulted unable to induce CCL23 production
in both human neutrophils (Figure 6A) and CD14+-monocytes
(data not shown). IL-18 and IL-33 also did not modulate the
levels of CCL23 produced by R848-treated neutrophils (data not
shown).
Given that R848-treated neutrophils are known to produce
elevated amounts of TNFα (Zimmermann et al., 2015), we
then investigated whether CCL23 production could be amplified
by endogenous TNFα, as occurring in the case of IL-6
(Zimmermann et al., 2015). This was found to be the case, as
adalimumab or etanercept, two potent TNFα-neutralizing drugs
(Tracey et al., 2008), diminished the detection of extracellular
CCL23 in supernatants from neutrophils treated with R848 for
24 h by, respectively, 44.7 ± 5.5% (n = 3) and 45.7 ± 11.4%
(n = 3) (Figure 6C). Altogether, data uncover that neutrophils
produce CCL23 in response to discrete stimuli. Data also
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demonstrate that, at least in the case of R848-treated neutrophils,
CCL23 production is amplified via endogenous TNFα.
DISCUSSION
Neutrophils are among the first cell types that infiltrate
inflammatory sites. As such, they may play an important role
in coordinating the subsequent recruitment of other leukocytes
via the generation of a variety of chemoattractants, including
chemokines (Tecchio and Cassatella, 2016). Among the latter
molecules, neutrophils have been already shown to represent
sources of some CCR1-binding chemokines, namely CCL3 and
CCL4 (Kasama et al., 1994; Scapini et al., 2000), known to act
on monocytes, DCs and resting T lymphocytes (Patel et al., 1997;
Nardelli et al., 1999; Viola and Luster, 2008).
In this study, we show that human neutrophils are able to
produce another CCR1-binding chemokine, namely CCL23, in
response to ligands for TLR2 (Pam3CSK4), TLR4 (LPS), and
much more efficiently, TLR8 (R848 and CL075). By contrast,
a variety of inflammatory mediators previously identified as
being effective stimuli for the production of chemokines by
neutrophils, for instance G-CSF, GM-CSF, and fMLF (Cassatella,
1999), failed to trigger CCL23 production. Other CCR1-binding
chemokines, including CCL5, CCL7, CCL13, CCL14, CCL15,
and CCL16 were found as not induced in neutrophils, at
least after R848-treatment. Surprisingly, the amounts of CCL23
produced by neutrophils incubated with R848 for 24 h were
comparable to those made by the same number of autologous
R848-treated monocytes. This finding is quite unusual because,
on a per cell basis, activated monocytes usually produce
higher cytokine/chemokine levels than autologous neutrophils
(Cassatella, 1999; Dale et al., 2008), although some other
exceptions exist, for instance CCL19/MIP3β (Scapini et al.,
2001). Whatever the case is, our findings exclude that the
observed CCL23 production by R848-treated neutrophils derives
from potential contaminating monocytes. Moreover, they also
imply that appropriately activated neutrophils may represent
major sources of CCL23, even in consideration of the fact
that, during bacterial or viral infections, neutrophils often
outnumber mononuclear leukocytes by one to two orders of
magnitude.
We also report that, differently from autologous monocytes
(Novak et al., 2007), neutrophils do not produce CCL23 upon
incubation with IL-4, a Th2 cytokine, even though they promptly
accumulate IL-1ra mRNA (Re et al., 1993; Crepaldi et al., 2002).
Although we do not have a formal molecular explanation for the
inability of IL-4-treated neutrophils to express CCL23 mRNA
yet, our preliminary genome-wide map of both histone H3
monomethylated at K4 (H3K4me1, which is associated with
active or poised genomic regulatory elements) (Smale et al.,
2014) and PU.1 (an Ets-family transcription factor marking
the majority of regulatory elements in myeloid cells) (Smale
et al., 2014) would reveal that neutrophils contain only one
regulatory region at the CCL23 locus (1 kb upstream from CCL23
TSS), while monocytes contain two ones (1 and 25 kb upstream
from CCL23 TSS). Such a different chromatin conformation
might be responsible for the differential ability of neutrophils
and monocytes to express CCL23 mRNA in response to IL-
4 stimulation, as the “closed” chromatin conformation in
neutrophils would, in fact, prevent the binding of IL-4-activated
transcription factor(s) to it, and consequently the transcription
of CCL23 mRNA. Interestingly, other Th2 cytokines, namely
IL-18 and IL-33, were found unable to trigger the production
of CCL23 by human neutrophils. Therefore, along with the
findings on IL-4, our data would exclude the generation of
neutrophils conditioned by Th2 cytokines and associated to Th2-
microenvironment.
According to previous findings (Youn et al., 1998), CCL23
may exist in multiple forms arising from both alternative splicing
and post-translational processing. CCL23 cDNA encodes, in
fact, a signal sequence of 21 aa followed by either a 99
aa (also known as CKβ8) or 116 aa (CKβ8-1) mature
proteins, which both represent putative ligands for CCR1
(Youn et al., 1998). In such regard, our preliminary RT-qPCR
experiments would indicate that R848-stimulated neutrophils
express both mRNA isoforms, while monocytes express only
CKβ8-1 mRNA (NT, FA, and MAC, unpublished results).
As mentioned, eosinophils have been shown to express and
release CCL23, and, similarly to R848-activated neutrophils, they
accumulate both mRNA isoforms of CCL23 (Matsumoto et al.,
2011). In any case, we exclude that the two CCL23 mRNAs
detected in neutrophils derive from potential contaminating
eosinophils, as our neutrophil purification method reduces
eosinophil contamination below 0.1% (Calzetti et al., 2017).
Moreover, GM-CSF, which triggers the release of CCL23 by
eosinophils (Matsumoto et al., 2011), resulted ineffective in
neutrophils.
In this work, we also report that the production of
CCR1-binding chemokines by R848-activated neutrophils is
differentially modulated by IFNα. In fact, while production
of CCL3 and CCL4 was not affected by the addition of
IFNα to neutrophils, that of CCL23 was strongly inhibited. By
contrast, CCL2 production was strongly enhanced in neutrophils
incubated with R848 in the presence of IFNα, similarly to
what previously observed in neutrophils treated with IFNγ
plus LPS (Yoshimura and Takahashi, 2007). Together, our data
therefore reinforce the notion that type I interferons do not
act as mere enhancers of inflammatory gene expression, but
represent instead fine tuners regulating the transcription of
a variety of mediators (González-Navajas et al., 2012; McNab
et al., 2015), including neutrophil-derived chemokines. Given the
potent effect of TLR8 agonists in inducing neutrophil-derived
CCL23, and its negative regulation by IFNα, data also contribute
to extend our knowledge on the complex role of neutrophils
to both host defense and disease in response to viral infections
(Tamassia and Cassatella, 2013; Galani and Andreakos, 2015).
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Neutrophils are known to perform a series of effector functions that are crucial for the 
innate and adaptive responses, including the synthesis and secretion of a variety of 
cytokines. In light of the controversial data in the literature, the main objective of this 
study was to more in-depth reevaluate the capacity of human neutrophils to express 
and produce cytokines of the IL-17 family in vitro. By reverse transcription quantitative 
real-time PCR, protein measurement via commercial ELISA, immunohistochemistry 
(IHC) and immunofluorescence (IF), flow cytometry, immunoblotting, chromatin immu-
noprecipitation (ChIP), and ChIP-seq experiments, we found that highly pure (>99.7%) 
populations of human neutrophils do not express/produce IL-17A, IL-17F, IL-17AF, or 
IL-17B mRNA/protein upon incubation with a variety of agonists. Similar findings were 
observed by analyzing neutrophils isolated from active psoriatic patients. In contrast 
with published studies, IL-17A and IL-17F mRNA expression/production was not even 
found when neutrophils were incubated with extremely high concentrations of IL-6 plus 
IL-23, regardless of their combination with inactivated hyphae or conidia from Aspergillus 
fumigatus. Consistently, no deposition of histone marks for active (H3K27Ac) and poised 
(H3K4me1) genomic regulatory elements was detected at the IL-17A and IL-17F locus 
of resting and IL-6 plus IL-23-stimulated neutrophils, indicating a closed chromatin 
conformation. Concurrent experiments revealed that some commercial anti-IL-17A and 
anti-IL-17B antibodies (Abs), although staining neutrophils either spotted on cytospin 
slides or present in inflamed tissue samples by IHC/IF, do not recognize intracellular 
protein having the molecular weight corresponding to IL-17A or IL-17B, respectively, 
in immunoblotting experiments of whole neutrophil lysates. By contrast, the same Abs 
were found to more specifically recognize other intracellular proteins of neutrophils, 
suggesting that their ability to positively stain neutrophils in cytospin preparations and, 
eventually, tissue samples derives from IL-17A- or IL-17B-independent detections. In 
2Tamassia et al. IL-17 Absence in Human Neutrophils
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sum, our data confirm and extend, also at epigenetic level, previous findings on the 
inability of highly purified populations of human neutrophils to express/produce IL-17A, 
IL-17B, and IL-17F mRNAs/proteins in vitro, at least under the experimental conditions 
herein tested. Data also provide a number of justifications explaining, in part, why it is 
possible to false positively detect IL-17A+-neutrophils.
Keywords: neutrophils, il-17 members, il-17a, il-17B, il-17F
inTrODUcTiOn
The IL-17 family of cytokines consists of six members, namely 
IL-17A (usually referred to as IL-17), IL-17B, IL-17C, IL-17D, 
IL-17E (also known as IL-25), and IL-17F (1). After the discovery 
of a subtype of CD4+ T helper, expressing IL-17A and IL-17F 
(currently known as Th17 cells), plenty of studies have been pub-
lished correlating Th17 cells with a wide range of physiological 
and pathological processes. IL-17A and IL-17F are not only the 
most studied but also the most closely related, since they share 
50% of amino acid sequence identity, adjacent gene localization 
(2) and binding to the same IL-17R, in this case composed by the 
IL-17RA and IL-17RC subunits (1). The IL-17R group comprises, 
in fact, five receptor subunits, IL-17RA, IL-17RB, IL-17RC, 
IL-17RD, and IL-17RE (3). IL-17RA was the first to be described, 
is ubiquitously expressed (particularly in hematopoietic cells), 
and functions as a common receptor subunit used by at least four 
ligands, namely IL-17A, IL-17C, IL-17E, and IL-17F (3). IL-17F 
is often coproduced with IL-17A, so that together they can also 
form an IL-17F/IL-17A heterodimer (4) binding to the IL-17RA/
IL17RC complex as either homodimers or heterodimers (3). 
IL-17A and IL-17F are proinflammatory cytokines that play key 
regulatory roles in host defense and inflammatory diseases. They 
mainly mediate immune regulatory functions by promoting 
the generation of proinflammatory cytokines/growth factors 
(including G-CSF, GM-CSF, and IL-6) and chemokines (such 
as CXCL8, CXCL6, and CXCL1) by epithelial and other stromal 
cells, which ultimately lead to the attraction and activation of 
neutrophils and macrophages into the inflammatory site (5), 
as well as to granulopoeisis (6). Although crucial in protecting 
the host from invasion by many types of pathogens, including 
bacteria and fungi (7), dysregulated IL-17A and IL-17F produc-
tion can lead to the development of autoimmune diseases, such 
as psoriasis, multiple sclerosis, and rheumatoid arthritis (RA), as 
well as cancer progression (5, 8). The latter observations hence 
make IL-17A/F as a very important target for the development of 
new therapies (1, 8).
As mentioned, Th17  cells are considered the main sources 
of IL-17A and IL-17F. However, other innate immune cells 
produce these cytokines, including γδ T  cells, natural killer 
T cells, invariant natural killer cells, Paneth cells, TCRβ+ natural 
Th17 cells, lymphoid-tissue inducer-like cells, IL-17-expressing 
type 3 innate lymphoid cells, and mast cells (8, 9). By contrast, it 
is still questionable whether human polymorphonuclear neutro-
phils represent sources of IL-17A or IL-17F. It is currently well 
established that neutrophils are crucial players in innate immune 
responses, not only for their capacity to perform defensive func-
tions (10) but also for their ability to produce a large variety of 
cytokines (11). Concerning IL-17A and/or IL-17F, in 2010, we 
reported that highly purified populations of human neutrophils 
(>99.7%), incubated for up to 20 h with IFNγ and/or LPS in vitro, 
do not produce IL-17A (12). While a few papers substantially 
confirm our findings (13–17), the majority of the subsequent 
studies report that human neutrophils may represent sources 
of IL-17A (18–53). Experimental evidence proving that human 
neutrophils express IL-17A mostly, but not only, derives by 
immunohistochemistry (IHC) and/or immunofluorescence (IF) 
studies documenting IL-17A+-neutrophils in tissue specimens 
from a variety of pathological conditions (18, 19, 21, 22, 25, 27, 
28, 30–32, 34, 36–39, 41–43, 45, 47–49, 51, 53). Interestingly, 
many of these studies focus on psoriasis (20, 25, 30, 32, 35, 49), 
a disease characterized by an early accumulation of neutrophils 
in skin lesions in which neutrophil-derived mediators (such as 
reactive oxygen species, granule proteins, and cytokines) may 
alter the homeostatic state of keratinocytes and endothelial cells 
(54). At the end of 2014, however, Tamarozzi et al. (13) not only 
reported the absence of IL-17A mRNA expression and produc-
tion by highly pure (99.9%) populations of resting or activated 
neutrophils but also demonstrated that some of the commercial 
polyclonal anti-IL-17A antibodies (Abs) stain neutrophils for 
their non-specific recognition of various intracellular proteins 
different from antigenic IL-17A. Nevertheless, reports describ-
ing either IL-17A-positive neutrophils in tissue samples from 
diseases or in vitro-stimulated neutrophils as sources of IL-17A, 
continue to be published (20, 23, 24, 26, 29, 33, 35, 40, 44, 46, 
50, 52). Based on these premises, we decided to more accurately 
analyze the issue of whether human neutrophils produce IL-17A, 
as well as other IL-17 members in vitro.
MaTerials anD MeThODs
cell Purification and culture
Neutrophils were isolated from buffy coats of healthy donors 
(HDs) and manipulated under endotoxin-free conditions (12). 
In selected experiments, neutrophils were also isolated from 
peripheral blood of patients with severe psoriasis, as defined by 
either >10% body surface area involved, or Psoriasis Area and 
Severity Index score >10, or Dermatology Life Quality Index 
score >10 (55). After Ficoll-Paque gradient centrifugation of buffy 
coats or peripheral blood, followed by dextran sedimentation of 
granulocytes and hypotonic lysis of erythrocytes, neutrophils 
were isolated to reach 99.7 ± 0.2% purity by positively removing 
all contaminating cells using the EasySep neutrophil enrich-
ment kit (StemCell Technologies, Vancouver, BC, Canada) (56). 
Neutrophils were then suspended at 5 ×  106/ml in RPMI 1640 
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medium supplemented with 10% low (<0.5  EU/ml) endotoxin 
FBS (BioWhittaker-Lonza, Basel, Switzerland), incubated with or 
without 5 µM R848, 500 µg/ml particulate β-glucan (Invivogen, 
San Diego, CA, USA), 100  ng/ml ultrapure LPS (from E. coli 
0111:B4 strain, Alexis, Enzo Life Sciences, Farmingdale, NY, USA), 
1 µg/ml Pam3CSK4 (Invivogen), 50 µg/ml poly(I:C) (Invivogen), 
1,000 U/ml G-CSF (Myelostim, Italfarmaco Spa, Milano, Italy), 
100 U/ml IFNγ (R&D Systems, Minneapolis, MN, USA), 10 ng/ml 
GM-CSF (Miltenyi Biotec), 5 ng/ml TNFα (Peprotech, Rocky Hill, 
NJ, USA), 2–20  µg/ml IL-6 (R&D Systems), 0.2–2  µg/ml IL-23 
(R&D Systems), 100–500 ng/ml IL-17A (R&D Systems), 10 µg/
ml anti-IL-17A neutralizing Abs (secukinumab, Novartis, Basel, 
Switzerland), 100  nM fMLF, 500  µg/ml curdlan (Sigma, Saint 
Louis, MO, USA), 20  ng/ml phorbol mysistate acetate (PMA) 
(Sigma), 1  µg/ml Ionomycin (Sigma), 100  µg/ml CpG oligode-
oxynucleotides (ODN) (Invivogen), and 1,000  U/ml PEGylated 
IFNα-2a (Pegasys, Roche, Basel, Switzerland). Inactivated conidia 
and hyphae from Aspergillus fumigatus were kindly provided by 
prof. Luigina Romani (University of Perugia, Italy), and used at 
a neutrophil-fungi ratio of 1:5 for A. fumigatus conidia and 1:1 
for A. fumigatus hyphae, as previously described (57). Neutrophils 
were plated either in 6/24-well tissue culture plates or in polysty-
rene flasks (from Greiner Bio-One, Kremsmünster, Austria) for 
culture at 37°C, 5% CO2 atmosphere. After the desired incuba-
tion period, neutrophils were either processed for chromatin 
immunoprecipitation (ChIP) experiments or collected and spun 
at 300 × g for 5 min for other types of assays. In the latter case, cell-
free supernatants were immediately frozen in liquid nitrogen and 
stored at −80°C, while the corresponding cell pellets were either 
extracted for total RNA or lysed for protein analysis. Th1 and Th17 
clones (58) were kindly provided by prof. Francesco Annunziato 
(University of Firenze). CD4+ T cells were isolated by CD4+ T Cell 
Isolation Kit (Miltenyi Biotec) and stimulated for up 72 h with 
anti-CD3 and anti-CD28 mAbs (5 µg/ml, BD Biosciences).
Flow cytometry experiments
For flow cytometry, 105 neutrophils were harvested after the desired 
treatment, centrifuged, and suspended in 100 µl PBS containing 
10% complement-inactivated human serum for FcγR blocking. 
Neutrophils were then stained for 15 min at T room with: APC 
anti-human IL-17RA/CD217 (clone 424LTS) and APC mouse 
IgG1к, as isotype control (clone P3.6.2.8.1) from eBioscience (San 
Diego, CA, USA); PE anti-human IL-17RC (clone 309822) and 
mouse PE IgG2B isotype control from R&D systems; PE-vio770 
anti-human CD11b (clone ICRF44), FITC anti-human CD66b 
(clone G10F5), and PerCP-Cy5.6 anti-human CD16 (clone 3G8) 
from BioLegend (San Diego, CA, USA); APC anti-human CD62L 
(clone 145/15 Miltenyi Biotec), all at working dilutions specified 
in the corresponding datasheets. Sample fluorescence was then 
measured by MACSQuant Analyzer (Miltenyi Biotec), while 
data analysis performed using FlowJo software version 10 from 
Tree Star (Ashland, OR, USA) (59). For neutrophils of psoriatic 
patients, 100 µl whole blood were stained with APC anti-human 
IL-17RA and PE anti-human IL-17RC Abs in combination with 
the following mAbs: VioBlue anti-human CD14 (clone TÜK4), 
PE anti-human CD56 (clone AF12-7H3), PE-Vio770 anti-human 
CD3 (clone BW264/56), APC anti-human CD19 (clone LT19) 
from Miltenyi; Brilliant Violet anti-human CD45 (clone 2D1), 
PerCP-Cy5.5 anti-human CD16 (clone 3G8), and APC-Cy7 anti-
human HLA-DR (clone L243) from BioLegend. After red cells 
lysis by the ammonium chloride buffer, sample fluorescence was 
immediately measured as previously described.
superoxide anion Measurement
After isolation, neutrophils were suspended at the concentration 
of 2 × 106 cells/ml in HBSS buffer containing 0.5 mM CaCl2 and 
1 mg/ml glucose. Neutrophils (100 µl/well) were then distributed 
in a 96-well plate and incubated for 10 min at 37°C prior to the 
addition of 80 µM cytochrome c, 2 mM NaN3 (Sigma) and the 
indicated stimuli, including 20 ng/ml PMA as control. Plates were 
then incubated at 37°C in an automated ELx808IU microplate 
reader (BioTek Instruments, Inc., Winooski, VT, USA) to record 
cytochrome c reduction (via absorbance at 550 and 468 nm, at 
intervals of 5 min for 90 min). O2− production was finally calcu-
lated using an extinction coefficient of 24.5 mM (60).
immunocitochemistry, ihc and iF
Cytospin preparations of neutrophils (61) previously cultured 
with the indicated stimuli were stained by ematoxylin and eosin 
for morphological evaluation. After coverslip removal, specimens 
were rehydrated through a scale of alcohols, with endogenous per-
oxidase activity blocked by treatment with 0.3% H2O2 in methanol 
for 20 min. Anti-human IL-17A (AF-317-NA), IL-17B (AF1248), 
and CXCL8 (AF-208) goat IgG pAbs from R&D Systems were 1:50 
diluted, added to specimens for 60 min and then revealed using 
the goat-on-Rodent HRP-polymer (Biocare Medical, Pacheco, CA, 
USA) followed by diaminobenzidine. Omission of the primary 
antibody, as well as isotype control staining, was also performed as 
negative controls. For IL-17A and IL-17B tissue immunostaining, 
4-µm tissue sections from two FFPE cases of pustular psoriasis 
were deparaffinized and rehydrated through a scale of alcohols. 
Endogenous peroxidase activity was then blocked by treatment 
with 0.3% H2O2 in methanol for 20  min. Epitope retrieval was 
performed using a microwave oven in 1.0 mM EDTA buffer (pH 
8.0), for 3 cycles of 5 min at 750 W. IL-17A and IL-17B were diluted 
1:50 and revealed using the goat HRP-polymer (IHC) or the horse 
anti-goat IgG biotinylated (Vector Laboratories, Peterborough, UK) 
followed by streptavidin-FITC (Southern Biotech, Birmingham, 
AL, USA). DAPI was used for counterstaining. For double IHC, 
anti-IL-17A and IL-17B Abs were diluted 1:500, and after rev-
elation (as detailed above), anti-CD66b Abs (diluted 1:80 from 
BioLegend) were added to the sections. Mach4 AP polymer was 
used as secondary antibody followed by Ferangi Blue as chromo-
gen. Ematoxylin was used for counterstaining.
cytokine Production
Cytokine concentrations in cell-free supernatants and cell lysates 
were measured by commercial enzyme-linked immunosorbent 
(ELISA) kits, specific for: IL-17A (DY317 from R&D systems 
and 88-7176 from eBioscience), IL-17A/F (88-7117, eBiosci-
ence), IL-17B [ABKA2223 from Abnova (Taipei, Taiwan) and 
ab171344 from Abcam (Cambridge, United Kingdom)], IL-17F 
(887478, eBioscience), and CXCL8 (Mabtech, Nacka Strand, 
Sweden). ELISA detection limits were 4 pg/ml (eBioscience) and 
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15.6 pg/ml (R&D) for IL-17A, 30 pg/ml for IL-17A/F, 24 pg/ml 
(Abnova) and 10 pg/ml (Abcam) for IL-17B, 16 pg/ml for IL-17F, 
and 8 pg/ml for CXCL8.
reverse Transcription Quantitative  
real-Time Pcr (rT-qPcr)
Total RNA was extracted from neutrophils by the RNeasy Mini 
Kit (Qiagen, Venlo, Limburg, Netherlands), as previously detailed 
(62). To completely remove any possible contaminating DNA, 
an on-column DNase digestion with the RNase-free DNase set 
(Qiagen) was performed during total RNA isolation. Total RNA 
was then reverse-transcribed into cDNA using Superscript III 
(Life Technologies, Carlsbad, CA, USA) and random hexamer 
primers (Life Technologies), while qPCR was carried out using 
Fast SYBR® Green Master Mix (Life Technologies). Sequences of 
gene-specific primer pairs (Life Technologies) are listed in Table 
S1 in Supplementary Material. Data were calculated by Q-Gene 
software1 and expressed as mean normalized expression units 
after GAPDH normalization (63).
immunoblotting experiments
Total neutrophil proteins were recovered from protein-rich flow-
through solutions after the first centrifugation step of the RNeasy 
mini kit (Qiagen) procedure used for total RNA extraction, as 
previously described (62). Protein-rich flow-through from neu-
trophils were then immunoblotted by standard procedures using 
the anti-human IL-17A (AF-317-NA) and IL-17B (AF1248) 
goat IgG pAbs from R&D Systems; anti-human phospho-STAT3 
(Tyr705) rabbit pAbs (#9131, Cell Signaling, Beverly, MA, 
USA); anti-human STAT3 rabbit pAbs (sc-482, Santa Cruz 
Biotechnology, Dallas, TX, USA), and anti-human β-actin mAbs 
(A5060 from Sigma). Blotted proteins were detected by using the 
Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, 
NE, USA) (62).
chiP assays
Chromatin immunoprecipitation experiments were performed 
exactly as previously described (62). Briefly, nuclear extracts from 
2 × 106 neutrophils or Th17 cell lines were immunoprecipitated 
using 1 µl anti-H3K4me1 (ab8895) and anti-H3K27Ac (ab4729) 
pAbs (both from Abcam, Cambridge, United Kingdom). 
Coimmunoprecipitated material was subjected to qPCR analy-
sis using the specific promoter primers (purchased from Life 
Technologies) listed in Table S2 in Supplementary Material. Data 
from qPCR were expressed as percentage over input DNA and are 
displayed as mean ± SEM.
chiP-seq
Purified DNA from H3K27Ac and H3K4me1 ChIP assays 
(performed as described in the previous paragraph) was adapter-
ligated and PCR-amplified for sequencing on HiSeq2000 platform 
(Illumina, Cambridge, UK) using TruSeq DNA Library Prep Kit 
(Illumina). After sequencing, reads were quality-filtered according 
1 http://www.gene-quantification.de/download.html (Accessed: February 10, 2018).
to the Illumina pipeline. Single end (51  bp) reads were then 
mapped to the human genome (Genome Reference Consortium 
GRCh37, Feb/2009) using BOWTIE v1.0.0 (64). Only reads with 
no more than two mismatches (when compared to the reference 
genome) were converted to tag directories using HOMER’s module 
known as “makeTagDirectory,” and then converted to BedGraph 
format using HOMER’s module known as “makeUCSCfile,” to be 
finally normalized to 107 total tag counts. ChIP-seq signals were 
visualized using Integrative Genomics Viewer. For H3K4me1 and 
H3K27Ac ChIP-seqs of Th17 cells, 36 bp reads, already filtered 
and mapped, were downloaded from database of the “roadmap 
epigenomics project”2 (NIH Epigenomics Roadmap Initiative). 
Aligned reads were then converted to BedGraph format and 
normalized to 107 total tag counts.
gene expression Data set of normal 
hematopoietic stem and Progenitor cells
Gene expression profiles of cells from normal bone marrow at 
different stages of human granulopoiesis were downloaded from 
Gene Expression Omnibus Database (GEO number: GSE42519) 
(65). Gene expression means and SEs were calculated from the 
values of the biological replicates present in the GEO database.
statistical analysis
Data are expressed as mean ±  SEM or mean ±  SD. Statistical 
evaluation was performed by using, depending on the experi-
ment type, Student’s t-test or two-way ANOVA followed by 
Bonferroni’s post  hoc test. P values <0.05 were considered as 
statistically significant.
study approval
Human samples were obtained following informed written con-
sent by both HDs and psoriatic patients. This study was carried 
out in accordance with the recommendations of Ethic Committee 
of the Azienda Ospedaliera Universitaria Integrata di Verona 
(Italy). All the experimental protocols were approved by the 
Ethic Committee and all subjects gave written informed consent 
in accordance with the Declaration of Helsinki.
resUlTs
human neutrophils incubated With a 
Variety of agonists In Vitro Do not express 
il-17 Members at Both mrna and Protein 
levels
We have previously shown that human neutrophils (>99.7% 
purity), incubated with 100  U/ml IFNγ and/or 100  ng/ml 
ultrapure LPS for up to 20 h in vitro, do not produce IL-17A 
protein (12). Additional RT-qPCR experiments not only con-
firmed our previous data (Figure  1A) but also revealed that 
other agonists, including 5 µM R848 and/or 1,000 U/ml IFNα 
(Figure  1B), 10  ng/ml GM-CSF, 100  nM fMLF (Figure  1C), 
2 http://egg2.wustl.edu/roadmap/web_portal/processed_data.html (Accessed: 
February 10, 2018)
FigUre 1 | IL-17A, IL-17F, CXCL8, and IL-1ra mRNA expression levels in human neutrophils activated by a variety of stimuli. Human neutrophils were cultured  
at 5 × 106/ml for up to 20 h with (a) 100 U/ml IFNγ and/or 100 ng/ml LPS; (B) 1,000 U/ml IFNα and/or 5 µM R848; (c) 10 ng/ml GM-CSF or 100 nM fMLF;  
(D) 1,000 U/ml G-CSF or 5 ng/ml TNFα. IL-17A, IL-17F, CXCL8, and IL-1ra mRNA expression was evaluated by reverse transcription quantitative real-time PCR  
(RT-qPCR) and data depicted as mean normalized expression (MNE) units after GAPDH mRNA normalization. The experiments depicted in each panels (a–D) are 
representative of at least three ones with similar results. Error bars stand for SEs calculated from triplicate qPCR reactions.
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1,000 U/ml G-CSF, and 5 ng/ml TNFα (Figure 1D), similarly 
fail to induce an accumulation of transcripts encoding IL-17A 
(Figures  1A–D, left panels), IL-17F (Figures  1A–D, middle 
panels), IL-17B, IL-17C, IL-17D, and IL-17E (data not shown) 
in neutrophils. LPS and/or IFNγ, R848 and/or IFNα, GM-CSF 
or fMLF, however, were found to modulate the expression of 
CXCL8 mRNA (Figures 1A–C, right panels), while G-CSF or 
TNFα modulated that of IL-1ra mRNA (Figure 1D, right panel), 
as expected (62, 66, 67). Consistent with the gene expression 
data, neither IL-17A, IL-17F (Table 1) nor IL-17A/F and IL-17B 
(data not shown) proteins could be detected in supernatants 
harvested from neutrophils incubated for 20 h with the stimuli 
used for the experiments shown in Figure  1, as well as with 
500  µg/ml β-glucan, 500  µg/ml curdlan, 1  µg/ml Pam3CSK4, 
TaBle 1 | Lack of IL-17A and IL-17F production by activated human 
neutrophils.
stimuli il-17a (pg/ml) il-17F (pg/ml) cXcl8 (ng/ml)
neutrophils
– nd nd 0.07 ± 0.05
500 μg/ml β-glucan nd nd 0.41 ± 0.16*
500 µg/ml curdlan nd nd 0.49 ± 0.02***
10 ng/ml GM-CSF nd nd 0.30 ± 0.13*
100 nM fMLF nd nd 0.33 ± 0.12*
5 ng/ml TNFα nd nd 1.22 ± 0.90
1 µg/ml Pam3CyS nd nd 10.31 ± 3.85**
50 µg/ml poly(I:C) nd nd 0.02 ± 0.02
100 ng/ml LPS nd nd 0.89 ± 0.22**
5 µM R848 nd nd 9.47 ± 3.35**
100 µg/ml CpG ODN nd nd 5.57 ± 1.1***
100 U/ml IFNγ nd nd 0.10 ± 0.04
100 U/ml IFNγ + 100 ng/
ml LPS
nd nd 2.51 ± 1.1**
cD4+ T cells
– nd nd 2.51 ± 1.1
5 µg/ml anti-CD3/CD28 739.6 ± 56.6*** 948.9 ± 95.4*** 172.6 ± 25.1***
Human neutrophils (5 × 106/ml) were cultured for 20 h with the indicated stimuli. CD4+ 
T cells were stimulated for up to 72 h with anti-CD3 and anti-CD28 mAbs. Cell-free 
supernatants were then harvested and IL-17A, IL-17F, and CXCL8 content measured 
by specific ELISA. Values represent the mean ± SD (n = 3).
Asterisks stand for significant increases as compared to untreated cells: *P < 0.05, 
**P < 0.01, ***P < 0.001, by Student’s t-test.
nd, not detected; ODN, oligodeoxynucleotides.
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50  µg/ml poly(IC), and 100  µg/ml CpG ODN. Noteworthy, 
we used ELISA kits from two different commercial sources 
(see Materials and Methods) for either IL-17A or IL-17B, in 
both cases giving equivalent information. On the other hand, 
stimulus-dependent levels of CXCL8 could be measured in 
supernatants from our stimulated neutrophils, indicating that 
agonists were effective and cells fully responsive (Table 1). In 
any case, validity of both IL-17 primers and ELISA kits was 
demonstrated by the detection of either IL-17A, IL-17D, IL-17E, 
and IL-17F transcripts in human Th17, but not Th1, cell lines 
(Figure S1 in Supplementary Material), or IL-17A and IL-17F 
proteins in supernatants from CD4+ T  cells activated with 
anti-CD3/anti-CD28 mAbs (Table  1). We could also detect 
intracellular IL-17B in lysates of human cerebral cortex (data 
not shown), as expected (68).
In other experiments, neutrophils were incubated for 3 h with 
20 µg/ml IL-6 plus 2 µg/ml IL-23, in the presence or the absence 
of inactivated conidia, or hyphae, from A. fumigatus. These 
experiments were done with the purpose to mimic, as much as 
possible, recently described experimental conditions shown to 
induce not only IL-17A and IL-17F but also IL-17RC, mRNA 
expression (23, 24, 29, 39, 40, 44). Neutrophils were also incu-
bated with 100–500 ng/ml IL-17A to reinvestigate (12) whether 
they respond to IL-17A or not. As shown in Figure 2, neutrophils 
treated with either IL-17A or IL-6 plus IL-23 (in the presence or 
the absence of inactivated A. fumigatus conidia/hyphae), showed 
neither induction of IL-17A (Figure  2A), IL-17F (Figure  2B), 
and IL-17RC (Figure  2C) mRNAs nor upregulation of the 
constitutively expressed IL-17RA transcript levels (Figure 2D). 
Similar results were obtained when incubation was prolonged up 
to 6  h (data not shown), or when neutrophils were stimulated 
with PMA/ionomycin after pretreatment for 1 h with IL-6 plus 
IL-23 (Figure S2 in Supplementary Material). Elevated levels of 
IL-17RC mRNAs were, however, detected in HBECs (data not 
shown), used as control cells (12), thus confirming that our prim-
ers were correctly designed. Importantly, the capacity of IL-6 plus 
IL-23 to stimulate neutrophils was evidenced by their ability to 
time-dependently promote STAT3 phosphorylation (Figure 2E), 
as well as to upregulate SOCS3 mRNA expression (Figure 2F), 
such an effect being potentiated by inactivated A. fumigatus 
conidia/hyphae (Figure  2F). By contrast, IL-17A-treatment 
influenced neither SOCS3 (Figure  2F) nor CXCL8 (data not 
shown) mRNA levels in neutrophils. Furthermore, no IL-17A 
(Figure  3A), IL-17F, or IL-17AF (data not shown) proteins 
were detected by ELISA either intracellularly or in supernatants 
harvested from neutrophils incubated with IL-6 plus IL-23, in 
the presence or the absence of inactivated A. fumigatus conidia/
hyphae. Under the same experimental conditions, CXCL8 pro-
tein was newly synthesized and released by neutrophils incubated 
with IL-6 plus IL-23 in the presence of inactivated A. fumigatus 
conidia/hyphae, but not in their absence (Figure 3B). Finally, no 
IL-17A was detected in IL-6 plus IL-23-stimulated neutrophils 
by intracellular staining experiments (data not shown), using the 
anti-human IL-17A eBio64DEC17 mouse IgG1 (from eBiosci-
ence) previously shown to function under identical experimental 
conditions by Taylor et al. (39). We have no clues explaining why 
we did not reproduce the positive effects on IL-17 expression by 
IL-6 plus IL-23 (23, 24, 29, 39, 40), with or without inactivated 
A. fumigatus conidia/hyphae. One possibility is that the hyphal 
extracts from A. fumigatus used by Taylor and colleagues (39), 
but not our inactivated conidia/hyphae, contain some undefined 
PAMP(s) that effectively promote(s) IL-17A production/IL-17RC 
expression by human neutrophils.
Taken together, our data extend previous findings on the 
inability of human neutrophils to express IL-17 members at the 
mRNA and protein levels under various activating conditions 
(13–16). Data also confirm and extend our previous findings 
(12) on the inability of IL-17A to directly modify IL-17A, IL-17F, 
IL-17RA, IL-17RC, SOCS3, and CXCL8 gene expression in human 
neutrophils.
human neutrophils incubated With il-6 
Plus il-23, in the Presence or the absence 
of inactivated A. fumigatus hyphae/
conidia, Do not express il-17rc
Flow cyometry experiments confirmed (12) that neutrophils, 
either freshly isolated, or incubated for 3  h in the absence, 
or the presence of IFNγ plus LPS (Figure  4A), display only 
surface IL-17RA, but not IL-17RC. No IL-17RC surface levels 
were also observed in neutrophils incubated with either R848 
(Figure 4A), or IL-6 plus IL-23, in the latter case in the absence, 
or in the presence of either inactivated A. fumigatus conidia/
hyphae, or IL-17A (Figure  4B). IL-17RA surface levels were 
downregulated in neutrophils treated with IFNγ plus LPS, R848 
(Figure 4A) and IL-6 plus IL-23 with IL-17A (Figure 4B). In 
these experiments, HBEC were, again, used as positive control 
FigUre 2 | No induction of IL-17A, IL-17F, and IL-17RC mRNA expression in neutrophils incubated with IL-6 plus IL-23, in combination with inactivated Aspergillus 
fumigatus hyphae or conidia. Neutrophils (5 × 106/ml) were incubated either with 100 ng/ml rIL-17A for 2 h or with or without 20 µg/ml IL-6 plus 2 µg/ml IL-23 for 
1 h, prior to adding, or not, inactivated A. fumigatus conidia (1:5 neutrophils/conidia ratio) and hyphae (1:1 neutrophils/hyphae ratio) for additional 1 h. Neutrophils 
were then harvested for RNA extraction to evaluate IL-17A (a), IL-17F (B), IL-17RC (c), IL-17RA (D), and SOCS3 (F) mRNA expression by reverse transcription 
quantitative real-time PCR. Gene expression data are depicted as mean normalized expression (MNE) units after GAPDH mRNA normalization (mean ± SEM, n = 4). 
Asterisks stand for significant differences as compared to untreated cells: *P < 0.05, **P < 0.01, by Student’s t-test. (e) Immunoblot displaying STAT3 tyrosine 
phosphorylation in neutrophils, either untreated or cultured for 15 or 60 min with 20 µg/ml IL-6 plus 2 µg/ml IL-23 (representative experiment, n = 2).
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for both IL-17RA and IL-17RC surface expression (data not 
shown) (12). It should be pointed out that, for the investiga-
tion of surface IL-17RC, we have been using the same anti-
IL-17RC, directly PE-conjugated, Abs used in Taylor et  al.’s 
study (39), other than the anti-IL-17RC biotin-conjugated Abs 
that necessitate PE-conjugated streptavidin for detection (12), 
without noticing any difference between them. By the way, IFNγ 
plus LPS and R848 (Figure S3A in Supplementary Material), as 
well as IL-6 plus IL-23 in the presence of inactivated A. fumiga-
tus conidia/hyphae (Figure S3B in Supplementary Material), 
FigUre 4 | Expression of surface IL-17RA and IL-17RC in neutrophils 
activated under various experimental conditions. Expression of surface 
IL-17RA (left panel) and IL-17RC (right panel) was evaluated by flow 
cytometry in neutrophils either freshly isolated or cultured for 3 h without or 
with 100 U/ml IFNγ plus 100 ng/ml LPS, 5 µM R848 (a), 20 µg/ml IL-6 plus 
2 µg/ml IL-23 alone or in the presence of inactivated Aspergillus fumigatus 
conidia, hyphae or 500 ng/ml rIL-17A (B). Graphs depict a representative 
experiment out of three independent ones with similar results. Histograms 
show staining by specific and isotype control Abs, respectively, for each 
stimulatory condition.
FigUre 3 | Lack of IL-17A and IL-17F production by human neutrophils 
activated by IL-6 plus IL-23 in combination with inactivated Aspergillus 
fumigatus hyphae or conidia. Neutrophils (5 × 106/ml) were incubated with or 
without 20 µg/ml IL-6 plus 2 µg/ml IL-23 and then cultured for three more 
hours in the presence or not of inactivated A. fumigatus conidia and hyphae 
(used at 1:5 and 1:1, respectively). After incubation, IL-17A (a) and CXCL8 
(B) levels were determined in cell-free supernatants and in corresponding cell 
pellets by specific ELISA. Values are depicted as the mean ± SD or as not 
detected (nd) when values were under the detection limit (n = 3). Asterisks 
stand for significant differences as compared to untreated cells: *P < 0.05, 
**P < 0.01, by Student’s t-test.
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variably modulated both CD11b and CD62L expression. All 
in all, data illustrate that IL-6 plus IL-23, regardless of their 
combination with inactivated A. fumigatus conidia/hyphae, 
and despite their capacity to upregulate SOCS3 mRNA expres-
sion (Figure 2F), do not induce the expression of IL-17RC in 
our hands, contradicting some studies (39, 44).
O2
- Production by neutrophils stimulated 
With inactivated A. fumigatus hyphae 
after Preincubation With il-6 plus il-23 is 
not Modified by either exogenous il-17a 
or il-17a inhibitors
We then measured the capacity to release O2− by neutrophils 
preincubated with or without IL-6 plus IL-23 for 1 h, and then 
treated for one additional hour with inactivated A. fumigatus 
hyphae, in the presence or the absence of either IL-17A or 
anti-IL-17A neutralizing Abs (Figure S4 in Supplementary 
Material). As control, neutrophils were also stimulated with 
either inactivated A. fumigatus hyphae alone or 20 ng/ml PMA. 
As shown in Figure S4 in Supplementary Material, inactivated 
A. fumigatus hyphae were found to trigger a remarkable O2− 
production by neutrophils, even though lower than PMA. 
However, A. fumigatus hyphae-stimulated O2− release was not 
potentiated by the preincubation of neutrophils with IL-6 plus 
IL-23 (which, by themselves, did not trigger any O2− produc-
tion) (Figure S4 in Supplementary Material). Under the latter 
experimental conditions, addition of either IL-17A or anti-
IL-17A neutralizing Abs (αIL-17A Abs) did not influence the 
effect of inactivated A. fumigatus hyphae on neutrophil-derived 
O2− (Figure S4 in Supplementary Material), supporting the lack 
of induction of surface IL-17RC expression and endogenous 
IL-17A, respectively.
chromatin Organization at the il-17a and 
il-17F genomic loci of human 
neutrophils
Signatures of histone posttranslational modifications at a spe-
cific gene locus provide indicative elements to predict whether 
such a gene can be transcribed or not (69, 70). Therefore, 
we evaluated the presence of histone marks associated to 
active (e.g., H3K27Ac) and poised (e.g., H3K4me1) genomic 
regulatory elements (71) at the IL17A and IL17F loci of human 
neutrophils. Genome-wide ChIP-seq assays demonstrated that, 
in freshly isolated neutrophils, the entire genomic region con-
taining IL17A and IL17F loci is completely devoid of H3K27Ac 
and H3K4me1 (Figure 5). By contrast, based on data available 
from the NIH Epigenomics Roadmap Initiative (72), multiple 
H3K4me1 peaks are present in the same genomic regions of 
PMA/ionomcyin-stimulated Th17 cells, while H3K27Ac peaks 
FigUre 5 | Chromatin immunoprecipitation (ChIP)-Seq profiles of H3K4me1 and H3K27Ac at the IL17A and IL17F loci in human neutrophils and Th17 cell lines. 
Representative snapshots depicting H3K4me1 and H3K27Ac ChIP-seqs at the IL17A and IL17F genomic loci in freshly isolated human neutrophils or, as retrieved 
from NIH Epigenomics Roadmap Initiative (72), in phorbol mysistate acetate/ionomycin-stimulated Th17 cell lines.
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localize at the IL17A locus only (Figure  5). To validate the 
previous data, we performed H3K27Ac and H3K4me1 qPCR 
ChIPs using neutrophils incubated for 1  h either with or 
without 20 µg/ml IL-6 plus 2 µg/ml IL-23, as well as Th17 cell 
lines (in which IL-17A and IL-17F mRNA is constitutively 
transcribed), used as positive controls (Figure  6). Based on 
the H3K4me1 peaks from the ChIP-seqs of Th17 cell lines (72) 
(Figure 5), we designed specific primers amplifying potential 
regulatory regions at the IL17A and IL17F genomic loci, 
namely IL-17A#1 and IL-17F#1 for enhancers, and IL-17A#2, 
IL-17A#3, and IL-17F#2 for promoters (Figures  6A,B). As 
expected, Th17  cell lines displayed constitutively bound 
H3K4me1 at their IL-17A and IL-17F promoters and enhanc-
ers (Figures 6A,B, left panels). We also detected high levels of 
H3K27Ac at the IL-17A and IL-17F promoters and enhancers 
of Th17 cell lines (Figures 6A,B, right panels), in line with their 
constitutive expression of both IL-17A and IL-17F mRNA (data 
not shown). By contrast, we did not observe any H3K4me1 or 
H3K27Ac at the IL17A and IL17F loci of neutrophils, either 
under resting conditions (thus confirming the ChIP-seq data 
shown in Figure  5) or after incubation with IL-6 plus IL-23 
(Figures 6A,B). In fact, the H3K4me1 and H3K27Ac levels at 
the IL-17A and IL-17F enhancers in neutrophils were similar to 
those ones present at the PRL promoter, a genomic region with 
a closed chromatin conformation in myeloid cells, herein used 
to determine the signal background (Figures 6A,B). Notably, 
measurable amounts of H3K4me1 and H3K27Ac were found at 
the SOCS3 promoter of neutrophils under resting conditions, 
as well as in Th17 cell lines (Figure 6C). Interestingly, H3K27Ac 
levels tended to increase in neutrophils incubated with IL-6 
plus IL-23 (Figure 6C), in accordance with a supposed STAT3-
dependent induction of SOCS3 mRNA (73). Taken together, 
data indicate that the organization of the IL17A and IL17F loci 
in human neutrophils is characterized by the absence of poised 
chromatin marks, unlike that of IL-17A- and IL-17F-producing 
Th17 cell lines. Data also indicate that human neutrophils do 
not reorganize the chromatin of the IL17A and IL17F loci in 
response to IL-6 plus IL-23, consistent with their inability to de 
novo accumulate IL-17A and IL-17F mRNA.
human neutrophils From Patients With 
Psoriasis Do not express il-17a and/or 
il-17F mrna
We subsequently investigated whether neutrophils isolated from 
patients with active psoriasis could express/produce IL-17A, 
IL-17F, and/or IL-17RC mRNA, either constitutively or upon 
incubation for 20 h with IFNγ plus LPS, R848, or IL-17A. As shown 
in Figure 7A, the latter was not the case, as psoriatic neutrophils 
behaved similarly to neutrophils from HDs. Psoriatic neutrophils 
did not also respond to IL-17A (Figure 7A), due to their lack of 
surface IL-17RC expression (Figure 7B). Nonetheless, psoriatic 
neutrophils fully responded to either R848 or IFNγ plus LPS, as 
they accumulated CXCL8, TNFα, and SOCS3 transcripts at levels 
comparable to those in HD neutrophils (Figure 7A).
commercial anti-il-17a abs (aF-317-na) 
Positively stain cytospins of resting and 
activated neutrophils due to Their non-
specific recognition of neutrophil 
intracellular Proteins Different From  
il-17a
In additional experiments, cytospin slides of resting and R848-
stimulated neutrophils were incubated with goat anti-human 
IL-17A AF-317-NA Abs, previously shown to stain neutrophils 
in pathological tissues (18–22, 25, 27, 28, 30–33, 35, 36, 41–43, 45, 
47–50), as also confirmed by our IHC/IF staining of inflamed pso-
riatic tissue (Figure 8A). Consistently, neutrophil cytospin slides 
became strongly positive upon incubation with AF-317-NA, yet 
with no difference between resting or R848-activated neutrophils 
(Figure 8B). By contrast, immunostaining of the same cytospins 
slides with anti-human CXCL8 Abs showed a strong positivity 
only in R848-treated neutrophils (Figure  8B), thus excluding 
methodological artifacts. Not surprisingly, neutrophils from the 
same experiments were found totally negative for both IL-17A 
mRNA expression and IL-17A production once processed for 
RT-qPCR analysis and ELISA. The detection of IL-17A-positive 
neutrophils by IHC, in the absence of IL-17A mRNA, could 
FigUre 6 | Continued
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FigUre 6 | H3K4me1 or H3K27Ac levels at the IL-17A, IL-17F, and SOCS3 genomic loci of Th17 cell lines and resting/IL-6 plus IL-23-activated neutrophils. 
Enrichment levels of H3K4me1 (left panels) and H3K27Ac (right panels) at the IL-17A (a), IL-17F (B), and SOCS3 (c) genomic loci by chromatin 
immunoprecipitation (ChIP) analysis in human Th17 cell lines and neutrophils incubated for 1 h with or without 20 µg/ml IL-6 plus 2 µg/ml IL-23. (a–c) Schemes 
illustrating the positions of the designed primer pairs amplifying promoter and potential enhancer regions of IL-17A, IL-17F, and SOCS3 for ChIP analysis are 
depicted at the top of each panel. Coimmunoprecipitated DNA samples were expressed as percent of the total input. Panels in (a–c) depict a representative 
experiment out of two independent ones with similar results. Error bars represent SEs calculated from triplicate qPCR reactions.
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be explained by the fact that the cytokine may be synthesized 
in bone marrow neutrophil precursors, at stages during which 
granule proteins, such as myeloperoxidase (MPO), elastase, 
and azurocidin 1, are formed (74). However, in transcriptomes 
made by Rapin et  al., generated from cells isolated at different 
stages during granulopoiesis (65), we did not identify any IL-17A 
mRNA accumulation (Figure 9). In the same database, we not 
even detected IL-17RC and IL-10 mRNA (Figure 9), consistent 
with the inability of mature neutrophils to express them (12, 70). 
By contrast, we did find MPO, elastase, and azurocidin 1 mRNA 
expression only in transcriptomes of neutrophil precursors, as 
expected (74), thus validating the reliability of the database (65) 
(Figure 9). In any case, consistent with the absence of intracellu-
lar IL-17 (Figure 3A), immunoblots performed with AF-317-NA 
revealed that whole neutrophil lysates did not show any positive 
signal in correspondence of recombinant human IL-17A (rhIL-
17A) molecular weight (MW) (Figure  8C). In these experi-
ments, neutrophils were either freshly isolated (D1 and D2 in 
Figure 8C), or cultured for 3 h with or without R848, 2 µg/ml IL-6 
plus 0.2 µg/ml IL-23 (low IL-6 plus IL-23 in Figure 8C), or 20 µg/
ml IL-6 plus 2 µg/ml IL-23 (high IL-6 plus IL-23 in Figure 8C). 
By contrast, AF-317-NA strongly reacted in correspondence of 
neutrophil proteins displaying higher MW than that of rIL-17A, 
with no difference in signals among freshly isolated, stimulated, 
or untreated neutrophils (Figure 8C). While these data confirm 
the observations reported by Tamarozzi et al. (13), who also used 
mouse anti-IL-17A mAbs (#41802, from R&D) in addition to 
AF-317-NA, they are in contrast with Lin et  al.’s findings (30) 
illustrating a constitutive IL-17A (but not IL-17F) expression in 
neutrophil lysates, as revealed by immunoblotting with #41802. 
Halwani et  al. (23) too found constitutive IL-17A amounts in 
lysates of neutrophils from asthmatic patients, even increasing 
upon cell incubation with IL-21 and/or IL-23 for 18 h, as revealed 
by immunoblotting with unspecified Abs from R&D. However, 
since only portions of the immunoblots are shown in Halwani 
et al. (23) and Lin et al. (30) paper, it is not known whether addi-
tional proteins were recognized by Abs used. Whatever the case 
is, our experiments suggest that the positive staining of neutro-
phils detected by IHC and IF using AF-317-NA on cytospins and, 
possibly, tissue slides, stands for an IL-17A-unrelated binding(s) 
to neutrophils.
human neutrophils Do not express/
Produce il-17B
In a separate set of experiments, we also tested goat anti-IL-17B 
(AF1248) Abs that, in recent publications, have been shown to 
positively stain, by IHC and IF, neutrophils present in tissue 
samples from RA (75) and colon carcinoma (CCR) (76) patients. 
Consistently, we found that also neutrophils present in inflamed 
psoriatic tissue were strongly detectable by IHC and IF stainings 
with AF1248 (Figure 10A). On cytospin slides, AF1248 stained 
neutrophils isolated from the blood of HDs and incubated for 3 h 
with or without 5 µM R848 in an equivalent manner (Figure 10B). 
However, by immunoblotting of whole lysates prepared from 
neutrophils treated with R848 or IL-6 plus IL-23, AF1248 did 
not recognize any protein corresponding to the rhIL-17B MW 
(Figure 10C). These negative observations were also confirmed 
by measurement of intracellular, as well as, released IL-17B by two 
commercial ELISA (see Materials and Methods). Accordingly, 
no antigenic IL-17B could be measured in supernatants and 
whole lysates from neutrophils incubated with 5 µM R848 with 
or without 1,000  U/ml IFNα, 100  µg/ml LPS with or without 
100  U/ml IFNγ, 2/20 μg/ml IL-6 plus 2  µg/ml IL-23 (data not 
shown), in agreement with the lack of IL-17B mRNA induction. 
Detectable IL-17B levels were, however, measured in lysates of 
human cerebral cortex (68), demonstrating that our two IL-17B 
ELISA kits were sensitive enough. Altogether, our data indicate 
that, similarly to the case of AF-317-NA, the positive stainings 
of neutrophils in cytospin slides and, possibly, tissue samples 
by AF1248, likely stand for an IL-17B-unrelated, non-specific, 
recognition occurring in human neutrophils.
DiscUssiOn
In this study, we have reinvestigated in-depth whether human 
neutrophils produce IL-17A, IL-17B, IL-17F, and IL-17A/F 
in vitro. According to the literature, in fact, information on such 
an issue appears discordant, as the majority of papers sustain that 
human neutrophils do express/produce IL-17A (18–53), while a 
minority fail to detect it (12–17). This issue is even more critical 
if one takes into account that also the capacity of murine neutro-
phils to produce IL-17A, shown in a variety of mouse models of 
infectious and autoimmune inflammation (24, 39, 40, 77–81), has 
been recently questioned (82, 83). Preclinical models evidencing 
neutrophil-derived IL-17 as pathogenic in diseases might be, 
in fact, prematurely taken as proof-of-concept for immediate 
translational applications in humans.
Herein, by using multiple methodological approaches 
(RT-qPCR, ChIP, ChIP-seq, ELISA, intracellular staining, and 
immunoblotting), we confirm and greatly extend our previous 
findings (12) showing that highly purified (>99.7%) populations 
of human neutrophils, either resting or activated by a variety of 
stimulatory conditions, including TLR and dectin ligands, fungal 
PAMPs and cytokines, used singly or in combinations, neither 
express IL-17A, IL-17F, IL-17B, IL-17C, IL-17D, and IL-17E 
mRNA nor produce IL-17A, IL-17F, IL-17A/F, and IL-17B 
in  vitro. Similarly, we show that also neutrophils isolated from 
FigUre 7 | IL-17A, IL-17F, IL-17RA, IL-17RC, CXCL8, TNFα, and SOCS3 
mRNA expression, as well as IL-17R surface expression, in neutrophils from 
patients with psoriasis. (a) Neutrophils isolated from healthy donors (HDs) 
(n = 3) or psoriatic patients (n = 3) were cultured for 20 h with 100 U/ml IFNγ 
plus 100 ng/ml LPS, 5 µM R848, or 500 ng/ml IL-17A to evaluate IL-17A, 
IL-17F, IL-17RA, IL-17RC, CXCL8, TNFα, and SOCS3 mRNA expression by 
reverse transcription quantitative real-time PCR. Gene expression data are 
depicted as mean normalized expression (MNE) units after GAPDH mRNA 
normalization. (B) Surface IL-17RA and IL-17RC expression evaluated by 
flow cytometry in human neutrophils from HDs or psoriatic patients. Values 
represent the mean ± SEM (n = 3). For the data of panels (a,B) no significant 
differences between HDs or psoriatic patients were observed by two-way 
ANOVA followed by Bonferroni’s post-test.
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patients with active psoriasis do not express IL-17F, IL-17B, 
IL-17C, IL-17D, and IL-17E as well as IL-17RC mRNA when 
activated by R848, IFNγ plus LPS, and IL-17A in vitro. In such 
regard, RNA-Seq experiments made by Tamarozzi et  al. (13), 
using neutrophils isolated by negative-selection (>99.9% pure) 
from HDs or RA patients (as we do), then treated for 1 h with 
a range of inflammatory cytokines (TNFα, GM-CSF, G-CSF, 
IL-6, IL-1β, CXCL8, IFNα, and IFNγ), also failed to detect any 
of the mRNA for IL-17 cytokine family. By contrast, Yamanaka 
et al. (15) have been recently reported the presence of constitu-
tive IL-17A transcripts in neutrophils from HDs and psoriasis 
patients isolated by density gradient cell separation (92% purity). 
However, when the same cell populations were further purified by 
magnetic sorting (reaching a 99% purity), they were found totally 
devoid of IL-17A mRNA (15), indicating that contaminating 
monocytes/lymphocytes were actually responsible for the IL-17A 
mRNA expression in unsorted “neutrophils.” Needless to say that 
Yamanaka et al.’s observations (15) are example of a notion that 
we have been always recommending in our studies (56, 59, 84), 
namely the requirement of using highly purified cell populations 
if one wants to obtain correct results when examining neutrophil 
gene expression or neutrophil-derived cytokines.
Interestingly, other studies confirm that human neutrophils 
do not constitutively contain IL-17A transcripts (13, 24, 29, 30, 
35, 39, 40, 44), including those ultimately showing a concurrent 
positivity for IL-17A protein, as revealed by intracellular flow 
cytometry (24, 39, 40), ELISA (24, 39), confocal microscopy (39), 
or IHC (29). Some authors (30, 35) speculated that the absence of 
IL-17A mRNA in mature neutrophils indicates that the cytokine 
is synthesized in bone marrow neutrophil precursors, at the 
stages when granule proteins are formed (74). However, we would 
exclude such a hypothesis, as our analysis of transcriptomes 
generated from all types of bone marrow cell populations (65) 
failed to identify an IL-17A mRNA accumulation at any stage of 
neutrophil maturation.
We were unable to detect IL-17A and IL-17F mRNA/produc-
tion/release even by human neutrophils incubated with IL-6 
plus IL-23, in contrast to what repeatedly found (23, 24, 29, 
39, 40). In our experiments, neutrophils did, however, respond 
to IL-6 plus IL-23 in terms of STAT3 phosphorylation and 
SOCS3 mRNA induction, indicating that the two cytokines are 
effectively stimulatory for neutrophils. It is intriguing that, apart 
from Halwani et  al. (23), who found that either 20 ng/ml IL-6 
or 20 ng/ml IL-23, singly used, directly induced IL-17A mRNA 
and protein in a fraction of neutrophils from asthmatic patients, 
other groups highlighted the necessity to use at least 20 µg/ml 
IL-6 plus 2 µg/ml IL-23 (29, 39, 40) (as we did). In this context, 
the paper by Hu et al. (24), based on the use of neutralizing Abs 
and pharmacological inhibitors, identified endogenous IL-6 and 
IL-23 as indirect inducers of IL-17A expression in a fraction 
of neutrophils either infected with Mycobacterium tuberculosis 
(MTB), or stimulated with LPS or Pam3CSK4. In this latter 
study, however, IL-6 and IL-23 levels corresponded to 1 ng/ml 
at the best. Herein, we failed to detect IL-17A mRNA expres-
sion and production in neutrophils incubated with either LPS 
FigUre 8 | Staining human neutrophils by anti-IL-17A (AF-317-NA) polyclonal antibodies (Abs). (a) Immunofluorescence (top panels) and immunohistochemistry 
(lower panels) stainings of two FFPE cases of human pustular psoriasis using anti-IL-17A (AF-317-NA) and anti-CD66b Abs (as labeled). Top panels show DAPI, 
FITC channel, and merge to recognize neutrophil shape; lower panels show different magnification of IHC and double IHC to characterize IL-17A+ cells with the 
neutrophil marker CD66b. (B) Cytospins of neutrophils, either untreated (top panels) or treated with 5 µM R848 (bottom panels) for 3 h, were stained with 
anti-IL-17A (AF-317-NA, left panels) and anti-CXCL8 (right panels) Abs. Original magnification 200× [first row in (a) and left image in third row, scale bar 100 µm] 
and 400× [second row in (a), center/right images in third row in (a), as well as in (B), scale bar 50 µm]. Images of the second row in (a) represent magnifications of 
images in first row. (c) AF-317-NA immunoblot of lysates from neutrophils either freshly isolated (T0, from two donors) or incubated for 3 h with or without 2 µg/ml 
IL-6 plus 0.2 µg/ml IL-23 (low), 20 µg/ml IL-6 plus 2 µg/ml IL-23 (high), or 5 µM R848. Recombinant human IL-17A (rhIL-17A) was used as positive control. Panels 
(B,c) display representative experiments out of two independent ones with similar results.
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or Pam3CSK4, even if it is true that they produce IL-6 (62) and 
IL-23 (our unpublished observations). Whether stimulation of 
neutrophils with MTB effectively promotes IL-17A expression via 
endogenous IL-6 and IL-23 remains to be verified. However, no 
IL-17A, IL-17B, IL-17C, or IFNγ secretion from Mycobacterium 
bovis Bacille-Calmette Guerin (BCG)-stimulated neutrophils 
was recently reported (14). It should be also remarked that the 
purity of neutrophils in studies showing an IL-17 production in 
FigUre 9 | Levels of IL-17A, IL-17B, IL-17F, IL-10, IL-17RC, IL-17RA, azurocidin, neutrophil elastase, and myeloperoxidase (MPO) mRNA expression in neutrophils 
at different stages of maturation. mRNA expression data derive from Gene Expression Omnibus database (accession number GSE42519) (65). (a) IL-17A, IL-17B, 
IL-17F, IL-10, IL-17RC, and IL-17RA or (B) azurocidin (AZU1), neutrophil elastase (ELANE), and MPO mRNA expression levels were measured in the following cell 
types: hematopoietic stem cells (HSCs), multipotent progenitors (MPPs), common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), early 
and late promyelocytes (PMs), myelocytes (MYs), metamyelocytes (MMs), band cells (BCs), and bone marrow polymorphonuclear neutrophil granulocytes. Values 
represent the mean ± SEM as calculated from data of the biological replicates present in the database.
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response to IL-6 plus IL-23 (23, 29, 39, 40), reported to be >96% 
at the best (29), does not sufficiently secure fully genuine results 
at least in our opinion.
Nevertheless, we investigated potential mechanisms helping 
to clarify whether human neutrophils respond to IL-6 plus IL-23 
in terms of IL-17A expression or not. ChIP assays revealed that, 
in resting, as well as in IL-6 plus IL-23-stimulated, neutrophils, 
but not in Th17 cell lines, the IL17A locus does not contain any 
H3K4me1 and H3K27Ac, which are two histone marks that 
are usually present in those genomic regions that act as active 
enhancers (85). On the other hand, the levels of H3K27Ac were 
found increased at the SOCS3 promoter of neutrophils incubated 
with IL-6 plus IL-23, consistent with the potentially inducible 
SOCS3 mRNA transcription. Notably, the complete absence 
of H3K4me1 at the IL17A locus of neutrophils is particularly 
informative, since such a histone modification is known to 
precede very early, but time-consuming (86), events necessary 
for the assembly of the transcriptional machinery, including 
nucleosomal depletion, H3K27Ac deposition, and enhancer 
activation (85). Based on our data, it appears that the chromatin 
at the IL17A locus of human neutrophils likely displays a closed 
conformation, inaccessible to transcription factors and, conse-
quently, RNA polymerase, ultimately preventing IL-17A mRNA 
transcription in resting as well as stimulated neutrophils. It is 
thus very unlikely that H3K4me1 modification could be induced 
within 1 h, e.g., the time-point at which IL-17 mRNA expression 
in IL-6 plus IL23-stimulated neutrophils has been observed (29, 
39, 40). Obviously, this does not exclude that there could exist 
some stimulatory conditions able to modify the chromatin at the 
IL17A or IL17F loci of human neutrophils.
A variety of studies report the presence of IL-17A+-neutrophils 
in sample tissues from many diseases, including psoriasis (20, 25, 
30, 32, 35, 49), skin inflammation (27), bullous pemphigoid (28), 
hidradenitis suppurativa (50), fungal keratitis (26), RA (31, 75), 
ankylosing spondylitis (18), systemic lupus erythematosus (41, 
52), human ANCA-associated glomerulonephritis (47), cystic 
fibrosis (19, 36, 44), nasal polyps (53), chronic obstructive pulmo-
nary disease (22), lung tissues during bacterial pneumonia (46), 
alcoholic liver diseases (48), acute renal allograft rejection (42), 
atherosclerotic plaques (21), cutaneous T cell lymphoma lesions 
(45), gastric cancer (29), cervical cancer (33), and prostate cancer 
(51), as revealed by IHC, IF, or intracellular flow cytometry using 
various commercial anti-IL-17A Abs. Not surprisingly, results 
occasionally appear discordant. For example, while Moran et al. 
(31) reported IL-17A-positive synovial tissue neutrophils using 
the AF-317-NA, van Baarsen et al. (16) show that synovial tissue 
neutrophils from arthritis patients are not stained by another 
antibody, namely #41802. By IHC experiments using AF-317-NA, 
we too detected IL-17A+-neutrophils not only in skin sections 
of psoriasis patients but also in cytospin slides of neutrophils 
isolated from HDs and incubated for 3 h with or without R848, 
at similar levels. By contrast, we found that whole lysates of the 
same neutrophil populations displayed major signals at levels of 
proteins having MW not corresponding to that of IL-17A when 
FigUre 10 | Staining human neutrophils by anti-IL-17B (AF1248) antibodies (Abs). (a) Immunofluorescence (top panels) and immunohistochemistry (lower panels) 
staining of two FFPE cases of human pustular psoriasis using anti-IL-17B (AF1248) and CD66b Abs (as labeled). Top panels show DAPI, FITC channel, and merge 
to recognize neutrophil shape; lower panels show different magnification of IHC and double IHC to characterize IL-17A+ cells with the neutrophil marker CD66b.  
(B) Cytospins of neutrophils incubated without (top panel) or with 5 µM R848 (bottom panel) for 3 h. Original magnification 200× [first row in (a) and left image in 
third row, scale bar 100 µm] and 400× [second row in (a), center/right images in third row in (a), as well as in (B), scale bar 50 µm]. Images of the second row in  
(a) represent magnifications of images in first row. (c) AF1248 immunoblot of lysates from neutrophils either freshly isolated (T0, from two donors) or incubated for 
3 h with or without 2 µg/ml IL-6 plus 0.2 µg/ml IL-23 (low), 20 µg/ml IL-6 plus 2 µg/ml IL-23 (high), or 5 µM R848. Recombinant human IL-17B (rhIL-17B) was used 
as positive control. Panels (B,c) display representative experiments out of two independent ones with similar results.
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immunoblotted with AF-317-NA. Our findings substantially 
confirm the observations previously made by Tamarozzi et  al. 
(13) who also did not detect any IL-17A expression in highly 
pure populations of neutrophils (99.9%) by using a variety of 
assays including RT-qPCR, RNA-seq, western blot and ELISA, 
despite of finding IL-17A+-neutrophils in Wolbachia Onchocerca 
volvulus-positive nodules by IHC using AF-317-NA. Notably, by 
immunoprecipitation experiments followed by mass spectrom-
etry, Tamarozzi et al. (13) also uncovered that both AF-317-NA 
and #41802 bind to several proteins expressed in granules 
(including MPO, lactoferroxin, and lysozyme C) and cytoskel-
eton (such as keratin and profilin) of neutrophils, while other 
anti-human IL-17A Abs (sc-6077 from Santa Cruz, and PRS4877 
from Sigma) were found to recognize multiple non-specific bands 
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in neutrophil immunoblots (13). All in all, data suggest that the 
IL-17A-positivity of human neutrophils detected by AF-317-NA 
and #41802 is, at least in vitro, likely an artifact. Whether these or 
other anti-IL-17A Abs, including sc-7927 (from Santa Cruz) (33, 
43), ab9565 (from Abcam) (37), ab136668 (from Abcam) (46), 
500-P07 and 500-P07G (from Peprotech) (43), and eBio64Dec17 
(from eBioscience) (20, 26, 43), are instead reliable in specifically 
detecting IL-17A+-neutrophils in tissue samples should be more 
convincingly established. For instance, in models of skin inflam-
mation resembling psoriasis (27), accumulated neutrophils 
stained by AF-317-NA were shown to express IL-17 mRNA tran-
scripts. In other studies, tissue neutrophil staining by AF-317-NA 
was blocked after antibody pre-adsorption with rIL-17A (18, 47), 
or confirmed by costaining of the same section by eBio64DEC17 
(47). It is worth recalling that neutrophils express high levels 
of IL-17RA (12) that could in theory bind exogenously derived 
IL-17A, consequently leading to a positive signal in IHC or IF 
experiments without actual intracellular IL-17 production (87), 
as observed in the case of mast cells (88). Whatever the case is, 
we would recommend to always validate by multiple investigation 
methods an eventual detection of IL-17A-positive neutrophils 
exclusively by IHC, or IF or intracellular flow cytometry (18, 19, 
21, 22, 28, 32–34, 36–38, 42, 43, 48–52).
Similar concerns can be made for the, to date, reported IL-17B 
expression by human neutrophils. Accordingly, IL-17B has been 
detected in neutrophils infiltrating the synovial membrane of 
RA patients (75) and the stroma of CCR cancer (76) by IHC/IF, 
as well as in freshly isolated neutrophils by immunoblotting (75), 
in all cases using #AF1248 Abs. We also detected IL-17B-positive 
neutrophils in psoriasis plaques and cytospin slides of freshly 
isolated neutrophils by IHC using #AF1248. However, we could 
not measure any IL-17B in lysates of freshly isolated/activated 
neutrophils either by using two different commercial ELISA or 
by #AF1248 immunoblotting. In the latter experiments, many 
proteins with MW different from that of rIL-17B were recog-
nized by #AF1248, thus invalidating at least the cytospin results. 
Intriguingly, Kouri et al. (75) did detect IL-17B protein in lysates 
of neutrophils (95% pure), by both ELISA and immunoblotting 
using #AF1248. However, these authors showed only a portion 
of the western blot (75), thus rendering impossible to know 
whether additional major proteins were recognized by #AF1248. 
Curiously, we, Tamarozzi et  al. (13) and Kouri et  al. (75), all 
found that human neutrophils do not transcribe IL-17B mRNA 
under resting or activating condition. Furthermore, no IL-17B 
secretion from BCG-stimulated neutrophils was recently shown 
(14). In such regard, Koury et al. (75) suggested that IL-17B is 
synthesized only at the promyelocyte and myelocyte stage in the 
bone marrow, disappearing in mature neutrophils. However, 
our analysis of transcriptomes generated from all types of bone 
marrow cell populations (65) revealed that, similarly to IL-17A, 
also IL-17B is never transcribed during the different stages of 
neutrophil maturation. Altogether, data suggest that human 
neutrophils do not express IL-17B in  vitro. They also suggest 
that the positive staining of neutrophils by IHC using AF1248 
is likely due to a non-specific, IL-17B independent, binding of 
these Abs.
In conclusion, data shown in this study are consistent with the 
notion that human neutrophils are unable to express and produce 
IL-17A, IL-17B, or IL-17F in vitro.
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